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Abstract 
 
Most of the biological effects of cannabis are due to the activation of specific 
cannabinoid receptors. To date, two such receptors have been discovered and are 
found predominantly in the central nervous system (the CB1 receptor) or the 
immune system (the CB2 receptor). Endogenous cannabinoid receptor ligands, the 
endocannabinoids, have also been isolated and the mechanisms of their synthesis 
and degradation postulated. By modulating the activation of cannabinoid receptors 
and endocannabinoid metabolism, synthetic cannabimimetic compounds have 
enormous therapeutic potential for the treatment of such diverse symptoms and 
diseases as pain, inflammation, cancer, hypertension, schizophrenia and multiple 
sclerosis. This thesis describes the design, synthesis and subsequent biological 
evaluation of three classes of novel, potentially cannabimimetic drugs, namely 
aryl ethanolamides, phenylphosphinic acids and alkylphosphinic acids. In order to 
assess cannabimimetic activity, the ability of these compounds to bind to the 
cannabinoid receptors and to inhibit endocannabinoid uptake and enzymatic 
hydrolysis was examined.  
Affinity for the CB1 receptor was assessed using radioligand binding assays in rat 
brain membranes. Although none of the compounds proved to be high-affinity 
CB1 receptor ligands, two aryl ethanolamide compounds exhibited some affinity 
for this receptor, suggesting that this general class of compound may have 
cannabimimetic potential. 
In order to ascertain whether the test compounds had affinity for the CB2 receptor, 
a radioligand binding assay was developed using porcine spleen membranes. To 
date, only the human, murine and rat CB2 receptors have been cloned and there 
has been no detailed examination of the cannabinoid binding profile of the porcine 
CB2 receptor. The Kd of the radiolabelled cannabinoid [3H]-CP-55,940 was 
determined in porcine spleen membranes and the Bmax subsequently calculated. 
The Ki values of a number of cannabinoid receptor ligands were then determined. 
These values were shown to be similar to the corresponding values obtained using 
cloned CB2 receptors. However, when the test compounds were assessed in this 
assay system, no affinity for the CB2 receptor was observed. 
 iv
To determine the effect, if any, of the test compounds on the endocannabinoid 
uptake system, accumulation of the radiolabelled endocannabinoid [3H]-
anandamide into N18TG2 mouse neuroblastoma cells was examined.                 
[3H]-Anandamide accumulation had previously been reported in this cell line but, 
until now, this mechanism had not been characterized. This accumulation was 
shown to be time-, temperature- and concentration-dependent and was inhibited 
by AM404 and bromocresol green, known inhibitors of the endocannabinoid 
carrier system. [3H]-Anandamide accumulation exhibited  a Km value similar to 
those previously described for rat astrocytes and neurones and the time taken to 
achieve half maximal rate was shown to be considerably greater than in these rat 
cells. None of the test compounds significantly inhibited [3H]-anandamide uptake 
by N18TG2 cells although one phenylphosphinic acid compound, with structural 
similarities to AM404, appeared to be inhibitory at high concentrations. 
The final biological target examined was fatty acid amide hydrolase (FAAH), the 
enzyme that catalyses the hydrolysis of endocannabinoids. For FAAH studies, a 
novel, inexpensive and rapid spectrophotometric assay was developed as an 
alternative to the traditional radiochemical- and chromatography-based assays. 
Using this novel assay system, the Km and Vmax values of rat liver FAAH were 
determined and shown to be similar to those published in the literature. Known 
FAAH inhibitors were shown to inhibit FAAH in a concentration-dependent 
manner with IC50 values comparable to previously published data. In addition, this 
assay was used to demonstrate differences in FAAH activity between soluble and 
insoluble membrane preparations from rat liver and brain, possibly indicating the 
presence of, as yet, unknown FAAH enzymes. Attempts were also made to adapt 
this assay for use on a microtiter plate, where it was possible to detect FAAH 
inhibitors. Therefore, this spectrophotometric assay may prove to be of use in the 
high-throughput screening of chemical libraries for drugs that cause 
cannabimimetic effects via FAAH inhibition. None of the test compounds 
synthesized inhibited FAAH activity and this, combined with their lack of 
biological activity at the other targets tested, showed that they exerted no 
cannabimimetic effects. 
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The most exciting phrase to hear in science, the one that heralds new discoveries, 
is not Eureka! (I found it!) but rather, “hmm.... that's funny...” 
 
 
Isaac Asimov 
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AAI   aminoalkylindole 
ADP   adenosine diphosphate 
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2-AG 2-arachidonylglycerol 
AM251 N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide 
AM281 N-(piperidin-1-yl)-1-((2,4-dichlorophenyl)-5-(4-
iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide 
AM404  N-(4-hydroxyphenyl)arachidonylamide  
AM630 6-iodopravadoline 
Anandamide arachidonylethanolamide 
ANOVA analysis of variance 
APA alkylphosphinic acid  
ATP adenosine triphosphate 
B0 specific radioligand binding  
Bmax receptor number 
Bromocresol green 3’,3’’,5’,5’’-tetrabromo-m-cresolsulphone phthalein 
BSA   bovine serum albumin 
BTSP bis(trimethylsilyl)phosphonite 
BTSPP bis(trimethylsilyl)phenylphosphonite 
cAMP cyclic adenosine monophosphate 
E-CD E-cyclodextrin 
cDNA complementary DNA 
CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1-propane 
sulphonate 
CHO Chinese hamster ovary 
Ci Curie 
CMK megakaryoblastic cells 
CNS central nervous system 
COX cyclooxygenase 
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CP-47,497 (Z)-3-[4-(1,1-dimethylheptyl)-2-hydroxyphenyl] 
cyclohexanol 
CP-55,940 (1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-
trans-4-(3-hydroxypropyl)cyclohexan-1-ol 
CPF crude particulate fraction 
CREAE chronic relapsing experimental allergic encephalomyelitis 
CT-3 1’,1’-dimethylheptyl-'8-tetrahydrocannabinol-11-oic acid 
DAUDA 11-(5-dimethylamino naphthalenesulphonyl)-undecanoic 
acid 
DCM dichloromethane 
DIPEA diisopropylethylamine 
DMAP 4-dimethylaminopyridine 
DMEM  Dulbecco’s modified Eagle medium 
DMF N,N-dimethylformamide 
DMSO   dimethyl sulphoxide 
dpm  disintegrations per minute 
EC50 concentration of drug required for 50 % of maximum 
response 
ED50 dose of drug required for 50 % of maximum response 
EDC 1-(3-dimethylaminopropyl)-3-ethycarbodiimide 
hydrochloride 
EDHF endothelium-derived hyperpolarizing factor 
EDRF endothelium-derived relaxant factor 
EDTA   ethylenediamine tetraacetic acid 
ERK extracellular signal-regulated kinase 
FAAH   fatty acid amide hydrolase 
FABP fatty acid binding protein 
FBS foetal bovine serum 
GABA J-aminobutyric acid 
GDH  L-glutamate dehydrogenase 
GDP guanosine diphosphate 
GI gastrointestinal 
Glu   L-glutamate 
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GPCR   G protein-coupled receptor 
GTP   guanosine triphosphate 
GTP-J-S  guanosine 5’-O-thiotriphosphate 
HBCC human breast cancer cells 
HEPES  N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulphonic acid) 
HHC 9-nor-9E-hydroxyhexahydrocannabinol 
HMDS hexamethyldisilazane 
HOBt 1-hydroxybenzotriazole 
HPLC high-performance liquid chromatography 
5-HT 5-hydroxytryptamine 
HTS high-throughput screening 
HU-210 3-(1,1-dimethylheptyl)-(-)-11-hydroxy-'8-tetrahydro 
cannabinol 
HU-211 3-(1,1-dimethylheptyl)-(+)-11-hydroxy-'8-tetrahydro 
cannabinol 
HU-243 11-hydroxy-3-(1,1’-dimethylheptyl)hexahydrocannabinol 
HU-308 4-[4-(1,1-dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-
dimethyl-(1R,4R,5R)-(+)-bicyclo[3.1.1]hept-2-ene-2-
methanol 
i.p.   intra-peritoneal 
i.v.   intra-venous 
IC50 concentration required to produce 50 % of the maximum 
possible inhibition 
IL interleukin 
iNOS inducible nitric oxide synthase 
JWH-015 1-propyl-2-methyl-3-(1-naphthoyl)indole 
JWH-051 1-deoxy-11-hydroxy-'8-tetrahydrocannabinol-
dimethylheptyl 
Kd dissociation constant 
Ki inhibitory constant 
Km Michaelis constant 
D-KG D-ketoglutaric acid 
kDa kilo Daltons 
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kU kilo units 
L759633 (6aR,10aR)-3-(1,1-dimethyl-heptyl)-1-methoxy-6,6,9-
trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene 
L759656 (6aR,10aR)-3-(1,1-dimethyl-heptyl)-1-methoxy-6,6-
dimethyl-9-methylene-6a,7,8,9,10,10a-hexahydro-6H-
benzo[c]chromene 
L-759,787 2-methyl-3-(4-morpholinylmethyl)-1-(1-naphthalenyl 
carbonyl)-1H-indole 
L-768,242 1-(2,3-dichlorobenzoyl)-5-methoxy-2-methyl-3-[2-(4-
morpholinyl)ethyl]-1H-indole 
LPS lipopolysaccharide 
LY320135 [6-methoxy-2-(4-methoxyphenyl)benzo[b]thien-3-yl][4-
cyanophenyl]methanone 
M moles/dm3 
m.p.   melting point 
MAFP   methylarachidonyl fluorophosphonate 
MAPK mitogen-activated protein kinase 
MCP-1 monocyte chemotactic protein-1  
MHz megahertz 
mRNA messenger RNA 
MS multiple sclerosis 
NAD+ nicotinamide adenine dinucleotide 
NADH   nicotinamide adenine dinucleotide (reduced form) 
NF nuclear factor 
NGF nerve growth factor 
NMR   nuclear magnetic resonance 
NSAID  non-steroidal anti-inflammatory drug 
Oleamide cis-9,10-octadecenamide 
PAA N-propyl arachidonyl amide 
PAG periaqueductal gray 
PBS   phosphate buffered saline 
PDMAA N-propyl-D,D-dimethylarachidonyl amide 
PEI   polyethylenimine 
 x
PMAA N-propyl-D-methylarachidonyl amide 
PMSF   phenylmethylsulphonyl fluoride 
PPA phenylphosphinic acid 
ppm   parts per million 
Pravadoline (4-methoxyphenyl)[2-methyl-1-[2-(4-morpholinyl)-ethyl]-
1H-indol-3-yl]methanone 
PRLr prolactin receptor 
RP-HPLC reverse-phase high-performance liquid chromatography 
RT-PCR reverse transcriptase polymerase chain reaction 
SEM standard error of mean 
SPECT single photon emission computed topography 
SR141716A N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide 
hydrochloride 
SR144528 N-[(1S)-endo-1,3,3-trimethyl bicyclo [2.2.1] heptan-2-yl]-5-
(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-
carboxamide 
THC   tetrahydrocannabinol 
TLC   thin layer chromatography 
TMEV Theiler’s murine encephalomyelitis virus 
TMSCl trimethylsilyl chloride 
TNFD tumour necrosis factor D 
Tris   tris(hydroxymethyl)aminomethane 
TX-100  t-octylphenoxypolyethoxy ethanol 
Vmax maximum rate 
WIN 55-212,2  (R)-(+)-[2,3-dihydro-5-methyl-3-[(4-morpholinly) 
methyl]pyrrolo[1,2,3-de-]-1,4-benzoxazin-6-yl](1-
naphthalenyl) methanone 
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All chemicals used in this research were of the highest grade possible and 
obtained from the following commercial sources: 
 
Affiniti Research Products Ltd., Exeter, U.K. - MAFP  
Aldrich, Poole, U.K. – alkyl iodides, bromocresol green, 3-bromopropan-1-ol, 
carboxylic acids, DIPEA, DMAP, ethanolamine, HMDS, HOBt, hypophosphorus 
acid, KHSO4, oxalyl chloride, phenylphosphinic acid, TMSCl and triethylamine 
Amersham Pharmacia Biotech, Amersham U.K. – [35S]-GTP-J-S and [3H]-
SR141716A 
Avocado Research Chemicals Ltd., Heysham, U.K. - EDC 
BDH Laboratory Supplies, Poole, U.K. – EDTA, ethanol, D-(+)-glucose, NaCl, 
NaHCO3, NaOH and Tris 
Calbiochem, Nottingham, U.K. – GDH, D-KG and NADH. 
Fisher Scientific Ltd., Loughborough, U.K. - cyclohexane, dichloromethane, ethyl 
acetate, HCl, hexane, methanol, MgSO4 and sucrose 
Fisons Scientific Equipment, Loughborough, U.K. - CaCl2, chloroform, DMSO, 
KCl, methanol and orthophosphoric acid 
ICN Biomedicals Inc., Basingstoke, U.K. - GDP 
NEN Life Science Products Inc., Hounslow, UK - [3H]-anandamide and [3H]-CP-
55,940 
Sigma, Poole, U.K.- ADP, ammonium acetate, BSA, CHAPS, coomassie Brilliant 
Blue G, DMEM, Dulbecco’s PBS, FBS, glycerol, HEPES, PMSF, 
polyethylenimine, theophylline, triethanolamine, trypsin and TX-100 
Tocris Cookson Ltd., Avonmouth, U.K. - AM404 and HU210 
Research Biochemicals International, Dorset, U.K. - E-CD 
Life Technologies Ltd., Paisley, U.K. - L-glutamine 
 
SR141716A and SR 144528 were a generous gift from Dr F. Barth, Sanofi-
Synthelabo, Paris. CP-55,940 was a kind gift from Pfizer Central Research, 
Groton, CT, U.S.A.  
Anandamide and oleamide were synthesized as described in appendix A. 
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Chapter 1: 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 2
1.1 Cannabis 
 
The plant cannabis sativa has been extensively utilized by mankind throughout 
history. It has been used as a source of textiles and food, but it is most widely 
known as a psychoactive drug of abuse. The earliest recorded use of cannabis is 
from China nearly four thousand years ago where it was used as a sedative and 
all-purpose medicine, although there is no evidence of widespread use for its 
psychoactive properties. From China, the use of cannabis spread through Asia to 
the Middle East and Europe. There are many references to its use in religious 
ceremonies where it was thought, like many psychoactive drugs, to promote union 
with God, but its medicinal properties superseded its religious use. Medicinally, 
cannabis was used in many cultures to treat diverse complaints including sickness, 
pain, convulsions, inflammation, urinary infections, asthma and lack of appetite. 
The drug preparation was usually taken orally but, in India, the practice of 
smoking cannabis became established. As smoking cannabis leads to a more rapid 
onset of its effects compared to oral delivery, this practice soon spread globally. 
 
Although preparations of cannabis sativa were known to contain numerous 
“cannabinoid” compounds, it was not known whether the effects of cannabis were 
due to a single compound, a number of compounds or metabolites of the 
cannabinoids. The only cannabinoid to be isolated in a pure form by the middle of 
the twentieth century was cannabinol, which is not psychoactive. However, in 
1964, the major active constituent of cannabis was isolated and characterized as (-
)-'9-tetrahydrocannabinol ('9-THC), an oily, viscous liquid (Gaoni & 
Mechoulam, 1964). When used in pharmacological tests, purified '9-THC 
demonstrated the same effects as cannabis preparations. Subsequent research 
demonstrated the existence of a number of structurally related cannabinoids in 
cannabis sativa, with '8-THC, an isomer of '9-THC, also being psychoactive but 
found in lower levels than '9-THC. Other naturally occurring cannabinoids 
include the tetrahydrocannabinolic acids, cannabidiol and cannabidiolic acid, all 
of which are non-psychoactive (figure 1.1). 
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Figure 1.1: The structures of some of the cannabinoids found in cannabis sativa, 
showing the widely accepted dibenzopyran numbering system. 
 
Although cannabis has well established medicinal effects, its widespread abuse for 
the psychotropic “high” it produces means that it remains an illegal substance. Yet 
today, many thousands of people continue to risk arrest and imprisonment by 
using cannabis to relieve chronic symptoms that are not helped by prescription 
medicines. One of the most publicized illnesses in which cannabis is particularly 
effective at relieving symptoms is multiple sclerosis (MS). Indeed, research has 
recently confirmed that '9-THC is effective at reducing spasticity and tremor in a 
mouse model of MS (Baker et al., 2000). Understandably, the medicinal use of 
cannabis is an extremely controversial and widely debated issue, particularly in 
recent years. Even if cannabis were to be decriminalized for medicinal use, 
smoking preparations of the plant is an undesirable route of administration. 
Although smoking enables a rapid onset of the effects of cannabis and enables 
effective self-administration of a suitable dose by the user, there is a major 
disadvantage. Like cigarettes, smoking cannabis is extremely damaging to the 
lungs. Recently, this was highlighted by a study which showed that smoking three 
R=H: Cannabinol 
R=CO2H: Cannabinolic acid 
R=H: Cannabidiol 
R=CO2H: Cannabidiolic acid 
R = H: '9-THC 
R = CO2H: '9-Tetrahydrocannabinolic acid 
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to four cannabis cigarettes per day produces histological effects on the lungs 
comparable to smoking 20 tobacco cigarettes (Johnson et al., 2000). In order to 
deliver the medicinal effects of cannabis safely, research in to the delivery of this 
drug is now concentrating on pure '9-THC. Currently, studies are being 
performed to investigate its delivery by nasal inhalers and dermal patches similar 
to those used in nicotine and hormone replacement therapies. Indeed, a recent 
publication using aerosolized cannabinoids has demonstrated the feasibility of this 
route of administration (Lichtman et al., 2000). If effective delivery can be 
demonstrated by these routes, '9-THC may well become a licensed drug in the 
future. 
 
During the last decade, research in to cannabis has greatly accelerated. The 
discovery of specific cannabinoid receptors in the body and an entire endogenous 
cannabinoid system has led to the development of numerous synthetic 
cannabimimetic drugs and a greater understanding of their effects at the cellular 
level. The rest of this chapter describes the cannabinoid receptors, their 
endogenous ligands and the potential therapeutic uses of modulators of this 
endogenous cannabinoid system.  
  
 
1.2 Cannabinoid Receptors 
 
The pharmacological potencies of cannabinoids both in vitro and in vivo are 
dependent on their stereochemistry, with (-)-enantiomers usually being 
considerably more potent than (+)-enantiomers. For example, the synthetic 
cannabinoid 3-(1,1-dimethylheptyl)-(-)-11-hydroxy-'8-tetrahydrocannabinol was 
shown to be highly psychotropic in mice, rats and pigeons while its (+)-
enantiomer was inactive at doses up to several thousand times higher (Mechoulam 
et al., 1988). The psychotropic potencies of cannabinoids are also on a par with 
those of drugs that are known to act via receptors, and much greater than those of 
drugs, such as ethanol, that do not. This evidence indicated that the actions of 
cannabinoids may be receptor mediated. Further evidence suggested that 
cannabinoids exert their effects via a G protein-coupled receptor (GPCR). Many 
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GPCRs use cyclic AMP (cAMP) as a second messenger and influence its 
enzymatic synthesis by adenylate cyclase. In its inactive state, the G protein 
component of GPCRs exists as a trimer of GD, GE and GJ subunits with a molecule 
of GDP bound to GD. On ligand binding, a conformational change in GD reduces 
its affinity for GDP and results in its displacement by GTP. This, in turn, causes 
GD to dissociate from GEJ and, if the GPCR is coupled to adenylate cyclase, GD 
binds to the enzyme (see figure 1.2) either stimulating or inhibiting it, depending 
on whether the D subunit is stimulatory (GsD) or inhibitory (GiD). This effect is 
terminated when the GTP bound to GD is hydrolysed to GDP by GTPase, causing 
inactivation of the receptor. Cannabinoids were shown to exert a concentration-
dependent inhibition of both basal and forskolin-stimulated cAMP production in 
N18TG2 neuroblastoma cell membranes (Howlett, 1984; Howlett, 1985). A 
further study showed that when N18TG2 cells were pre-treated with pertussis 
toxin, a substance which inhibits Gi/o proteins, the cannabinoid-induced inhibition 
of cAMP accumulation was abolished (Howlett et al., 1986). This further 
supported the idea that the effect of cannabinoids on cAMP production is GPCR-
mediated and not a result of a direct interaction with adenylate cyclase. 
Ligand
GPCR
Adenylate 
cyclase
GTP
cAMPATP
A B
Di
cAMPATP
Di
GDP
 
 
Figure 1.2: The inactive (A) and active (B) states of an adenylate cyclase-linked 
inhibitory G protein-coupled receptor. 
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1.2.1 The CB1 Cannabinoid Receptor 
The search for cannabinoid receptors was initially impeded by the high 
lipophilicity of '9-THC and its synthetic analogues. This made them unsuitable 
candidates for radioligands to probe for the existence of cannabinoid receptors, as 
their tendency to randomly partition in to biological membranes would mask any 
specific binding sites. However, experiments using the 3H analogue of the 
synthetic compound CP-55,940, a more polar molecule than previous 
cannabinoids, demonstrated a single population of specific cannabinoid binding 
sites in rat brain P2 membranes (Devane et al., 1988). This first cannabinoid 
receptor, now termed the CB1 receptor, was subsequently cloned from a rat 
cerebral cortex complementary DNA (cDNA) library (Matsuda et al., 1990) and 
shown to be a protein of 473 amino acid residues. When this receptor was 
functionally expressed in Chinese hamster ovary (CHO) cells, it was shown that 
both '9-THC and CP-55,940 inhibited forskolin-sensitive cAMP accumulation in 
a concentration-dependent manner, with the (-) enantiomers being considerably 
more potent than the (+) enantiomers. This inhibition of cAMP production was 
abolished by pre-treatment with pertussis toxin, indicating that the response was 
Gi/o protein-mediated. In addition, neither '9-THC nor CP-55,940 affected cAMP 
accumulation in CHO cells that were not transfected with the putative cannabinoid 
receptor cDNA. Analysis of the amino acid sequence of the rat CB1 receptor 
(rCB1) confirmed that it belonged to the GPCR superfamily, possessing seven 
hydrophobic transmembrane domains, a cytosolic C-terminus and an extracellular 
N-terminus containing three possible glycosylation sites (Song & Howlett, 1995). 
 
Mammalian CB1 receptors were subsequently cloned from human (Gerard et al., 
1991) and mouse brain (Chakrabarti et al., 1995) and shown to be proteins of 472 
and 473 amino acids, respectively. Sequence analysis of these peptides 
demonstrated extensive homologies between them and the rCB1 receptor. The 
human receptor (hCB1) had 97.3 % amino acid identity with rCB1, while the 
murine CB1 receptor (mCB1) exhibited 99 % and 97 % identity with rCB1 and 
hCB1, respectively, suggesting that the CB1 receptor is a pharmacologically 
important molecule, at least in mammals.  
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Alternate splicing of CB1 receptor messenger RNA (mRNA) has also been 
demonstrated in both human and rat, resulting in an isoform of the receptor named 
CB1A. This receptor is functionally similar to CB1 but is 61 amino acids shorter 
at its N-terminus, resulting in the absence of two of the three possible 
glycosylation sites. In addition, the first 28 amino acids of the peptide are totally 
different to CB1, being more hydrophobic. A study of the relative distribution of 
mRNA for the two isoforms using RT-PCR showed that CB1A is present at levels 
up to a maximum of 20 % of those for CB1, depending on the tissue (Shire et al., 
1995). Studies to compare cannabinoid binding to the two CB1 receptor isoforms 
showed that [3H]-CP-55,940 binds to both receptors in a highly specific and 
saturable manner. Of the cannabinoids compounds tested, the order of affinity for 
both CB1 and CB1A was CP-55,940 > '9-THC > WIN 55-212,2, although the 
affinity of these compounds for CB1A was approximately three times less than for 
the CB1 receptor (Rinaldi-Carmona et al., 1996). 
 
In addition to the mammalian CB1 receptors cloned to date, CB1 receptors have 
also been cloned from two other vertebrate species. The nCB1 receptor from the 
roughskin newt Taricha granulosa (Soderstrom et al., 2000) and the FCB1A and 
FCB1B receptor isoforms from the puffer fish Fugu rubripes (Yamaguchi et al., 
1996) have been shown to exhibit 84.2, 72.2 and 59.0 % amino acid homology 
with hCB1, respectively. There is also functional evidence of the CB1 receptor in 
a number of other non-mammalian species including chicken, turtle, frog and trout 
(Howlett et al., 1990) and a possible CB1-like receptor in the leech central 
nervous system (CNS) with 49.3 % amino acid homology compared to hCB1. 
This receptor appears to be a chimeric cannabinoid/melanocortin receptor that 
may be a “living fossil” of the CB1 and melanocortin receptors found today in 
higher organisms (Elphick, 1998; Stefano et al., 1997). The conservation of CB1 
amino acid sequence in species that are evolutionary distant suggests that the 
evolution of the CB1 receptor itself was an ancient event and that this receptor 
plays a key physiological role. 
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CB1 Receptor Tissue Distribution 
The CB1 receptor is predominantly expressed within the CNS and its distribution 
appears to be consistent with the known psychoactive effects of cannabinoids. A 
detailed, quantitative autoradiographic study of CB1 receptor distribution in 
human brain using [3H]-CP-55,940 has demonstrated that the expression of CB1 is 
heterogeneous (Glass et al., 1997). Furthermore, the CB1 receptor distribution 
revealed in this study is consistent with the effects cannabinoids have on 
behaviour and locomotion. Specific binding of [3H]-CP-55,940 was observed in 
all areas of the brain and spinal cord, with the highest levels of CB1 receptor 
expression in the areas responsible for memory, movement, higher cognitive 
functions and control of the autonomic nervous system. 
The CB1 receptor has also been shown to be present in a number of peripheral 
tissues. Both functional studies and isolation of CB1 receptor mRNA have shown 
the receptor to be present in testis (Gerard et al., 1991), lung (Rice et al., 1997), 
heart, kidney, colon, pancreas, spleen, placenta and liver (Shire et al., 1995). 
However, evidence from the ileum (Croci et al., 1998), urinary bladder (Pertwee 
& Fernando, 1996), vas deferens, whole gut and myenteric plexus longitudinal 
muscle (Griffin et al., 1997), suggests that the presence of CB1 in these tissues 
may be confined to peripheral nerve terminals. The CB1 receptor has also recently 
been found in the retinas of rhesus monkey, rat, mouse, chick, salamander and 
goldfish using a subtype-specific monoclonal antibody (Straiker et al., 1999). 
In the immune system, the CB1 receptor has been described in a number of 
primary cells and cell lines. Northern blotting has shown CB1 to be present in 
mouse spleen, but not in the thymus (Schatz et al., 1997), suggesting that the 
receptor is predominantly expressed in B cells. In the same study, quantitative RT-
PCR showed CB1 receptor mRNA to be present in mouse spleen at 1.96 x 102 
molecules/100 ng RNA compared to 2.8 x 105 molecules/10 ng RNA in the brain. 
A more detailed study of CB1 mRNA expression within the human immune 
system demonstrated the presence of the receptor in tonsils, spleen and 
leukocytes, although at levels much lower than CB1 mRNA expression in the 
CNS (Bouaboula et al., 1993). The rank order of CB1 receptor mRNA expression 
in immune cells was B cells > natural killer cells t polymorphonuclear neutrophils  
t T8 cells > monocytes > T4 cells.  
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1.2.2 The CB2 Cannabinoid Receptor 
Consistent with the anti-inflammatory and immunosuppressive effects of 
cannabis, a second cannabinoid receptor, CB2, was reported in the human 
macrophage-derived cell line HL60 (Munro et al., 1993). When the human CB2 
(hCB2) cDNA was transfected into COS cells, which do not usually express any 
receptors for cannabinoids, a saturable number of high affinity binding sites for 
the synthetic cannabinoids WIN 55-212,2 and CP-55,940 were observed with 
dissociation constants (Kd) of 3.7 and 1.6 nM, respectively, for the two 
compounds. In the same expression system, it was also shown that, like CB1, the 
CB2 receptor is negatively coupled to adenylate cyclase via the Gi/o GTP binding 
protein (Bayewitch et al., 1995; Shire et al., 1996). Analysis of the hCB2 receptor 
amino acid sequence indicated that it also belongs to the GPCR superfamily with 
the characteristic seven transmembrane domains, an intracellular C-terminal 
domain and an extracellular N-terminus. However, the homology between the 
hCB1 and hCB2 receptors was relatively low, with an overall amino acid identity 
of only 44 %, rising to 68 % in the transmembrane domains. Despite this 
structural difference, many cannabinoid compounds display nearly equal affinity 
for the two receptors (see section 1.7.1). 
 
Mouse and rat CB2 receptors (mCB2 and rCB2) were subsequently cloned and, 
although the amino acid sequences are highly conserved between the species, they 
are more divergent than the CB1 receptor. The mCB2 receptor is 13 amino acids 
shorter at the C-terminus than the hCB2 receptor and shares 82 % amino acid 
identity (Shire et al., 1996), whereas the rCB2 receptor is the same length as 
hCB2, with 93 % homology (Griffin et al., 2000). In addition to the human, 
murine and rat CB2 receptors, there is also evidence for the existence of CB2 
receptors in a number of other species. 
  
CB2 Receptor Tissue Distribution 
In contrast to the high levels of CB1 receptor expression within the CNS, the CB2 
receptor is found predominantly in the immune system. There is little evidence of 
any CB2 receptor expression in the CNS except one report of CB2 mRNA in 
mouse cerebellar granule cells, although the level of CB2 expression was not 
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determined (Skaper et al., 1996). In addition, there is evidence of the CB2 
receptor being present in the peripheral nervous system. Functional studies and 
RT-PCR have demonstrated the presence of the CB2 receptor on peripheral nerve 
terminals in mouse vas deferens (Griffin et al., 1997).   
In the immune system, as well as the HL60 macrophage cell line that the receptor 
was originally cloned from, CB2 has been reported in a number of different cells 
from various species. These include primary rat peritoneal mast cells and the 
leaukaemic basophil cell line RBL-2H3 (Facci et al., 1995), primary mouse 
splenocytic T-cells (Schatz et al., 1997), the macrophage cell line RAW264.7 
(Jeon et al., 1996), the murine T-cell line EL4.IL-2 (Condie et al., 1996) and 
primary murine natural killer cells (Massi et al., 2000). Quantitative RT-PCR has 
demonstrated the presence of CB2 receptor mRNA in mouse spleen and thymus at 
3.69 x 103 and 3.6 x 102 molecules/100 ng RNA, respectively (Schatz et al., 
1997). A more in-depth study of CB2 receptor mRNA expression within the 
immune system revealed that in spleen and tonsils, CB2 mRNA levels are 
equivalent to those of CB1 mRNA in the CNS (Galiègue et al., 1995). The rank 
order of CB2 mRNA expression in immune cells was determined as B cells > 
natural killer cells >> monocytes > polymorphonuclear neutrophils > T8 cells > 
T4 cells, similar to the rank order for CB1 mRNA expression. However, CB2 
receptor mRNA expression was found to be between 10 and 100 times greater 
than that of the CB1 receptor. 
 
1.2.3 Cannabinoid Receptor Signal Transduction 
As described earlier in this section, both CB1 and CB2 receptors are negatively 
coupled to adenylate cyclase, their activation causing a decrease in intracellular 
cAMP levels. This inhibition of cAMP synthesis results in a number of 
downstream events, which will be dealt with later in this chapter. However, the 
coupling of cannabinoid receptors to adenylate cyclase may not be as simple as 
originally thought. There is evidence in the literature that in the striatum, where 
CB1 receptors are localized on the same neurones as Gi/o-coupled dopamine D2 
receptors, cannabinoid agonists can cause an accumulation of cAMP through the 
stimulatory G protein, Gs (Glass & Felder, 1997). This effect was also seen in 
CHO cells transfected with the CB1 receptor, but was not observed in cells 
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transfected with CB2. Although the effect of cannabinoid receptors on adenylate 
cyclase is a major route of cannabinoid signal transduction, other mechanisms are 
known. Soon after the discovery of the CB1 receptor, it was demonstrated that its 
activation caused an inhibition of N-type Ca2+ channels in the NG108-15 
neuroblastoma-glioma cell line (Mackie & Hille, 1992; Caulfield & Brown, 
1992). Since this discovery, it has also been shown that activation of the CB1 
receptor inhibits P/Q-type Ca2+ channels and activates inwardly rectifying K+ 
currents within the CNS (Mackie et al., 1995; Felder et al., 1995; Twitchell et al., 
1997). This cannabinoid-induced modulation of intracellular Ca2+ and K+ ion 
levels affects the electrochemical properties of neurones and, ultimately, results in 
the well-documented neuromodulatory effects of cannabinoid compounds. These 
effects, however, are exclusively CB1 receptor-mediated and there is no evidence 
to date of CB2 receptor coupling to ion channels.  
A signal transduction mechanism common to both CB1 and CB2 receptors is the 
Gi/o-dependent activation of mitogen-activated protein kinase (MAPK) 
(Bouaboula et al., 1997; Bouaboula et al., 1999). This enzyme phosphorylates 
other proteins downstream of it, modulating their activities and subsequently 
affecting cellular processes. 
 
 
1.3 Endogenous Cannabinoid Receptor Ligands 
 
With the discovery of cannabinoid receptors came an effort to isolate and 
characterize putative endogenous cannabinoid receptor ligands, the 
“endocannabinoids”, and the first of these compounds was isolated from porcine 
brain by Devane et al. (1992). Organic solvent extracts of brain were partially 
purified by chromatography and assayed for their ability to displace a 
radiolabelled cannabinoid, [3H]-HU-243, from rat synaptosomal membranes. 
Further purification of the fractions that displaced [3H]-HU-243 yielded a single 
compound that was spectroscopically characterized as N-
arachidonylethanolamide, an arachidonic acid derivative, subsequently named 
anandamide (“ananda” meaning bliss in Sanskrit). Anandamide was shown to 
inhibit the specific binding of [3H]-HU-243 to synaptosomal membranes with an 
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inhibition constant (Ki) of 52 nM, compared to 46 nM for '9-THC using the same 
assay system. Anandamide is also a ligand for the CB2 cannabinoid receptor. 
When CB2 was originally discovered, anandamide was shown to inhibit [3H]-
WIN 55-212,2 binding to CB2 expressed in COS cells with a Ki of 1.6 PM, 
compared to 320 nM for '9-THC. In addition, anandamide, like known 
psychotropic cannabinoids, was shown to inhibit the twitch response of isolated 
murine vas deferens in a concentration-dependent manner (Devane et al., 1992a). 
In the tetrad of pharmacological tests commonly used to define cannabimimetic 
activity, anandamide reduced spontaneous activity, caused antinociception and 
catalepsy and reduced core body temperature in a similar manner to '9-THC, 
although it was between 1.3 and 18 times less potent (Smith et al., 1994). 
Soon after the discovery of anandamide, a slightly different approach resulted in 
the discovery of two more endocannabinoids. Rather than isolating the 
compounds directly from brain preparations, long chain, unsaturated fatty acid 
ethanolamides related to anandamide were synthesized and their presence, or lack 
of, was examined in porcine brain by thin layer chromatography. The two 
compounds that were found to exist in this tissue, homo-J-linolenyl ethanolamide 
and docosatetraenyl ethanolamide, displaced [3H]-HU-243 from rat synaptosomal 
membranes with Ki values of 53.4 and 34.4 nM, respectively (Hanus et al., 1993). 
More recently, a fourth endocannabinoid was isolated from canine small intestine 
(Mechoulam et al., 1995) and was characterized as 2-arachidonyl glycerol (2-
AG). Like anandamide, 2-AG is a derivative of arachidonic acid but differs from 
the other endocannabinoids by being a monoglyceride rather than an 
ethanolamide. Initial binding studies demonstrated that 2-AG displaced [3H]-HU-
243 from membranes of COS-7 cells transfected with CB1 or CB2 receptors with 
Ki values of 472 and 1400 nM, respectively. These values are much higher than 
those determined for anandamide, although later work by the same group showed 
that 2-AG exhibited Ki values for the CB1 and CB2 receptors of 58.3 and 145 nM, 
respectively, using the same assay system (Ben-Shabat et al., 1998). When 
assayed with cells that were not transfected with either cannabinoid receptor, no 
2-AG binding was observed. In addition to binding to both cannabinoid receptors, 
2-AG inhibited electrically evoked contractions of isolated mouse vas deferens, 
although it was less potent than '9-THC. In the tetrad of pharmacological tests, 2-
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AG reduced spontaneous activity, induced antinociception and catalepsy and 
reduced rectal temperature after intra-venous (i.v.) administration to mice 
(Mechoulam et al., 1995). Although 2-AG was approximately equipotent with 
anandamide, it was less potent than '9-THC and was lethal within two minutes of 
injection at 60 mg/kg. The mechanism of this effect was not determined. The 
structures of the endocannabinoids are shown in figure 1.3. 
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Figure 1.3: The endogenous cannabinoids, showing the numbering system for the 
carbon chain. 
 
 
1.3.1 Other Endocannabinoid Candidates 
There are two particular endogenous fatty acid amides that are candidate 
endocannabinoids, although there are varying reports of their abilities to bind to 
the cannabinoid receptors. The first of these, palmitoylethanolamide (figure 1.4), 
was originally described as an endogenous CB2 receptor ligand, binding to and 
activating this receptor with a higher affinity than anandamide (Facci et al., 1995). 
However, subsequent binding studies have indicated that palmitoylethanolamide 
and its analogues have little or no affinity for either the CB1 or CB2 receptors 
(Showalter et al., 1996; Sheskin et al., 1997; Lambert et al., 1999). Despite this 
apparent lack of cannabinoid receptor affinity, palmitoylethanolamide has been 
shown to be orally active in down-regulating mast cell activity in rodent models of 
inflammation (Mazzari et al., 1996) and has also been shown to be involved in the 
Homo-J-linolenyl ethanolamide Anandamide 
2-Arachidonyl glycerol Docosatetraenyl ethanolamide 
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control of pain initiation in mice. This effect will be described in more detail in 
section 1.8.  
 
 
 
Figure 1.4: The structure of palmitoylethanolamide, a putative endocannabinoid. 
  
The other endocannabinoid candidate is oleamide (cis-9,10-octadecenamide) 
(figure 1.5), a sleep-inducing lipid originally isolated from the cerebrospinal fluid 
of sleep deprived cats (Cravatt et al., 1995). This compound has been shown to 
allosterically modulate ligand binding to 5-hydroxytryptamine (5-HT) and GABA 
receptors (Huidobro-Toro & Harris, 1996; Lees et al., 1998). Although there is 
conflicting evidence concerning the affinity of oleamide for cannabinoid 
receptors, recent evidence suggests that it does have some affinity, albeit low, for 
the CB1 receptor (Cheer et al., 1999). The same group also demonstrated that the 
CB1 receptor is involved in the allosteric regulation of 5-HT receptors by 
oleamide, possibly due to a direct interaction between the two receptors.  
 
 
 
 
Figure 1.5: The structure of oleamide, an endogenous sleep-inducing ligand and 
possible modulator of endocannabinoid signalling. 
 
1.3.2 Tissue Distribution of Anandamide and 2-AG 
Quantification of anandamide in rat brain showed that it is present at levels 
ranging from 20 pmol/g of tissue in the thalamus to 29 pmol/g in the 
hippocampus. In human brain, anandamide was found in all of the five regions 
tested, with levels ranging from 25 pmol/g of tissue in the cerebellum to 148 
pmol/g in the hippocampus (Felder et al., 1996). However, 2-arachidonyl glycerol 
has been shown to be present at much higher levels than anandamide. In the rat 
brain, 2-AG was shown to be present at up to 4 nmol/g of tissue, over 100 times 
more concentrated than anandamide, suggesting that 2-AG may be the 
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predominant endocannabinoid (Sugiura et al., 1995; Stella et al., 1997). Both 
anandamide and 2-AG have been found in peripheral tissues, albeit at lower levels 
than in the brain. So far, both compounds have been found in the spleen (Felder et 
al., 1996; Ben-Shabat et al., 1998) and kidney (Deutsch et al., 1997a; Kondo et 
al., 1998), while anandamide has been found in the uterus (Schmid et al., 1997) 
and heart (Felder et al., 1996) with 2-AG found in the gut (Mechoulam et al., 
1995), liver, lung and plasma (Kondo et al., 1998). There is also evidence that, 
like the CB1 cannabinoid receptor, endocannabinoids are present in invertebrate 
species. To date, anandamide has been isolated from five species of bivalve 
mollusc (Sepe et al., 1998) and the ovaries of sea urchins (Bisogno et al., 1997b). 
Interestingly, anandamide levels have been shown to increase in post-mortem 
brain, possibly due to activation of the biosynthetic pathways implicated in 
anandamide formation (Felder et al., 1996). It remains to be seen whether this 
effect has any effect on cannabinoid assays using brain preparations. 
 
1.3.3 Endocannabinoid Signalling 
On binding to the CB1 or CB2 cannabinoid receptors, anandamide and 2-AG 
activate the signalling mechanisms described in section 1.2.3, namely inhibition 
of N- and P/Q-type Ca2+ channels, activation of inwardly rectifying K+ currents, 
inhibition of adenylate cyclase and activation of MAPK via the CB1 and CB2 
receptors. However, it is apparent that anandamide is only a partial agonist at the 
CB1 receptor, binding to the receptor but not fully activating it. When CB1 
receptor activation was measured in mouse brain membranes, the synthetic 
cannabinoids CP-55,940 and HU-210 were full agonists, while both anandamide 
and '9-THC elicited only a partial response (Burkey et al., 1997). In fact, 
anandamide exhibited greater efficacy than '9-THC, despite having a lower 
affinity for the receptor. Although 2-AG has a lower affinity for the cannabinoid 
receptors than anandamide it is fully efficacious, suggesting that 2-AG may be the 
primary endocannabinoid. 
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1.3.4 Metabolism of the Endogenous Cannabinoids 
There are three key mechanisms involved in the metabolism of the 
endocannabinoid compounds, namely their synthesis and release from the cell, 
transport from the extracellular space back in to the cytoplasm and hydrolytic 
degradation by an intracellular enzyme, inactivating them. As the research 
presented in this thesis aims to develop compounds that may inhibit the transport 
mechanism or the hydrolytic enzyme, these mechanisms will be described in the 
subsequent sections. Reviews of endocannabinoid synthesis may be found 
elsewhere (Hillard & Campbell, 1997; Piomelli et al., 1998). 
 
1.4 Anandamide Uptake 
 
In order for the termination of endogenous cannabinoid signalling to be achieved, 
the compounds must be removed from the extracellular space and in to the 
cytoplasm for enzymatic degradation. This may occur by simple diffusion across a 
concentration gradient or by a facilitated transport mechanism. The latter route is 
described below. 
 
The first reported evidence of a cellular uptake mechanism for endogenous 
cannabinoids was obtained using rat glioma C6 and mouse neuroblastoma 
N18TG2 cells. When these cells were incubated with [3H]-anandamide, there was 
a time-dependent decrease in its levels in the medium (Deutsch & Chin, 1993). A 
more detailed examination of anandamide uptake was carried out in primary rat 
neural cells and astrocytes (Di Marzo et al., 1994). In these cells, a rapid, 
saturable and temperature-dependent accumulation of [3H]-anandamide was 
observed. Moreover, this accumulation appeared to be specific for anandamide, as 
other N-acylethanolamines did not compete for [3H]-anandamide uptake. 
Subsequently, these characteristics for anandamide accumulation were also 
demonstrated in cerebellar granule cells (Hillard et al., 1997) and in the immune 
system using RBL-2H3 cells, a human leukocyte cell line (Bisogno et al., 1997a). 
In addition, a time-, temperature- and concentration-dependent anandamide uptake 
mechanism has been demonstrated in rat neurones and astrocytes (Beltramo et al., 
1997). Research has also shown that in both the CNS and immune system, cellular 
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accumulation of anandamide is independent of ATP and ion gradients and is 
significantly inhibited by phloretin, a non-specific inhibitor of carrier-mediated 
uptake systems (Hillard et al., 1997; Rakhshan et al., 2000). This evidence 
suggests that anandamide uptake is carrier-mediated and is a passive process, 
dependent on the anandamide concentration gradient across the cell membrane. 
Evidence also suggests that anandamide accumulation is independent of the CB1 
receptor. The potent CB1 receptor ligands WIN 55,212-2 and SR141716A failed 
to inhibit anandamide uptake at a concentration of 10 PM. However, the more 
lipophilic ligands '9-THC and HU-210 both inhibited this accumulation at the 
same concentration. This suggests that these lipophilic compounds affect 
anandamide uptake by non-specific effects on the cell membrane. Although it is 
widely accepted that anandamide is removed from the extracellular space by this 
mechanism, the transport of 2-AG is less clear. It was originally thought that 2-
AG crossed the membrane by diffusion (Di Marzo et al., 1998), but more recent 
evidence suggests that it is also a substrate of the anandamide transporter. 
Inhibition studies demonstrated that 2-AG inhibited the transport of anandamide 
in to astrocytoma cells with an IC50 (the concentration required to inhibit 50 % of 
anandamide uptake) of 18.5 PM. In addition, it was shown that [3H]-2-AG was 
accumulated by astrocytoma cells with comparable kinetics to anandamide 
accumulation (Piomelli et al., 1999). 
 
1.4.1 Substrate Specificity of the Anandamide Transporter 
Uptake and inhibition studies have revealed particular structural requirements for 
optimal translocation by the anandamide transporter (Piomelli et al., 1999). 
Perhaps the most important requirement is at least one cis double bond, indicating 
that it may be necessary for substrates to adopt a U-shaped configuration for 
transport. Of the anandamide analogues tested, most head groups were tolerated 
by the transporter with a para-phenolic substitution particularly favourable. 
Notable exceptions were benzyl analogues with para-methyl, methyl ester, cyano 
or chlorine groups. These alterations effectively abolished recognition by the 
transport mechanism. 
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1.5 Fatty Acid Amide Hydrolase 
 
With the discovery of anandamide, it was soon apparent that, as an amide, it was 
susceptible to hydrolytic inactivation. This was demonstrated using the non-
specific serine protease inhibitor phenylmethylsulphonyl fluoride (PMSF). This 
compound was shown to increase the potency of anandamide as an inhibitor of 
electrically evoked contractions of guinea pig myenteric plexus preparations 
(Pertwee et al., 1995a). The increase in potency was proportional to the 
concentration of PMSF, suggesting that it was inhibiting the hydrolysis of 
anandamide by a serine protease enzyme. However, even before the discovery of 
the endogenous cannabinoids, evidence existed in the literature for an 
amidohydrolase enzyme in rat liver and dog brain that catalysed the hydrolysis of 
N-acylethanolamines, a family of compounds of which anandamide is a member 
(Natarajan et al., 1984; Schmid et al., 1985). The first direct evidence of an 
enzyme activity that could hydrolyse anandamide was obtained using soluble or 
membrane fractions from mouse neuroblastoma N18TG2 and rat glioma C6 cells. 
The enzyme activity that hydrolysed anandamide was mainly localized in the 
membrane fractions and this activity was totally inhibited by PMSF at 
concentration of 1.5 mM. Furthermore, this enzyme activity was also present in 
homogenates of rat liver, brain, lung and kidney (Deutsch & Chin, 1993). 
Following this discovery, an amidohydrolase activity that hydrolysed anandamide 
was identified and partially characterized in rat brain microsomes. This 
“anandamide amidohydrolase” was highly selective for anandamide and other 
polyunsaturated N-acylethanolamines and demonstrated maximal activity at pH 6 
and 8 (Desarnaud et al., 1995). 
A similar enzyme activity was also described using oleamide. When incubated 
with rat brain membrane fractions, oleamide was rapidly hydrolysed to oleic acid 
and this enzymatic activity was also inhibited by 1 mM PMSF. Only a small 
amide hydrolysis activity was present in soluble rat brain fractions and no activity 
was present in rat pancreatic microsomes (Cravatt et al., 1995). This “oleamide 
hydrolase” was subsequently studied in rat liver plasma membranes and shown to 
be pH-dependent with a maximal rate at pH 10 (Patterson et al., 1996). In addition 
to this, a partially purified anandamide amidohydrolase activity from N18TG2 
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membrane fractions was shown to catalyse the hydrolysis of both anandamide and 
oleamide with identical pH and temperature profiles, suggesting both compounds 
were substrates of the same enzyme (Maurelli et al., 1995).  
Using detergent-solubilized rat liver plasma membranes, this enzyme was 
subsequently purified and cloned (Cravatt et al., 1996). The deduced amino acid 
sequence showed the enzyme to be a protein of 579 amino acids that exhibits 
extensive homology with members of the family of “amidase signature” enzymes. 
These enzymes exist in a diverse range of species, although this was the first (and, 
to date, only) mammalian member of the family. When the cloned enzyme was 
expressed in COS-7 cells, there was a high level of activity compared to 
untransfected cells. Using this expression system, anandamide and oleamide were 
both rapidly hydrolysed to their parent fatty acids with rates of 333 and 242 
nmol/min/mg protein, respectively (with both substrates at 100 PM). The enzyme 
was also shown to hydrolyse several other fatty acid amides in addition to 
anandamide and oleamide and, therefore, was named fatty acid amide hydrolase 
(FAAH). FAAH has since been cloned from both human and mouse liver (Giang 
& Cravatt, 1997) and pig brain (Goparaju et al., 1999a). All of these enzymes are 
579 amino acids in length with well conserved sequences and homologies ranging 
from 81 to 91 % (see table 1.1), suggesting an important physiological role.  
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Rat FAAH 63.3     
Mouse FAAH 63.4 91    
Human FAAH 63.0 82 84   
Pig FAAH 62.9 81 80 85  
 
Table 1.1: The sizes and cross-species homologies of cloned fatty  acid amide 
hydrolase enzymes. 
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1.5.1 Substrate Specificity of FAAH 
Biochemically, the four cloned FAAH enzymes have been shown to have similar, 
but subtly different, substrate specificities. FAAH hydrolyses all fatty acid amides 
to some extent, but there are structural features that define the recognition of 
substrates by the enzyme (Lang et al., 1999). For example, a primary amide is 
more rapidly hydrolysed by FAAH than a secondary or tertiary amide. 
Arachidonyl amide (100 PM) was shown to be hydrolysed by rat brain 
microsomal FAAH at a rate of 2.85 nmol/min/mg protein compared to 1.30 
nmol/min/mg protein for anandamide at the same concentration. The saturation of 
the carbon chain is also important, with increasing unsaturation resulting in a 
higher rate of hydrolysis. Thus, anandamide and other arachidonic acid derivatives 
are hydrolysed more rapidly than more saturated fatty acid amides. An important 
and unusual feature of FAAH is that, although classed as an amidase, it also 
catalyses the hydrolysis of esters, including 2-AG (Di Marzo et al., 1998). In fact, 
the rate of 2-AG hydrolysis by FAAH has been shown to be considerably greater 
than that of anandamide. When recombinant porcine FAAH was overexpressed in 
COS-7 cells, 100 PM anandamide was hydrolysed at a rate of 207 nmol/min/mg 
protein, whereas 2-AG was hydrolysed at 733 nmol/min/mg protein at the same 
concentration (Goparaju et al., 1999a). The difference in rate was even more 
pronounced using recombinant rat FAAH. 
 
1.5.2 Tissue Distribution of FAAH 
Northern blot analysis of rat tissues with a probe for FAAH revealed it to be most 
abundant in the brain and liver with lesser amounts in the lung, kidney, testes and 
spleen. The enzyme was not detectable in heart or skeletal muscle (Cravatt et al., 
1996). Subsequent work has demonstrated that low levels of FAAH are also 
detectable in the stomach, small intestine and colon while confirming the absence 
of the enzyme in heart and skeletal muscle (Katayama et al., 1997). More detailed 
analysis of FAAH in the rat brain has shown it to be heterogeneously distributed 
and predominantly localized on large principal neurones (Tsou et al., 1998; 
Egertova et al., 1998). This correlates well with the distribution of the CB1 
receptor, suggesting that anandamide and 2-AG are hydrolysed at their site of 
action. Discrepancies between FAAH and CB1 receptor co-localization may 
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indicate that FAAH is also important in inactivating other neuromodulatory fatty 
acid amides such as oleamide. 
 
1.5.3 Structural and Catalytic Features of FAAH 
As described above, the initial evidence for an enzymatic activity that hydrolysed 
anandamide suggested it was membrane-bound. When FAAH was initially 
purified and cloned, analysis of its amino acid sequence confirmed the presence of 
a transmembrane domain at the extreme N-terminus (Cravatt et al., 1996), FAAH 
being the only member of the “amidase signature” family with such a domain. 
Studies using a mutant of FAAH in which the transmembrane domain was deleted 
showed that this deletion did not prevent its tight association with the plasma 
membrane. In addition, when incubated with oleamide, the kinetic profiles of the 
mutant and wild type FAAH enzymes were nearly identical (Patricelli et al., 
1998). The only characteristic of the enzyme that appeared to be altered by this 
deletion was its ability to form oligomers. Both enzymes could achieve this, but 
the mutant could not form complexes as large as the wild type, suggesting a role 
for the transmembrane domain in self-association. 
 
Before the cloning and molecular characterization of FAAH, its inhibition by 
PMSF suggested that it was a serine protease and research using FAAH mutants 
has confirmed this. Replacing each of the three serine residues that are conserved 
in all amidase signature enzymes (serine-217, serine-218 and serine-241) with 
alanine residues severely compromized FAAH’s catalytic activity (Patricelli et al., 
1999). In addition, mutation of the conserved histidine residues did not affect 
activity, showing that FAAH does not contain the serine-histidine-aspartic acid 
catalytic unit commonly found in other mammalian serine proteases. More 
unusual is the ability of FAAH to catalyse the hydrolysis of both amides and 
esters. Further work with FAAH mutants demonstrated that the lysine-142 residue 
is essential for this catalysis and added to the evidence that FAAH may act via a 
novel catalytic mechanism (Patricelli & Cravatt, 1999). 
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1.5.4 Evidence for Other Enzymes That Hydrolyse Endogenous 
Cannabinoids 
Although FAAH is the only cloned enzyme that is known to hydrolyse 
endogenous cannabinoids, there is evidence in the literature that other such 
enzymes exist. Work comparing the ability of porcine brain preparations to 
hydrolyse anandamide and 2-AG demonstrated that the optimum pH for 2-AG 
hydrolysis was around 7.0, compared to a pH of around 9.0 for anandamide. In 
both the cytosol and particulate fraction, the 2-AG hydrolysing activity at pH 7.0 
was much greater than the corresponding anandamide hydrolysing activity at pH 
9.0, being 800- and 30-fold greater, respectively. When the 2-AG hydrolysing 
activity was partially purified from both cytosol and particulate fraction, it 
catalysed the hydrolysis of 2-AG at pH 7.0 with rates of 3480 and 4970 
nmol/min/mg protein, respectively. Anandamide hydrolysis by the partially 
purified enzymes was not detectable under the described assay conditions, 
suggesting that porcine brain has at least two enzymes capable of hydrolysing 2-
AG (Goparaju et al., 1999b). 
Evidence for the existence of another enzyme that catalyses anandamide 
hydrolysis has also been reported. Using a human megakaryoblastic cell line 
(CMK), this enzyme was solubilized by freeze-thawing the 12000g pellet of cell 
homogenate. The pH optimum of the enzyme was around 5.0, compared to around 
9.0 for FAAH. Activity was almost absent at alkaline pH, suggesting that this 
enzyme may be present in the acidic environment of lysozymes. Furthermore, the 
enzyme was less sensitive to PMSF than FAAH and effectively hydrolysed 
palmitoylethanolamide, a relatively poor substrate for FAAH (Ueda et al., 1999). 
 
 
1.6 Reinforcement of Endocannabinoid Signalling 
 
As described in the previous sections, endocannabinoid signalling is terminated by 
transport across the plasma membrane and subsequent enzymatic hydrolysis. This 
leads to a relatively short duration of endocannabinoid signalling, but naturally 
occurring mechanisms or the action of synthetic drugs may regulate this 
degradation.  
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1.6.1 The Entourage Effect 
As the endocannabinoids and their naturally occurring analogues are substrates for 
the anandamide uptake mechanism and/or FAAH, they compete with one another 
for uptake and hydrolysis. Thus, the duration of action of the endocannabinoids is 
lengthened by this competition. This “entourage effect” was first described for 2-
AG. In the brain, spleen and gut, two major 2-acyl glycerol esters, 2-linoleoyl 
glycerol and 2-palmitoyl glycerol, are present in addition to 2-AG. Neither of 
these esters binds to or activates the CB1 or CB2 receptors but, when incubated 
with 2-AG, they potentiated its binding to the receptors and its ability to inhibit 
adenylate cyclase (Ben-Shabat et al., 1998). In addition, these esters increased the 
potency of 2-AG in the tetrad of pharmacological assays in mice and, although 2-
palmitoyl glycerol was ineffective, 2-linoleoyl glycerol significantly inhibited the 
degradation of 2-AG by intact neuronal and basophilic cells.  A similar effect has 
also been demonstrated using 2-AG and anandamide. As 2-AG is found at much 
higher levels in vivo than anandamide, when 50 PM of 2-AG and 4 PM of 
radiolabelled anandamide were incubated together with intact RBL-2H3 cells, the 
hydrolysis of anandamide was significantly reduced (Di Marzo et al., 1998). 
However, in this study, anandamide uptake was not affected by the presence of 2-
AG conflicting with the evidence that 2-AG is a substrate of the anandamide 
transporter. Although there are conflicting reports in the literature, the data 
described above indicate that, in vivo, the action of endocannabinoids may be 
reinforced by other endocannabinoids and related compounds by the inhibition of 
FAAH, uptake and, possibly, other mechanisms such as allosteric activation of 
cannabinoid receptors. 
 
1.6.2 Artificial Reinforcement 
There is great therapeutic potential in the artificial reinforcement of 
endocannabinoid signalling by synthetic drugs with the two main therapeutic 
targets being the anandamide transporter and FAAH.  Inhibition of either, or both, 
of these targets would lead to a net increase in the amount of endocannabinoids 
available to bind to cannabinoid receptors or prolong their duration of action. An 
alternative strategy would be endocannabinoid analogues that activate 
cannabinoid receptors but are poor substrates for the anandamide transporter or 
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FAAH. In addition, drugs that inhibit uptake and/or FAAH and also activate 
cannabinoid receptors would have an additional mechanism of cannabimimetic 
activity. Synthetic compounds that artificially reinforce endocannabinoid 
signalling will be described in sections 1.7.2 and 1.7.3.  
 
 
1.7 Synthetic Cannabimimetic Compounds 
 
Even before the discovery of the endogenous cannabinoid system, there was a 
great deal of interest in the synthesis of cannabinoid compounds to mimic the 
therapeutic actions of '9-THC. The discovery of the CB1 and CB2 cannabinoid 
receptors, the anandamide transporter and FAAH, however, has led to a renewed 
effort to synthesize cannabimimetic drugs that bind to and modulate the activity of 
these targets. These compounds are described below. 
 
1.7.1 Cannabinoid Receptor Ligands 
There are three different types of cannabinoid receptor ligand, namely agonists, 
antagonists and inverse agonists. An agonist of a receptor is a compound that 
causes activation of that receptor upon binding, inducing the appropriate 
downstream events. For example, a CB1 receptor agonist will inhibit N-type 
calcium channels in neuroblastoma cells upon binding to the receptor. As 
described earlier, anandamide and '9-THC are only partial CB1 agonists, binding 
to but not fully activating the receptor. An antagonist of a receptor is a compound 
that occupies a receptor, yet fails to produce receptor activation and signalling. 
For example, a competitive cannabinoid receptor antagonist will decrease the 
level of adenylate cyclase inhibition caused by a cannabinoid receptor agonist by 
competing for a common binding site.  
It is now thought that many receptors, especially GPCRs, exist in an auto-
activated state thereby causing a basal level of signalling in the absence of a 
receptor ligand. Inverse agonists are thought to attenuate this basal activity by 
causing a conformational change in the receptor that inhibits its interaction with 
effector proteins. Both the CB1 and CB2 receptors have been shown to possess 
some tonic activity. This can be demonstrated by the fact that when either receptor 
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is stably transfected in to a cell line that does not normally express it, a basal level 
of signalling can be detected. Specific examples include the MAPK activity of 
Chinese hamster ovary cells. When wild type cells were compared to cells 
expressing hCB1, it was shown that the transfected cells showed an enhanced 
level of MAPK activity (Bouaboula et al., 1997). An inverse agonist reduces this 
basal receptor signalling in addition to antagonizing the effect of an agonist. 
The synthesis of high-affinity cannabinoid receptor ligands has been invaluable in 
the discovery of the cannabinoid receptors and the elucidation of their 
pharmacology. Perhaps the most important synthetic cannabinoids are the 
cannabinoid receptor antagonists/inverse agonists, which have been vital tools for 
demonstrating the receptor-mediated effects of cannabinoids. In addition, the 
design and synthesis of receptor-specific cannabinoid ligands has led to 
compounds with high affinities for one cannabinoid receptor over the other, 
therefore paving the way for cannabinoid drugs that target either the CNS or 
immune system. This section summarizes some of the compounds in the main 
structural classes of cannabinoid compounds. 
 
 
Classical Cannabinoid Receptor Agonists 
Before the discovery of the cannabinoid receptors, synthetic cannabinoids were 
almost exclusively based on the dibenzopyran ring system that characterizes '9-
THC and the other naturally occurring “classical” cannabinoids. However, of the 
numerous synthetic classical cannabinoids, the only one that is licensed for use in 
the U.K. is nabilone (figure 1.6), which is prescribed as an anti-emetic and to 
prevent weight loss in AIDS patients by stimulating appetite. There are many 
classical cannabinoid compounds that are more potent and selective than nabilone 
and, to date, all are cannabinoid receptor agonists. 
The classical cannabinoid that is perhaps most widely used in cannabinoid 
research, apart from '9-THC itself, is HU-210. This compound is an analogue of 
'8-THC, with a dimethylheptyl side chain replacing the pentyl side chain of the 
naturally occurring cannabinoids. In mice, rats and pigeons, HU-210 was shown 
to be psychotropic and approximately 90 times more potent than '9-THC 
(Mechoulam et al., 1988). 
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Figure 1.6: The structure of nabilone, the only cannabinoid drug licensed for use 
in the U.K. 
 
HU-210 and its saturated analogue HU-243 (Devane et al., 1992b) are among the 
most potent cannabinoids synthesized to date, although they do not exhibit 
selectivity for either the CB1 or CB2 cannabinoid receptors. Of the classical 
cannabinoids that are selective for one cannabinoid receptor over the other, three 
compounds are particularly noteworthy being selective agonists for the CB2 
receptor. JWH-051, the 1-deoxy analogue of HU-210, shows very high affinity for 
CB2 with a Ki of 0.032 nM, although the CB1/CB2 ratio is only 37.5. L759633 
and L759656, on the other hand, are less potent than JWH-051 but exhibit 
CB1/CB2 ratios of 163 and 414, respectively (Ross et al., 1999). The structures of 
these compounds and their Ki values at both cannabinoid receptors are 
summarized in figure 1.7 and table 1.2. 
 
Non-Classical Cannabinoid Receptor Agonists 
In an attempt to minimize the structural features necessary in order for 
cannabinoid compounds to produce analgesia, CP-47,497, an analogue of the 
potent analgesic compound HHC, was synthesized (see figure 1.8). This new 
compound was bicyclic, lacking the pyran ring of  HHC and, like the most potent 
classical cannabinoids, possessed a dimethylheptyl rather than a pentyl side chain. 
In five animal models of pain, CP-47,497 was as potent an analgesic as morphine, 
demonstrating that the pyran ring of HHC is not necessary for analgesia (Melvin 
et al., 1984). 
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Figure 1.7: The structures of some of the most significant synthetic classical 
cannabinoid receptor agonists. 
 
 
Compound 
CB1 Ki 
(nM) 
CB2 Ki 
(nM) 
CB1/CB2 
Ratio 
Reference 
'9-THC 53.3 
40.7 
75.3 
36.4 
0.71 
1.12 
Felder et al., 1998 
Showalter et al., 1996 
HU-210 
0.0608 
0.73 
0.524 
0.22 
0.12 
3.32 
Felder et al., 1998 
Showalter et al., 1996 
HU-243 2.3 2.3 1.00 Drake et al., 1998 
JWH-051 1.2 0.032 37.5 Huffman et al., 1996 
L759656 1043 6.4 163.0 Ross et al., 1999 
L759633 4888 11.8 414.2 Ross et al., 1999 
 
Table 1.2: The Ki values at the CB1 and CB2 receptors of some of the most 
significant classical cannabinoid receptor agonists. 
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Figure 1.8: Structures of the prototypical non-classical cannabinoid CP-47,497 
and the potent classical cannabinoid analgesic HHC. 
 
Hence, CP-47,497 became the prototype of the “non-classical” cannabinoid 
family of compounds which, like the classical cannabinoids, are all cannabinoid 
receptor agonists. Today, the most widely known and used non-classical 
cannabinoid is CP-55,940, which exhibits Ki values in the low nanomolar range at 
both cannabinoid receptors but does not show any specificity. As mentioned in 
section 1.2.1, the development of [3H]-CP-55,940, being less lipophilic than '9-
THC, resulted in the discovery of the CB1 receptor and [3H]-CP-55,940 is still 
probably the most widely used radiolabelled cannabinoid. Recently, HU-308, an 
extremely selective non-classical cannabinoid was described in the literature. This 
compound exhibits very high affinity for CB2 with a Ki of 22.7 nM compared to  
> 10 PM at the CB1 receptor, resulting in a CB1/CB2 ratio of > 441. HU-308 has 
also been shown to be effective at reducing blood pressure, blocking defecation, 
and inducing anti-inflammatory and analgesic effects (Hanus et al., 1999). The 
structures and Ki values of CP-55,940 and HU-308 are shown in figure 1.9 and 
table 1.3. 
 
 
 
 
 
 
Figure 1.9: The Structures of the potent non-classical cannabinoid receptor 
agonists CP-55,940 and HU-308. 
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Compound 
CB1 Ki 
(nM) 
CB2 Ki 
(nM) 
CB1/CB2 
Ratio 
Reference 
 
CP-55,940 
3.72 
0.58 
5.0 
2.55 
0.69 
1.8 
1.46 
0.84 
2.78 
Felder et al., 1998 
Showalter et al., 1996 
Ross et al., 1999 
HU-308 > 10 PM 22.7 > 441 Hanus et al., 1999 
 
Table 1.3: The Ki values at the CB1 and CB2 receptors of the non-classical 
cannabinoid receptor agonists CP-55,940 and HU-308. 
 
 
Aminoalkylindoles and Their Derivatives 
In an attempt to develop non-steroidal anti-inflammatory drugs (NSAIDs) with 
less ulcerogenicity than existing compounds of this class, Bell et al. (1991) 
synthesized the aminoalkylindole (AAI) derivative pravadoline (figure 1.10). This 
compound inhibited prostaglandin synthesis as it was designed to but, in addition, 
it exhibited antinociceptive activity in several animal assays. 
 
 
 
 
 
 
 
 
Figure 1.10: The structure of pravadoline, the prototypical aminoalkylindole 
cannabinoid receptor ligand. 
 
Further structural development of pravadoline culminated in the synthesis of WIN 
55-212,2, one of the most potent and widely used cannabinoid receptor agonists 
(Dambra et al., 1992). WIN 55-212,2 has Ki values in the low nanomolar range at 
both the CB1 and CB2 cannabinoid receptors, showing some selectivity for the 
CB2 receptor. A more selective, though less potent, member of this family of 
N
O
OMe
N
O
  
 30
compounds is JWH-015 which, again, is selective for the CB2 receptor. Other 
aminoalkylindole cannabinoid receptor agonists exhibit much higher selectivity. 
The compounds L-759,787 and L-768,242 are AAIs where the substitution at the 
1 and 3 positions is inverted compared to the classical AAI structure, resulting in 
CB1/CB2 Ki ratios of 160 and 103, respectively (Gallant et al., 1996). In addition 
to cannabinoid receptor agonists, aminoalkylindole cannabinoid receptor 
antagonists have been developed. AM630 is an iodinated analogue of pravadoline 
(Pertwee et al., 1995b) and, although originally described as a cannabinoid 
receptor antagonist in the brain, it is now known to act as a CB2 receptor-selective 
inverse agonist and a weak partial agonist at the CB1 receptor (Ross et al., 1999). 
A final noteworthy compound related to the AAIs is LY320135, a substituted 
benzofuran compound. This substance has been shown to be an extremely 
selective antagonist of the CB1 receptor with over one hundred times greater 
affinity for CB1 than CB2 (Felder et al., 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: The structures of some of the most significant aminoalkylindole 
cannabinoid receptor ligands and the related compound LY320135. 
 
Interestingly, there is evidence in the literature that the interaction of WIN 55-
212,2 and, presumably other members of the AAI family, with the CB1 receptor 
may be via a different mechanism than for other receptor agonists. A mutant CB1 
receptor in which the lysine-192 amino acid residue was replaced with alanine 
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was stably transfected in to HEK-293 cells. WIN 55-212,2 bound to and activated 
this mutant receptor, while HU-210, CP-55,940 and anandamide did not (Song & 
Bonner, 1996). The structures and Ki values of these AAI compounds are shown 
in figure 1.11 and table 1.4. 
 
Compound 
CB1 Ki 
(nM) 
CB2 Ki 
(nM) 
CB1/CB2 
Ratio 
Reference 
WIN 55-212,2 
62.3 
1.89 
3.3 
0.28 
18.88 
6.75 
Felder et al., 1998 
Showalter et al., 1996 
JWH-015 383 13.8 27.75 Showalter et al., 1996 
L-759,787 1917 12.0 159.8 Gallant et al., 1996 
L-768,242 877 8.5 103.2 Gallant et al., 1996 
AM-630 5152 31.2 165.1 Ross et al., 1999 
LY320135 141 14900 9.5x10-3 Felder et al., 1998 
 
Table 1.4: The Ki values at the CB1 and CB2 receptors of some of the 
aminoalkylindole cannabinoid receptor ligands. 
 
Diarylpyrazoles 
The diarylpyrazole cannabinoid receptor ligands were developed by Sanofi 
Recherche and have proved to be invaluable tools in elucidating the receptor-
mediated effects of cannabinoids. SR141716A and SR144528 were the first potent 
and selective antagonists of the CB1 and CB2 receptors, respectively (Rinaldi-
Carmona et al., 1994; Rinaldi-Carmona et al., 1998). Subsequent reports, 
however, suggest that these drugs both act as inverse agonists (Bouaboula et al., 
1997; Portier et al., 1999). SR141716A may also prove to be useful in 
characterizing CB1 cannabinoid receptor binding in vivo. Its iodinated analogue 
AM281 is a candidate for SPECT (single photon emission computed topography) 
imaging of living brain (Lan et al., 1999). The structures and Ki values of 
SR141716A and SR144528 are shown in figure 1.12 and table 1.5. 
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Figure 1.12: The structures of the CB1 and CB2 cannabinoid receptor-selective 
antagonists/inverse agonists SR141716A and SR144528. 
 
Compound 
CB1 Ki 
(nM) 
CB2 Ki 
(nM) 
CB1/CB2 
Ratio 
Reference 
SR141716A 
11.8 
12.3 
13200 
702 
8.9x10-4
 
0.018 
Felder et al., 1998 
Showalter et al., 1996 
SR144528 
> 10 PM 
437 
5.6 
0.6 
>1786 
728.3 
Ross et al., 1999 
Rinaldi-Carmona et al., 
1998 
 
Table1.5: The Ki values at the CB1 and CB2 receptors of the diarylpyrazole 
cannabinoid receptor antagonists/inverse agonists SR141716A and SR144528. 
 
 
Endocannabinoid Derivatives 
Since the discovery of endogenous cannabinoids, numerous analogues have been 
synthesized although few are as potent as the leading compounds from the other 
classes of cannabinoids described above. Endocannabinoid analogues can be 
divided in to two main classes: those that are head group analogues of anandamide 
or 2-AG (i.e. where the ethanolamide/glycerol substituent is altered) and those 
that have variations in the fatty carbon chain. The first endocannabinoid analogues 
were head group analogues and perhaps the best known is (R)-methanandamide 
(Abadji et al., 1994). This compound is identical to anandamide except for a 
methyl group at the 1’ carbon, that increases its potency approximately four-fold 
compared to its parent compound and confers a considerable degree of resistance 
to enzymatic hydrolysis. (R)-Methanandamide, like anandamide, also proved to be 
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selective for the CB1 receptor with a CB1/CB2 Ki ratio of 0.02 (Khanolkar et al., 
1996). Other notable head group analogues include fluoroanandamide (Showalter 
et al., 1996), chloroanandamide (Lin et al., 1998), N-propyl-D,D-
dimethylarachidonyl amide (PDMAA), N-propyl arachidonyl amide (PAA) and 
N-propyl-D-methylarachidonyl amide (PMAA) (Sheskin et al., 1997). The Ki 
values of these compounds demonstrate that the hydroxyl on the ethanolamide 
group of anandamide is not required for cannabinoid receptor affinity and, without 
it, these compounds are more potent than anandamide. 
The endocannabinoid analogues with an altered carbon chain are also more potent 
than the parent endocannabinoids. Dimethylheptyl anandamide, where the last 
five carbons of the carbon chain are replaced with a dimethylheptyl group (as is 
present in the most potent classical and non-classical cannabinoids) has an affinity 
for the CB1 receptor than is an order of magnitude higher than anandamide. This 
is also evident in the isolated mouse vas deferens assay and the mouse tetrad of in 
vivo assays where the EC50 and ED50 values (the effective concentration and dose 
required to achieve 50 % of the maximal response) are also reduced compared to 
anandamide (Ryan et al., 1997; Seltzman et al., 1997). The structures and Ki 
values of endocannabinoid analogues are summarized in figure 1.13 and table 
1.6.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13: The structures of anandamide, 2-AG and some of the most 
significant synthetic endogenous cannabinoid analogues. 
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CB1 Ki 
(nM) 
 
Compound 
N
o 
PM
SF
 
PM
SF
 
C
B2
 K
i (n
M
)b  
C
B1
/C
B2
 
R
at
io
 
 
Reference 
Anandamide 
N.D. 
N.D. 
5810 
89 
78 
61.0 
371 
1926 
1930 
0.24 
0.04 
0.03 
Showalter et al., 1996 
Khanolkar et al., 1996 
Lin et al., 1998 
2-AG N.D. 58.3 145 0.40 Ben-Shabat et al., 1998 
(R)-Meth- 
anandamide 
N.D. 
28.3 
20 
17.9 
815 
868 
0.02 
0.02 
Khanolkar et al., 1996 
Lin et al., 1998 
Fluoroanandamide 
N.D. 
4640
8.6 
26.7 
324 
908 
0.03 
0.03 
Showalter et al., 1996 
Lin et al., 1998 
Chloroanandamide 3400 5.29 195 0.03 Lin et al., 1998 
PDMAA 6.9a N.D. N.D. - Sheskin et al., 1997 
PMAA 7.4a N.D. N.D. - Sheskin et al., 1997 
PAA 11.7a N.D. N.D. - Sheskin et al., 1997 
Dimethylheptyl 
anandamide 
7.0 
N.D. 
N.D. 
1.9 
N.D. 
N.D. 
- 
- 
Ryan et al., 1997 
Seltzman et al., 1997 
 
 
Table 1.6: The Ki values at the CB1 and CB2 receptors of some of the 
endocannabinoid analogues. a. The centrifugation binding assay used to obtain 
these values is not affected by PMSF. b. PMSF not required as CB2 Ki values are 
obtained using transfected cells or spleen membranes where FAAH is not present. 
N.D. Not determined. 
 
 
1.7.2 Synthetic Inhibitors of Anandamide Uptake 
To date, the only selective inhibitor of cellular anandamide uptake is the synthetic 
fatty acid amide, AM404 (figure 1.14). This compound competitively inhibits 
anandamide uptake in rat cortical neurones and astrocytes with IC50 values of 1 
and 5 PM, respectively. AM404’s specificity for the anandamide transporter was 
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demonstrated by its low affinity for the CB1 receptor and failure to inhibit 
anandamide hydrolysis (Beltramo et al., 1997). The competitive nature of the 
AM404 inhibition of anandamide uptake suggested that this compound is a 
substrate of the transporter and this was confirmed using [3H]-AM404 (Piomelli et 
al., 1999). 
 
 
 
 
 
Figure 1.14: The structure of AM404, a selective inhibitor of the anandamide 
transporter.  
 
Since most anandamide analogues are substrates for the anandamide transporter, 
the endocannabinoid analogues described in the previous section are substrates for 
the transport mechanism and compete with anandamide, reducing its rate of 
uptake. This means that these compounds, including the endocannabinoids 
themselves, have a dual cannabimimetic action, binding to the cannabinoid 
receptors and increasing extracellular endocannabinoid levels by inhibiting 
uptake. The structures and IC50 values of some of the endocannabinoid analogues 
are shown in table 1.7. 
 
1.7.3 Synthetic FAAH Inhibitors 
As described in section 1.5, FAAH is a potential therapeutic target as its 
inhibition results in an increased level of endocannabinoids as well as other 
biologically important molecules such as oleamide. A number of potent FAAH 
inhibitors have been developed and, like the uptake inhibitors, some bind to the 
cannabinoid receptors giving them dual cannabimimetic activity. In addition, as 
substrates of FAAH, endocannabinoids and their related fatty acid amides and 
esters compete at FAAH resulting in the “entourage effect” described earlier. 
Perhaps the most widely used FAAH inhibitor is methyl arachidonyl 
fluorophosphonate (MAFP), a potent, irreversible inhibitor with an IC50 in the low 
nanomolar range (Deutsch et al., 1997c). 
O
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H
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Compound IC50 (PM) 
R
O
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H
OH
 
15.1 
R
O
N
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O
NH2
 
9.0 
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O
O
OH
 
6.7 
R
O
N
H
OH
 
37.7 
R
O
N
H
OH
 
10.4 
R
O
N
H
OH
 
7.6 
R
O
N
OH
 
10.0 
 
Table 1.7: The structures and IC50 values of some anandamide transport inhibitors 
(Piomelli et al., 1999). 
 
MAFP also exhibits cannabimimetic activity by irreversibly binding to the CB1 
receptor with a higher affinity than anandamide. Although MAFP is an 
anandamide analogue with four cis double bonds, a recent publication has 
demonstrated that saturated methyl fluorophosphonate analogues are also potent 
inhibitors of FAAH (Martin et al., 2000). The most potent of the series had a 
saturated 12 carbon chain, inhibited FAAH with an IC50 of 3.0 nM and was a 
high-affinity CB1 ligand.  
Other potent FAAH inhibitors include the sulphonyl fluorides and the 
trifluoromethyl ketones. The most potent sulphonyl fluoride compounds are 
saturated fatty acid analogues and, like the methyl fluorophosphonates, have IC50 
values in the low nanomolar range (Deutsch et al., 1997b). The trifluoromethyl 
ketones are less potent than the methyl fluorophosphonates and sulphonyl 
Anandamide 
AM404 
Arachidonyl amide 
(R)-Methanandamide  
(S)-Methanandamide 
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fluorides. The most potent of these compounds possesses the oleic acid carbon 
chain, but saturated analogues have similar IC50 values (Boger et al., 1999). The 
most potent FAAH inhibitors to date, however, were only described recently. 
These D-keto N4 oxazolopyridine compounds possess IC50 values as low as 140 
pM and are analogues of oleamide (Boger et al., 2000). The structures and IC50 
values of synthetic FAAH inhibitors are summarized in table 1.8. 
 
Compound IC50 (nM) Reference 
P
O
OMe
F
 
 
2.5 
 
Deutsch et al., 1997c 
H3C(H2C)7-R 15.0 Martin et al., 2000 
H3C(H2C)11-R 3.0 Martin et al., 2000 
H3C(H2C)15-R 78.0 Martin et al., 2000 
H3C(H2C)17-R 48.0 Martin et al., 2000 
H3C(H2C)11-R1 3.0 Deutsch et al., 1997b 
H3C(H2C)13-R1 6.0 Deutsch et al., 1997b 
H3C(H2C)15-R1 7.0 Deutsch et al., 1997b 
H3C(H2C)17-R1 4.0 Deutsch et al., 1997b 
CF3
O
 
460 Boger et al., 1999 
H3C(H2C)8-R2 600 Boger et al., 1999 
H3C(H2C)16-R2 1200 Boger et al., 1999 
O
O
N
N 2.3 Boger et al., 2000 
O
O
N
N
 
0.57 
 
Boger et al., 2000 
O
O
N
N
0.14 
 
Boger et al., 2000 
 
 
 
Table 1.8: The structures and IC50 values of fatty acid amide hydrolase inhibitors. 
MAFP 
P
O
F
OMe S
O
O
F
O
CF3
R1 = R = R2 = 
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It can be seen from this section that there are a large number of structurally 
diverse cannabimimetic compounds. The next section describes some of the 
pharmacological effects of cannabinoids and the potential therapeutic applications 
of drugs that enhance or inhibit the endocannabinoid system. 
 
 
1.8 Pharmacological Effects and Therapeutic Potential of 
Cannabimimetic Compounds 
 
Cannabinoid receptor ligands and modulators of endocannabinoid metabolism 
have numerous pharmacological effects throughout the body. In the nervous 
system, most, but certainly not all, actions of cannabinoid agonists are due to their 
influence on the transmission of nerve impulses. An essential feature of 
neurotransmission is the influx of Ca2+ into the pre-synaptic terminal by the 
activation of voltage-gated calcium channels. This increase in the intracellular 
concentration of Ca2+ induces vesicles containing neurotransmitter molecules to 
fuse with the pre-synaptic membrane, releasing the neurotransmitter in to the 
synaptic cleft. Diffusion of the neurotransmitter across the synaptic cleft to the 
post-synaptic membrane and binding to the appropriate receptors induces 
depolarization of the post-synaptic membrane and propagation of the nerve 
impulse. As mentioned in section 1.2.3, cannabinoids inhibit several different 
voltage-gated calcium channels via the CB1 receptor, thus preventing calcium 
influx into the pre-synaptic terminal and subsequent neurotransmitter release and 
nerve transmission. Cannabinoids have been shown to inhibit the release of 
glutamate (Shen et al., 1996), dopamine (Schlicker et al., 1996; Burkey et al., 
1997), noradrenaline (Schlicker et al., 1996) and acetylcholine (López-Redondo et 
al., 1997; Carta et al., 1998) and this mechanism possibly underlies a majority of 
the observed acute effects of cannabinoids including analgesia, reduced locomotor 
activity and memory deficits. In the immune system, however, there are a number 
of mechanisms by which cannabinoids exert their effects. The following sections 
describe the most promising therapeutic targets for the use of cannabimimetic 
drugs, although there are many other pharmacological effects that have no direct 
clinical applications at present. 
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1.8.1 Pain 
Cannabis is well known for its analgesic properties and there are a number of 
synthetic cannabinoid receptor agonists such as CP-55,940 that rival the analgesic 
potency of morphine. The mechanisms for cannabinoid-induced analgesia are now 
being elucidated and it is becoming apparent that they involve cannabinoid 
receptors on central and peripheral neurones as well as interaction with the opioid 
system. The central analgesic effects of cannabinoids have been demonstrated in 
both the brain and spinal cord. In the brain, the periaqueductal gray (PAG) area is 
involved in the processing of pain, with the ventral PAG involved in the control of 
pain by endogenous opioid compounds. However, the mediators of analgesia in 
the lateral and dorsal PAG were unknown. When the tails of laboratory rats are 
exposed to thermal pain, the observed pain response is tail flicking. Walker and 
co-workers electrically stimulated the lateral and dorsal PAG of rats exposed to 
thermal pain and observed antinociception. This analgesic effect was concurrent 
with the release of anandamide from the PAG and was blocked by SR141716A, 
suggesting that activation of the CB1 receptor is involved in the modulation of 
pain in the PAG (Walker et al., 1999). In addition, when pain was induced in the 
hind paws by injection of formalin, anandamide release occurred in the dorsal and 
lateral PAG, implying that endocannabinoids are involved in pain suppression. 
Pain suppression by endogenous cannabinoids has also been demonstrated in the 
spinal cord. When peripheral inflammation was induced by injection of 
carrageenin into rat hind paws, spinally administered anandamide inhibited 
nociceptive transmission by spinal neurones. This inhibitory effect was blocked in 
the presence of SR141617A, indicating that this effect was mediated by CB1 
cannabinoid receptors (Harris et al., 2000). When SR141716A was administered 
to carrageenin-inflamed rats in the absence of anandamide, nociceptive responses 
were not affected. However, a previous study demonstrated that SR141716A, but 
not SR144528, facilitated nociceptive transmission in non-inflamed rats 
(Chapman, 1999). Together, these data suggest that endocannabinoids are 
involved in the tonic control of pain in the spinal cord by activation of CB1 
receptors but this endogenous spinal cannabinoid tone is reduced following 
carrageenin-induced inflammation. Whether this effect is due to a decrease in the 
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number of CB1 receptors or an increase in endocannabinoid degradation remains 
to be seen. 
 
In the periphery, one mechanism of pain control is the release of opioid peptides 
by immune cells. These peptides then bind to opioid receptors resulting in 
analgesia. It has been shown that there is also a peripheral regulation of pain 
response by endogenous cannabinoids. When pain is induced in rat hind paws by 
injection of formalin, there is an immediate pain response, peaking after about five 
minutes, followed by a sustained pain response which begins after ten to fifteen 
minutes. Co-injection of formalin and anandamide blocked the first phase of pain, 
but not the second phase, while WIN 55-212,2 and HU-210 blocked both phases 
(Calignano et al., 1998). The inability of anandamide to suppress the second phase 
of pain was thought to be due to its rapid inactivation as the hydrolysis-resistant 
analogue (R)-methanandamide also blocked both phases. This blockade of the 
pain response by cannabinoids was antagonized by SR141716A, but not by 
SR144528 or the opioid receptor antagonist naloxone, suggesting a CB1 receptor-
mediated mechanism. The peripheral nature of this effect was demonstrated by 
intra-venous and intra-peritoneal injection of anandamide. The antinociceptive 
effect of anandamide was reduced 100-fold by i.v. injection and totally abolished 
by i.p. administration. Furthermore, palmitoylethanolamide, which does not bind 
to the CB1 or CB2 receptors, blocked both phases of the pain response when co-
injected with formalin. This effect was abolished by SR144528 but not by 
SR141716A or naloxone, suggesting an interaction with CB2-like receptors on 
peripheral nerves. When equal amounts of anandamide and 
palmitoylethanolamide were co-injected with formalin, the antinociceptive effect 
was 100 times more pronounced than administration of each compound alone, 
implicating participation of both CB1 and CB2-like receptors in the control of 
peripheral pain. When SR141716A or SR144528 were co-administered with 
formalin, a hyperalgesic response was observed, suggesting that locally generated 
anandamide and palmitoylethanolamide play a role in controlling the initiation of 
pain. The hyperalgesic effect of SR141716A has also been observed by other 
researchers (Strangman et al., 1998). 
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In addition to cannabinoid regulation of pain that is independent of the opioid 
system, interaction between the two systems does occur. When '9-THC was 
administered daily to rats i.p. for five days, it was observed that mRNA levels of 
the opioid peptide precursors prodynorphin and proenkephalin were elevated in 
the spinal cord compared to animals treated with the vehicle (Corchero et al., 
1997). This has implications for combined cannabinoid and opioid drug therapies 
to control pain. A review of the interaction between the cannabinoid and opioid 
systems can be found elsewhere (Manzanares et al., 1999). 
In summary, it is now becoming apparent that endogenous cannabinoid 
compounds are involved in the control of pain initiation. The peripheral 
administration of cannabinoids or inhibitors of endocannabinoid uptake and 
hydrolysis has the potential of relieving pain without undesirable psychotropic 
effects. The involvement of CB2-like receptors also offers the possibility of 
specific agonists for these receptors, totally removing the potential for effects on 
the CNS. Indeed, the CB2-selective agonist HU-308 has been shown to be an 
analgesic in the formalin model of pain without causing any psychotropic effects, 
presumably by binding to CB2-like receptors (Hanus et al., 1999). In addition, the 
non-psychotropic cannabinoid CT-3 (figure 1.15) is currently undergoing 
development as a potent, orally active analgesic, although its exact mechanism of 
action is unknown (Dajani et al., 1999).  
  
 
 
 
 
 
 
Figure 1.15: The structure of CT-3, a non-psychotropic cannabinoid with 
analgesic and anti-inflammatory activity. 
 
1.8.2 Multiple Sclerosis 
Multiple sclerosis (MS) is an autoimmune disease of the CNS caused by 
progressive damage or destruction of the myelin sheath surrounding nerves in the 
O
OH
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brain and spinal cord. This demyelination results in the disruption of nerve 
transmission which is manifested by numerous symptoms including numbness, 
tremors, weakness, pain, seizures and paralysis. Anecdotal evidence has shown 
that cannabis can be effective at relieving the symptoms of MS where prescription 
drugs have failed, but it was only recently that the therapeutic potential of 
cannabinoids to alleviate the symptoms of MS was rationalized scientifically. One 
important study in this area investigated the effect of anandamide on astrocytes 
isolated from mice infected with Theiler’s murine encephalomyelitis virus 
(TMEV), a model of MS which results in immune-mediated demyelination. IL-6 
is a cytokine that has anti-inflammatory and immunosuppressive effects and has 
been shown to suppress demyelination in the TMEV model of MS. Anandamide 
was shown to induce IL-6 production by astrocytes infected with TMEV and this 
effect was potentiated by arachidonyl trifluoromethyl ketone, an inhibitor of 
FAAH. In addition, the specific CB1 receptor antagonist SR141716A attenuated 
the effect of anandamide on IL-6 production, suggesting that this effect is CB1 
receptor-mediated (Molina-Holgado et al., 1998). A more recent study has 
implicated both the CB1 and CB2 receptors in alleviating the symptoms of MS. 
Using mice with chronic relapsing experimental allergic encephalomyelitis 
(CREAE), a model of MS, cannabinoid compounds were shown to quantitatively 
reduce tremor and spasticity (Baker et al., 2000). The relative involvement of CB1 
and CB2 receptors in alleviating the symptoms of CREA appears complex. The 
CB1 receptor antagonist SR141716A and the CB2 receptor antagonist SR144528 
both inhibited the ability of WIN 55-212,2 to inhibit tremor but, when 
administered alone, the antagonists exhibited distinguishable effects. 
Administration of SR141716A to animals with mild spasticity, but no tremor, 
increased spasticity compared to control animals and also induced tremor. When 
SR144528 was administered alone, a small increase in spasticity was observed. 
However, when animals treated with SR141716A were subsequently given 
SR144528, the spasticity was even more pronounced than in those animals treated 
with SR141716A alone. The fact that administration of cannabinoid receptor 
antagonists by themselves worsens the symptoms of CREAE indicates that 
endogenous cannabinoids play a role in controlling the symptoms of this disease. 
These data also indicate that the CB1 receptor has a role in the control of tremor 
while both cannabinoid receptors are involved in the control of spasticity. This 
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may pave the way for the development of synthetic compounds to treat the 
symptoms of MS. Although the CB1 receptor appears dominant in regulating the 
tremor and spasticity of MS, drugs that act via the CB1 receptor would inevitably 
produce psychotropic effects. It may be possible to partially alleviate symptoms 
with CB2-selective agonists or by increasing the levels of endocannabinoids with 
anandamide uptake and FAAH inhibitors. This would obviously be preferable to 
the illegal use of cannabis by many MS sufferers that occurs at present. 
 
1.8.3 Neuroprotection  
Cannabinoids may have a therapeutic role to play in the prevention of neuronal 
death caused by oxygen or glucose depletion, common following stroke or heart 
attack. This mechanism of damage is thought to involve the release of the 
neurotransmitter L-glutamate and it is also known that activation of pre-synaptic 
CB1 receptors by cannabinoid agonists inhibits Ca2+
 
influx and subsequent L-
glutamate release in the hippocampus (Shen et al., 1996). Therefore, the 
hypothesis that cannabinoid compounds could exert neuroprotective effects was 
tested by Nagayama et al. (1999). Ischemia was induced in laboratory rats and the 
effect of WIN 55-212,2 on neuronal survival determined. When administered i.p. 
40 minutes before ischemia, WIN 55-212,2 dose-dependently increased neuronal 
survival compared to control animals although it appeared to become neurotoxic 
at the highest concentrations tested. This effect was antagonized by SR141716A 
which had no effect when administered alone, suggesting a CB1 receptor-
mediated mechanism of neuroprotection. However, in cultured cortical neurones, 
the neuroprotective effect of cannabinoids was not as straightforward. WIN 55-
212,2 and anandamide both protected cells from death caused by ischemia and 
hypoglycaemia, but '9-THC did not. Pre-treatment with SR141716A or 
SR144528 did not antagonize the neuroprotective effect, suggesting a mechanism 
that is independent of both cannabinoid receptors. Although there may be more 
than one mechanism responsible for the neuroprotective effects of cannabinoids, 
there is real therapeutic potential for cannabinoid use to improve the neurological 
outcome of patients that suffer stroke or cardiac arrest.  
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1.8.4 Septic Shock 
Septic shock is a condition that can be caused by bacterial infection, trauma and 
ischemia, inducing the production of the pro-inflammatory cytokine tumour 
necrosis factor D (TNFD). The heightened levels of TNFD result in fever, 
sickness, hypotension, stimulation of pituitary and stress hormones, haemorrhage 
of the GI tract and lungs and, ultimately, death. There are no drugs currently 
available that are effective in treating septic shock, but a synthetic cannabinoid 
compound is now undergoing phase II clinical trials for severe head injury. This 
compound, dexanabinol (HU-211) (figure 1.16), is an enantiomer of the potent 
synthetic cannabinoid HU-210, but is non-psychotropic and has no significant 
affinity for the cannabinoid receptors. When septic shock was induced in rodents 
by administration of the bacterial endotoxin lipopolysaccharide (LPS), HU-211 
rescued a high percentage of the animals from death. In vitro, it was demonstrated 
that HU-211 markedly decreased TNFD production by cells exposed to LPS, 
though the mechanism of its action are unclear (Gallily et al., 1997). Currently, it 
is not known if the effects of HU-211 are totally receptor-independent or if it is 
acting at an, as yet, undiscovered cannabinoid receptor. Nevertheless, HU-211 
may prove to be a very important drug for the treatment of septic shock, which is 
a major cause of mortality in intensive care units worldwide. 
 
 
 
 
 
 
 
Figure 1.16: The structure of HU-211, a non-psychotropic cannabinoid effective 
in the treatment of septic shock. 
 
1.8.5 Inflammation  
Another historical use of cannabis is the treatment of inflammation. It is now clear 
that there are a number of mechanisms by which cannabinoids exert their anti-
inflammatory effects, and these are predominantly due to activation of CB2 
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receptors. One of the first studies suggesting that CB2 receptors are involved in 
the anti-inflammatory actions of cannabinoids was performed with the murine T-
cell line EL4.IL-2. In untreated cells, cAMP causes the activation of protein 
kinase A which, in turn, activates specific transcription factors that subsequently 
induce the transcription of genes encoding the pro-inflammatory cytokine 
interleukin-2 (IL-2) which is involved in both humoral and cell-mediated immune 
response. When cells were pre-treated with '9-THC, forskolin-stimulated cAMP 
synthesis was inhibited and subsequent transcription and secretion of IL-2 was 
also decreased. This effect was concentration-dependent and, as Northern blotting 
showed the presence of the CB2 receptor but not CB1, was assumed to be 
mediated by CB2 (Condie et al., 1996). However, at the time of this study, the 
CB2 receptor antagonist SR144528 had not been developed and, therefore, the 
role of CB2 was only speculative. 
A further mechanism for the anti-inflammatory effects of cannabinoids was 
demonstrated in the macrophage cell line RAW 264.7. When these cells were 
exposed to LPS, there was an increase in the nuclear binding of the transcription 
factor NF-NB/Rel which resulted in an increase in expression of inducible nitric 
oxide synthase (iNOS). iNOS catalyses the synthesis of nitric oxide (NO) which is 
involved in the cytolytic function of macrophages. Pre-treatment of these cells 
with '9-THC inhibited the LPS-induced up-regulation of NO production by 
inhibition of the cAMP cascade (Jeon et al., 1996), thereby down-regulating T-
cell cytolytic activity. Again, this work was done before the development of a 
CB2 receptor antagonist and, although CB2 receptor mRNA, but not CB1 receptor 
mRNA, was detected in these cells, it can only be implied that CB2 receptor 
activation caused this suppression.  
Further work published before the development of a CB2 receptor antagonist 
investigated the effect of cannabinoid receptor ligands on pulmonary 
inflammation in mice. Inhalation of LPS caused a macrophage-mediated 
inflammatory response, apparent by massive recruitment of neutrophils and 
release of TNFD. Both '9-THC and WIN 55-212,2 reduced neutrophil recruitment 
and TNFD production with WIN 55-212,2 being more effective, consistent with 
its higher affinity for the CB2 receptor. The effects of anandamide and 
palmitoylethanolamide were not as pronounced. Anandamide reduced TNFD and 
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neutrophil recruitment only at the lowest concentration tested, while 
palmitoylethanolamide decreased TNFD only at the highest concentration and did 
not affect neutrophil levels (Berdyshev et al., 1998). This suggests that 
anandamide and palmitoylethanolamide act at different receptors and, considering 
its lack of affinity for the CB1 and CB2 receptors, palmitoylethanolamide possibly 
exerts this effect by interaction with CB2-like receptors. 
More recently, a pro-inflammatory effect of cannabinoids has been described 
using HL60 cells, a human promyelocytic cell line that expresses the CB2 
receptor, but not the CB1 receptor. In these cells, CP-55,940 was shown to up-
regulate the synthesis of the D-chemokine interleukin-8 (IL-8) and the E-
chemokine monocyte chemotactic protein-1 (MCP-1). Both IL-8 and MCP-1 are 
pro-inflammatory and have been detected in a number of conditions including 
asthma, rheumatoid arthritis and inflammatory bowl disease. The CP-55,940-
stimulated synthesis of these chemokines was abolished by pre-treatment with 
pertussis toxin, suggesting the involvement of a Gi/o-coupled GPCR, and 
antagonized by SR144528, implicating activation of CB2 or CB2-like receptors 
(Jbilo et al., 1999).   
Cannabinoids undoubtedly have anti-inflammatory properties but the full extent of 
their actions within the immune system remains to be elucidated. The CB2 
receptor is emerging as a target for anti-inflammatory drugs, and the recently 
described CB2-selective agonists are likely to be able to exert anti-inflammatory 
effects without the psychotropic affects of non-selective cannabinoids. Indeed, the 
synthetic cannabinoid HU-308 has been shown to be inactive at the CB1 receptor, 
yet has an anti-inflammatory effect due to its high affinity for the CB2 receptor 
(Hanus et al., 1999). This is also true for the orally active anti-inflammatory 
cannabinoid CT-3. This compound is non-psychotropic, although the exact 
mechanism of its anti-inflammatory action is unknown (Dajani et al., 1999). There 
is also the potential for the development of novel therapeutic strategies to reverse 
cannabinoid-induced production of IL-8 and MCP-1. If an inverse agonist could 
down-regulate these chemokines, it may find applications in autoimmune 
diseases. 
 
 
  
 47
1.8.6 Cancer 
It is now becoming apparent that both endogenous and exogenous cannabinoids 
possess anti-cancer activity through receptor-independent and receptor-mediated 
mechanisms. The first potential anti-cancer mechanism is the induction of 
apoptosis (programmed cell death) by a cannabinoid receptor-independent route. 
'9-THC has been shown to induce apoptosis in murine splenocytes and peritoneal 
macrophages by a dual mechanism involving two intracellular proteins (Zhu et al., 
1998). The first of these, caspase-1, is involved in the processing of interleukin-1E 
(IL-1E), a cytokine implicated in the induction of apoptosis, from immature IL-1E 
to mature IL-1E. '9-THC increased caspase-1 levels in these cell types, hence 
increasing IL-1E processing. The second protein is encoded by the gene Bcl-2 and 
is involved in suppression of apoptosis. '9-THC inhibited transcription of Bcl-2, 
thus attenuating the protection from apoptosis. However, from this evidence it is 
not clear whether these effects are mediated by cannabinoid receptors or not as the 
effects of cannabinoid receptor antagonists on '9-THC-induced apoptosis were 
not studied. However, another study has shown that '9-THC-induced apoptosis is 
unlikely to be due to activation of cannabinoid receptors. Using human prostate 
cancer (PC-3) cells, '9-THC was shown to induce apoptosis in a dose-dependent 
manner. However, the synthetic aminoalkylindole WIN 55-212,2, which is more 
potent and efficacious than '9-THC at both cannabinoid receptors, failed to induce 
apoptosis in PC-3 cells. Moreover, the CB1 receptor antagonist AM251 failed to 
antagonize the effects of '9-THC. Pre-treatment of the cells with pertussis toxin 
also had no effect on '9-THC-induced apoptosis, suggesting that GPCRs are not 
involved in this mechanism (Ruiz et al., 1999). 
There is also evidence that cannabinoids can exhibit anti-tumoural activity via 
cannabinoid receptors. An in vivo study to investigate the effect of cannabinoids 
on malignant gliomas in rats demonstrated that when '9-THC or WIN 55-212,2 
were injected directly in to the tumour, there was a significant reduction in the 
size of the tumour in comparison to rats injected with the vehicle (Galve-Roperh 
et al., 2000). WIN 55-212,2 was more effective than '9-THC and was active at 
lower doses (10 % of the '9-THC dose), consistent with the relative affinities of 
the two compounds for the cannabinoid receptors. In addition, '9-THC, WIN 55-
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212,2, CP-55,940 and HU-210 were all shown to induce apoptosis in cultured rat 
glioma C6 cells. When cannabinoid receptor antagonists were added to the assay 
system, neither the CB1-selective antagonist SR141716A nor the CB2-selective 
antagonist SR144528 attenuated the apoptotic effect when added alone. However, 
when the two antagonists were added together, the effect of the cannabinoid 
receptor agonists was reversed, suggesting a synergistic mechanism involving 
both cannabinoid receptors. Further investigations in to the mechanism of 
cannabinoid-induced apoptosis showed that accumulation of ceramide and 
activation of the extracellular signal-regulated kinase (ERK) cascade, both 
implicated in apoptosis, were induced by '9-THC. 
Further anti-tumoural actions of cannabinoids have been described in human 
breast cancer cells (HBCCs). In the EFM-19 and MCF-7 cell lines, anandamide, 
2-AG, (R)-methanandamide and HU-210 were all shown to inhibit proliferation in 
a concentration-dependent manner. This effect was not due to cell toxicity or 
apoptosis and was inhibited by the CB1 receptor antagonist SR141716A (De 
Petrocellis et al., 1998). Furthermore, EFM-19 cells were shown to synthesize 
both anandamide and oleamide and express FAAH. Both compounds inhibited 
proliferation of the cells with IC50 values of 2.1 and 11.3 PM, respectively, and 
when an ineffective concentration of oleamide was incubated with anandamide, 
the anti-proliferative effect of anandamide was enhanced. The effects of both 
compounds were attenuated by SR141716A, suggesting a CB1-dependent 
mechanism of action. These data also suggest that oleamide exerts its effects by 
inhibition of FAAH, thus increasing the amount of anandamide available to bind 
to the CB1 receptor (Bisogno et al., 1998). A more in-depth study has revealed the 
potential signalling mechanisms for the anti-proliferative action of anandamide in 
HBCCs. In these cells, prolactin and nerve growth factor (NGF) induce 
proliferation by activating the prolactin receptor (PRLr) and the high affinity trk 
NGF receptor, respectively. Anandamide was shown to down-regulate PRLr and 
trk NGF receptor expression in MCF-7 HBCCs, thereby inhibiting their 
proliferation. This effect was antagonized by the SR141716A, implicating 
activation of the CB1 receptor, and was caused by the inhibition of adenylate 
cyclase and activation of MAPK signalling (Melck et al., 1999a). Furthermore, 
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oleamide also potentiated the anti-proliferative effect of anandamide in these cells, 
again suggesting enhancement of activity via the inhibition of FAAH.  
The data described above show that cancer chemotherapy is a potential 
therapeutic application of cannabinoids and cannabimimetic compounds, although 
the exact cellular mechanisms of action still require full elucidation. As described 
previously, cannabinoids are also immunosuppressive and may affect the body’s 
defences against cancer, though many of the immunosuppressive effects appear to 
be mediated via the CB2 cannabinoid receptor. The anti-tumoural effects, 
however, are predominantly CB1 receptor-mediated and, therefore, CB1-selective 
cannabinoid agonists may prove to be effective anti-tumoural drugs. 
 
1.8.7 Schizophrenia 
The causes of schizophrenia are not well understood, but there is evidence to 
suggest that dysfunction of the endogenous cannabinoid system may be a 
causative factor. An example of this is the examination of visual illusionary 
perception in non-schizophrenic patients before and after intoxication with '9-
THC. It was found that '9-THC induced abnormalities in perception that were 
similar to those exhibited by schizophrenic patients, suggesting a role for the CB1 
receptor in this process (Emrich et al., 1997). More recently, it has been shown 
that levels of anandamide and palmitoylethanolamide are significantly higher in 
the cerebrospinal fluid of schizophrenics compared to non-schizophrenic subjects 
(Leweke et al., 1999). Although wider ranging studies must be performed to 
confirm this and to elucidate the mechanisms by which these compounds affect 
schizophrenia, CB1 antagonists may prove to be novel therapeutics in alleviating 
the symptoms of this condition. Indeed, the selective CB1 receptor antagonist 
SR141716A is currently undergoing phase IIa clinical trials as a potential 
treatment for schizophrenia (Kendall, 2000). 
 
1.8.8 Hypertension 
It is well established that cannabis causes a reduction in blood pressure and the 
mechanisms by which this occurs are now, at least partially, understood. It is now 
apparent that the endothelium of blood vessels is an important regulator of 
vascular tone and there are two major endogenous species implicated in this 
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process. The first, endothelium-derived relaxant factor (EDRF), has been 
identified as nitric oxide while the identity of the second species remains unclear. 
This species is known as the endothelium-derived hyperpolarizing factor (EDHF) 
and causes hyperpolarization or repolarization of the endothelium via the 
activation of K+ channels, resulting in vasodilation. Both NO and EDHF are 
released from the vasculature by treatment with the acetylcholine receptor agonist 
carbachol. However, when NO synthesis was blocked, carbachol caused dose-
dependent relaxations in the rat mesenteric arterial bed that were antagonized by 
SR141716A. This suggests that EDHF may act via CB1 receptors and, therefore, 
may be an endogenous cannabinoid (Randall et al., 1996). Furthermore, thin layer 
chromatography analysis of the effluent from perfused mesenteries that had been 
pre-incubated with [3H]-arachidonic acid revealed a compound that co-eluted with 
synthetic anandamide. The production of this compound was increased by 
carbachol treatment, suggesting that anandamide, or a very closely related 
compound, may be an EDHF. However, there is also evidence that suggest that 
anandamide is not an EDHF. Plane et al. (1997) demonstrated that anandamide 
caused smooth muscle relaxation in the rat mesenteric artery but this relaxation, 
and that caused by EDHF, was not inhibited by SR141716A nor mimicked by 
HU-210 or WIN 55-212,2. However, further work by Randall et al. (1997) 
comparing the pharmacology of anandamide and EDHF strengthened the 
hypothesis that anandamide is an EDHF. The anandamide-induced and EDHF-
mediated relaxations of the isolated rat mesentery were both blocked by high K+ 
and opposed by blockading K+ channels. Putative EDHF inhibitors also inhibited 
anandamide-induced and EDHF-mediated relaxation, showing that the two 
species have very similar pharmacological profiles. This apparent relationship 
between the EDHF and anandamide has also been demonstrated in the coronary 
vasculature of the rat (Randall & Kendall, 1997). 
Further evidence that anandamide may be an endogenous mediator of vascular 
tone was demonstrated using the anandamide uptake inhibitor AM404. Systemic 
blood pressure in anaesthetized guinea-pigs was decreased by anandamide and 
this effect was antagonized by SR141716A, implicating a CB1 receptor-dependent 
mechanism. The anandamide-mediated decrease in blood pressure was 
independent of the autonomic nervous system and significantly prolonged by the 
AM404, suggesting that the anandamide transporter is present in the vasculature 
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and is one mechanism by which the vasodilatory effects of anandamide are 
terminated (Calignano et al., 1997). However, evidence now suggests that, 
although anandamide causes dilation of the vasculature, it is unlikely to be an 
EDHF. In the rat mesenteric arterial bed, EDHF-mediated vasorelaxations were 
inhibited by the selective CB1 receptor antagonist LY320135 but were insensitive 
to SR141716A, SR144528 and AM630. In addition, anandamide-induced 
vasorelaxations were insensitive to LY320135, suggesting that anandamide is not 
an EDHF and that a CB1-like receptor, but not CB2 receptors, may have a role in 
EDHF-mediated vasorelaxations (Harris et al., 1999; Harris, unpublished data). 
Further evidence exists that EDHF acts at an, as yet, unidentified cannabinoid 
receptor. The non-psychotropic cannabinoid abnormal cannabidiol (figure 1.17) 
does not bind to the CB1 cannabinoid receptor but causes SR141716A-sensitive 
hypotension and vasodilation in mice. This compound also induces these effects in 
mice lacking the CB1 receptor or both the CB1 and CB2 receptors. In addition, 
the vasodilation caused by abnormal cannabidiol is not affected by blockade of 
NO and is abolished by removal of the endothelium (Járai et al., 1999). Together 
these data suggest that abnormal cannabidiol is an agonist of a CB1-like receptor 
located within the endothelium and induces NO-independent vasodilation in the 
mesentery, consistent with the release of an EDHF. 
 
 
 
 
 
 
Figure 1.17: The structure of abnormal cannabidiol, a non-psychotropic 
hypertensive compound. 
 
Finally, evidence is now emerging that suggests 2-AG may be an EDHF. When 
carbachol was applied to the rat aorta, 2-AG levels were found to be five times 
higher than in control experiments and, when the endothelium was removed, no 
change in 2-AG levels was measured. In addition, when exogenous 2-AG was 
administered the mean arterial blood pressure was significantly reduced 
(Mechoulam et al., 1998). Although further investigations are necessary to 
OH
OH
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determine the role of 2-AG in endothelium-dependent vasorelaxations, the CB1-
like receptor implicated in the actions of LY320135 and abnormal cannabidiol 
may be an endogenous 2-AG receptor.  
 
Thus, it appears that endogenous cannabinoids, and particularly 2-AG, play a role 
in the maintenance of vascular tone, possibly via an as yet undiscovered CB1-like 
receptor in the endothelium. Specific agonists for this receptor as well as 
inhibitors of endocannabinoid uptake and hydrolysis have real therapeutic 
potential as anti-hypertensive drugs. 
 
 
1.8.9 Summary  
The effects of cannabinoids and cannabimimetics described above show that there 
is great potential for drugs that activate the cannabinoid receptors or increase 
endocannabinoid signalling by inhibiting uptake or hydrolysis. The increasing 
evidence indicating the existence of distinct CB1-like and CB2-like receptors also 
provides the possibility that specific agonists or antagonists of these receptors 
could become clinically important in the future. This would be especially 
significant if the positive therapeutic potential of cannabimimetics can be 
uncoupled from undesirable psychoactive effects as has been observed for 
compounds such as HU-308 and CT-3. 
 
 
1.9 Aims and Objectives 
 
At the time this research was started, elucidation of the endogenous cannabinoid 
system was at a relatively early stage. Although the cannabinoid receptors and 
FAAH had been discovered, the anandamide transporter had yet to be described 
and there was no evidence of CB1- and CB2-like receptors. In addition, there 
were few selective ligands for either cannabinoid receptor and only one 
antagonist, SR141716A. Nevertheless, it was obvious that there was great 
therapeutic potential in modulators of endocannabinoid signalling. Therefore, the 
aim of this research was to develop cannabimimetic drugs that could act as 
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pharmacological tools or therapeutic agents by acting as cannabinoid receptor 
ligands, whether agonists or antagonists, or inhibitors of FAAH. The following 
chapter describes the design and synthesis of these compounds. Subsequent 
chapters describe the analysis of the effects of these compounds, if any, on 
endocannabinoid signalling, namely their ability to bind to the cannabinoid 
receptors and inhibit both anandamide uptake and fatty acid amide hydrolase. 
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Chapter 2: 
 
Chemical Synthesis 
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2.1 Introduction 
 
As part of a strategy to develop potential cannabimimetic agents, three classes of 
target compound were proposed. This chapter describes the rationale behind the 
development of these novel species and the methodologies employed for their 
synthesis.  
 
2.1.1 Aryl Ethanolamides 
Anandamide is the ethanolamide derivative of arachidonic acid. With this in mind, 
it was hypothesized that the ethanolamides of compounds that mimic arachidonic 
acid may display cannabimimetic activity. Aspirin (figure 2.1) is a non-steroidal 
anti-inflammatory drug that competes for binding to cyclooxygenase (COX) 
enzymes with arachidonic acid, the natural substrate of COX. Preliminary 
evidence from the University of Nottingham showed that, at a concentration of 30 
PM, aspirin ethanolamide displaced 23 % of specific [3H]-CP-55,940 binding to 
rat cerebellar membranes and, therefore, this compound possessed some affinity 
for the CB1 receptor (Millns, unpublished data). Computer modelling studies have 
shown that in order to bind to the CB1 receptor, the carbon chain of anandamide 
must be folded and that this folding is energetically favourable (Thomas et al., 
1996). Therefore, the affinity of aspirin ethanolamide for the CB1 receptor may be 
at least partly explained by the distribution of negative charge in its benzene ring 
mimicking the “pocket” of negative charge formed by the double bonds of 
anandamide on the folding of its carbon chain.  
In addition to this preliminary data, there is also evidence in the literature of drugs 
with actions that overlap between COX enzyme inhibition and the endogenous 
cannabinoid system. Firstly, the development of the aminoalkylindole pravadoline 
and related compounds as described in section 1.7.1 demonstrated that inhibitors 
of COX enzymes could bind to the CB1 cannabinoid receptor (Bell et al., 1991). 
Relatively minor structural alterations of these compounds abolished their COX 
inhibition while dramatically increasing their CB1 affinity (Dambra et al., 1992). 
More recently it has been shown that the NSAID ibuprofen (figure 2.1) and its 
related compounds inhibit FAAH in rat brain (Fowler et al., 1997a; Fowler et al., 
1997b), thereby exerting a cannabimimetic effect by increasing endogenous 
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cannabinoid levels. Moreover, this inhibition occurs at pharmacologically relevant 
concentrations with IC50 values between 50 and 650 PM.  
 
 
 
 
 
 
 
Figure 2.1: The structures of the NSAIDs aspirin and ibuprofen. 
 
Based on the preliminary binding data for aspirin ethanolamide and the hypothesis 
of an interaction between NSAIDs and their derivatives and endocannabinoid 
signalling, the synthesis of aryl ethanolamides (AEs) with the general structure 
shown in figure 2.2 was proposed.  
 
 
 
 
 
 
Figure 2.2: The general structure of potential aryl ethanolamide cannabimimetics. 
R1-R4 represent substituent groups. 
 
 
As nothing was known about the structural requirements for AE binding to 
cannabinoid receptors, if any, it was necessary to include some structural diversity 
in their synthesis in order to elucidate any structure-activity relationships. To 
achieve this, target compounds were designed using commercially available 
starting materials that provided diversity in the substituent groups on the benzene 
ring and the presence or absence of a “spacer” between the benzene ring and the 
ethanolamide group. The initial novel target compounds are shown in table 2.1. If 
any of these compounds mimicked anandamide by showing affinity for the 
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cannabinoid receptors, it would also be likely that they would act as substrates for 
the anandamide transporter and FAAH. Therefore, the aryl ethanolamides had the 
potential to exert cannabimimetic activity in three ways, namely activation of the 
cannabinoid receptors and elevation of endocannabinoid levels by acting as 
competitive inhibitors of endocannabinoid transport and hydrolysis.  
 
 
Compound R1 R2 R3 R4 
AE1 CH=CH H OH H 
AE2 CH=CH H H H 
AE3 - H H H 
AE4 CH2 H H H 
AE5 CH2-CH2 H H H 
AE6 CH-CH3 H H H 
AE7 CH2 3-OH H H 
AE8 - 3- CH3O H 5- CH3O 
AE9 - 3-Cl H H 
AE10 - 2- CH3O H 6- CH3O 
AE11 - 2- CH3O CH3O H 
AE12 CH-OH H H H 
AE13 CH2 H Ph H 
AE14 Naphthyl- - - - 
 
Table 2.1: Target aryl ethanolamide compounds. 
 
 
2.1.2 Phosphinic Acids 
Phosphinic acids are phosphorus-containing species based on the tetrahedral 
parent compound phosphinic acid. Phosphinic acid itself exists in equilibrium 
with phosphonous acid but, as shown in figure 2.2, due to the stability of the 
phosphoryl group, the equilibrium lies well to the left. 
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Figure 2.2: The structures and equilibrium between phosphinic acid and 
phosphonous acid. 
 
A therapeutically significant use of phosphinic acid derivatives is the inhibition of 
amidase-catalysed amide bond hydrolysis. This process proceeds via a tetrahedral 
transition state as depicted in figure 2.3 and, as the phosphinic acid moiety is 
itself tetrahedral, it can act as a stable mimic of this intermediate structure. If the 
amide bond of a natural enzyme substrate is replaced with a phosphinic acid 
moiety, the resulting compound can act as a transition state enzyme inhibitor, 
competing with the natural substrate at the active site (Bartlett & Kezer, 1984; 
Bartlett et al., 1990).  
 
 
 
 
 
 
Figure 2.3: Proposed mechanism of amide bond hydrolysis. 
 
It was proposed that the ability of phosphinic acids to act as transition state 
enzyme inhibitors could be used to develop cannabimimetic compounds that 
inhibit the ability of FAAH to hydrolyse endogenous cannabinoids. To this end, 
two classes of phosphinic acid, the phenyl- and alkylphosphinic acids, were 
designed. 
 
Phenylphosphinic Acid Derivatives 
The phenylphosphinic acid (PPA) template (see table 2.2) is based on that of aryl 
ethanolamides, with the amide bond replaced by the phosphinic acid moiety. 
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Since AEs are potential cannabinoid receptor ligands and may themselves 
competitively inhibit FAAH, the phosphinic acid moiety should confer resistance 
to FAAH, making these compounds more potent at both targets. In addition to the 
inclusion of the phosphinic acid group, the PPA compounds are structurally 
different to the aryl ethanolamides. A report in the literature, published after the 
completion of AE synthesis, demonstrated that the hydroxyl group of anandamide 
is not necessary for CB1 receptor affinity and, in fact, is slightly detrimental 
(Sheskin et al., 1997). It was also shown that anandamide analogues with N-alkyl 
groups including propyl, butyl, isopropyl and isobutyl have higher affinity for the 
CB1 receptor than the parent compound. For this reason, the target PPA 
compounds shown in table 2.2 include these alkyl substituents as well as the 
hydroxypropyl group which was designed as a direct mimic of anandamide itself. 
As nothing was known about the interactions, if any, of this type of species with 
the endogenous cannabinoid system, the synthesis of compounds PPA2, PPA5 and 
PPA7 was also attempted. If biologically active, the long alkyl chains should offer 
increased lipophilicity, which may be important for transport across biological 
membranes. 
 
 
 
 
 
 
Compound R 
PPA1 Butyl 
PPA 2 Decyl 
PPA 3 3-Hydroxypropyl 
PPA 4 Isobutyl 
PPA 5 Octadecyl 
PPA 6 Isopropyl 
PPA 7 Hexadecyl 
PPA8 Propyl 
 
Table 2.2: Target phenylphosphinic acid derivatives. 
P
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Alkylphosphinic Acid Derivatives 
The ultimate aim of alkylphosphinic acid synthesis was the development of 
anandamide analogues in which the amide bond is replaced with the phosphinic 
acid moiety. In theory, such compounds would mimic the ability of anandamide to 
bind to the cannabinoid receptors and act as substrates of the anandamide 
transporter. In addition, these compounds would be stable to hydrolysis and act as 
transition state FAAH inhibitors, thereby having a longer duration of action than 
anandamide in vivo and increasing endocannabinoid levels. However, in order to 
utilize commercially available starting materials and develop an effective 
synthetic methodology, it was decided that saturated alkylphosphinic acid 
compounds would be synthesized before incorporation of unsaturated carbon 
chains was attempted. The target alkylphosphinic acid compounds shown in table 
2.3 also have cannabimimetic potential, however. The di-substituted compound 
APA6, for example, is the alkylphosphinic acid analogue of 
palmitoylethanolamide, albeit lacking the hydroxyl group. As described 
previously, palmitoylethanolamide is now thought to act at peripheral CB2-like 
receptors and has been shown to be a substrate for FAAH, competing with 
anandamide (Tiger et al., 2000). Compounds such as APA6 that are analogous to 
endogenous fatty acid amides should, in theory, also compete for FAAH binding 
while being resistant to hydrolysis themselves. It was shown in section 1.7.3 that 
there are a number of existing saturated synthetic FAAH inhibitors, namely the 
sulphonyl fluorides, the trifluoromethyl ketones and the methyl 
fluorophosphonates. These compounds potently inhibit FAAH with IC50 values as 
low as 3 nM and, therefore, analogous alkylphosphinic acids have the potential to 
exhibit similar pharmacological effects with the added possibility of affinity for 
the cannabinoid receptors. 
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Compound R R’ 
APA1 Decyl H 
APA2 Hexadecyl H 
APA3 Octadecyl H 
APA4 Decyl Decyl 
APA5 Decyl Butyl 
APA6 Hexadecyl Butyl 
APA7 Octadecyl Butyl 
 
Table 2.3. Target alkylphosphinic acids. 
 
 
The remainder of this chapter describes the methodologies utilized to synthesize 
the three classes of potential cannabimimetics and the results that were obtained. 
 
 
2.2 Experimental Methods 
 
2.2.1 Aryl Ethanolamides 
A simple disconnection of the aryl ethanolamides showed that they could be 
synthesized by the reaction of the appropriate carboxylic acid with ethanolamine. 
To achieve this, it was necessary to activate the carboxylic acid, thereby making it 
susceptible to nucleophilic attack by the amine. Two different methodologies were 
employed for aryl ethanolamide synthesis and are described below. 
 
Acid Chloride Strategy 
A common method used to activate a carboxylic acid is to convert it to its acid 
chloride derivative. This species can then undergo attack by a nucleophile, in this 
case ethanolamine, to form a new amide bond (scheme 2.1). 
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Scheme 2.1: Acid chloride strategy of aryl ethanolamide synthesis. R = aryl. 
 
It was proposed that this activation step should be carried out by the reaction of 
the carboxylic acid with an excess of oxalyl chloride. The advantage of this 
method is that the oxalic acid by-product of the reaction decomposes to liberate 
carbon monoxide and carbon dioxide, thus driving the reaction forward. Hence, 
for these reactions, the carboxylic acid was dissolved in an appropriate solvent 
and stirred with a slight molar excess of oxalyl chloride for between 30 minutes 
and 3 hours, with the progress of the reaction periodically monitored by thin layer 
chromatography (TLC) for disappearance of the carboxylic acid starting material. 
Acid chlorides are sensitive to moisture, undergoing hydrolysis back to the 
carboxylic acid so, to counter this problem, glassware was oven-dried and dry 
solvents were used. In order to prevent atmospheric water affecting the reaction, 
either a silica guard tube or a dry, inert atmosphere was employed. A mechanism 
for this reaction is proposed in scheme 2.2. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.2. Proposed mechanism for the reaction of a carboxylic acid with oxalyl 
chloride. 
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After the initial reaction with oxalyl chloride, synthesis of the aryl ethanolamide 
was attempted by the addition of excess ethanolamine to the reaction mixture and 
stirring for between 20 minutes and 2 hours (scheme 2.3), again monitoring the 
reaction by TLC.  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.3: Proposed mechanism of the reaction of ethanolamine with an acid 
chloride. 
 
On completion of the reaction, the solution was washed with aqueous acid and 
base to remove basic and acidic impurities, respectively, and the crude product 
analysed by TLC and 1H nuclear magnetic resonance (NMR) spectroscopy. In 1H 
NMR spectra, ethanolamide protons appear as a quartet and an adjacent, 
downfield, triplet at approximately G 3.0 to 4.0 ppm. If these peaks were observed 
in the NMR spectrum, the crude product was purified by flash column 
chromatography. 
If a synthesis proved to be unsuccessful, it was likely that the acid chloride had 
not formed in the first step, possibly because due to the carboxylic acid not being 
a strong enough nucleophile to react effectively with oxalyl chloride. In an 
attempt to drive the reaction forwards, two different approaches were taken. The 
first was to simply increase the reaction time, while the second was the use of 
N,N-dimethylformamide (DMF) as a catalyst as shown in scheme 2.4. 
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Scheme 2.4: Proposed mechanism of DMF-catalysed acid chloride synthesis 
using oxalyl chloride. 
 
Another possible detrimental effect on the synthesis was the reaction of 
ethanolamine with unreacted oxalyl chloride. Although the excess of 
ethanolamine used should have “mopped up” the oxalyl chloride, it, along with 
the reaction solvent, was removed in vacuo in some syntheses to prevent 
unwanted side-reactions. The crude acid chloride residue was then redissolved in 
an appropriate solvent before addition of excess ethanolamine. 
 
 
Coupling Strategy 
An alternative method employed in amide bond formation is the use of coupling 
agents, so called because they couple a carboxylic acid and an amine together via 
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an intermediate that is more susceptible to electrophilic attack than the parent 
acid. Using a coupling agent, amide bond synthesis can occur in two ways. When 
a coupling agent is reacted with a carboxylic acid, an O-acyl urea is formed. The 
first possible route of amide bond synthesis is the direct reaction of an amine with 
this species. The alternative route involves a second carboxylic acid molecule 
reacting with the O-acyl urea to form a symmetric anhydride, which can then react 
with the amine to form an amide bond. Both routes are likely to occur to varying 
extents when using a coupling agent and are depicted in scheme 2.5. 
 
 
 
 
 
 
 
 
 
Scheme 2.5: Coupling strategy of aryl ethanolamide synthesis. 
 
For some compounds, where the oxalyl chloride method proved unsuccessful, this 
reaction was attempted with the coupling agent 1-(3-dimethylaminopropyl)-3-
ethycarbodiimide hydrochloride (EDC). A mechanism for this reaction is 
proposed in scheme 2.6.   
 
For these reactions, the carboxylic acid was dissolved in an appropriate solvent 
and stirred with an excess of EDC for between 5 minutes and 1 hour. Excess 
ethanolamine was then added to the reaction mixture and stirred for 30 minutes to 
19 hours. A silica guard tube was employed for the duration of the reactions, 
which were monitored by TLC. 
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Scheme 2.6: Mechanism of aryl ethanolamide synthesis using the coupling agent 
EDC. 
 
Precipitated by-products were filtered off, the solution washed with aqueous base 
and the crude product analysed by TLC and 1H NMR spectroscopy. If the 
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ethanolamide product was evident, the crude product was purified by flash column 
chromatography. 
 
A problem that can occur in reactions of this type is the formation of N-acylureas, 
which reduce the yield of the desired product. These species form by inter- or 
intramolecular rearrangements (scheme 2.7) which may be reduced by the 
introduction of a catalyst to the reaction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.7: Mechanisms of intra- and intermolecular N-acylurea formation when 
using coupling agents. 
 
Two catalysts, 1-hydroxybenzotriazole (HOBt) and 4-dimethylaminopyridine 
(DMAP), were employed in these reactions to reduce N-acylurea occurrence. 
These compounds react with the O-acylurea and symmetric anyhdride as soon as 
they form, thereby reducing the formation of the N-acylurea. The intermediates 
formed by these reactions are more susceptible to nucleophilic attack by 
ethanolamine than the anhydride itself and, thus, the reaction is also catalysed 
(schemes 2.8 and 2.9). 
 
 
 
Intramolecular
N-Acyl urea 
Intermolecular
R O
O
C
N
NH
C
NH
NH
R O
O O
R O
O
R N
CO
NH
 68
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.8: Mechanism of HOBt catalysis in the EDC coupling reaction. 
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Scheme 2.9: Mechanism of DMAP catalysis in the EDC coupling reaction. 
 
The results of both the acid chloride and coupling strategies for aryl ethanolamide 
synthesis are described in section 2.3.1. 
 
 
2.2.2 Phenylphosphinic Acids 
Until recently, the formation of phenylphosphinic acid derivatives was limited by 
the lack of a suitable methodology for their synthesis under mild conditions. 
However, Boyd and co-workers developed a flexible synthetic strategy in which 
phenylphosphinic acid is silylated in the presence of a base to bis(trimethylsilyl) 
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phenylphosphonite (BTSPP). This trivalent species can then undergo nucleophilic 
attack to form a new carbon-phosphorus bond when reacted with various 
electrophilic species (Boyd et al., 1996). In order to synthesize the PPA 
derivatives shown in table 2.2, BTSPP was generated in situ by stirring a solution 
of phenylphosphinic acid with diisopropylethylamine (DIPEA) and trimethylsilyl 
chloride (TMSCl) for up to 3 hours. BTSPP was then stirred with the appropriate 
alkyl iodide and the intermediate washed with aqueous acid to hydrolyse the silyl 
groups. The only exception to this was PPA3, where 3-bromopropan-1-ol was 
used instead of an alkyl iodide. DIPEA was used in preference to other bases as its 
steric bulk reduces the risk of side-reactions between the base and electrophile. 
Since BTSPP is pyrophoric, these reactions were performed under an inert 
atmosphere. The mechanism of this synthetic route is shown in scheme 2.10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.10: Mechanism of the synthesis of phenylphosphinic acid derivatives 
via the formation of BTSPP. R = alkyl, X = I or Br. 
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One problem encountered in the purification of phosphinic acids is that they 
interact with silica and, therefore, conventional chromatographic techniques can 
not be used. Because of this, it was important that the reactions were driven to 
completion in these syntheses. When a crude product was obtained, it was 
analysed by 1H and 31P NMR spectroscopy. In 1H NMR spectra, any remaining 
phenylphosphinic acid produced a distinctive P-H doublet between G 6.0 and G 9.0 
ppm with a large coupling constant of 500-600 Hz, and a single 31P peak at 
approximately G 25-30 ppm. Alkyl-substituted PPAs gave a single 31P peak at 
approximately G 40-50 ppm. If a phenylphosphinic acid peak was evident, the 
reaction had not reached completion and repeat reactions were performed in 
which reaction time and equivalents of reagents were altered to drive the reaction 
forwards. The results of the phenylphosphinic acid syntheses are described in 
section 2.3.2. 
 
2.2.3 Alkylphosphinic Acids 
Until recently, the most common method of phosphinic acid synthesis was the 
Arbuzov reaction. This reaction involves the nucleophilic displacement of an 
appropriate leaving group, usually a halide, from carbon by a substituted 
phosphonite ester, resulting in a phosphinate ester. As depicted in scheme 2.11, 
subsequent acidic hydrolysis of the ester forms the free phosphinic acid. 
 
 
 
 
 
 
 
 
 
 
Scheme 2.11: Phosphinic acid synthesis via the Arbuzov reaction. R, R1, R2 = 
alkyl, X = halide. 
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However, the Arbuzov reaction is limited by the restricted availability of 
phosphonite starting materials and the high temperatures of 120-160 qC that are 
required. These temperatures mean that the starting material, halide and product 
must be thermally stable to withstand these harsh conditions. Recently, however, a 
flexible methodology was developed for phosphinic acid synthesis under mild 
conditions (Boyd et al., 1990; Boyd et al., 1994). In this methodology, similar to 
that used in the synthesis of phenylphosphinic acid derivatives, ammonium 
phosphinate is reacted with hexamethyldisilazane (HMDS) to silylate the oxygen 
atoms and form the reactive, trivalent bis(trimethylsilyl)phosphonite (BTSP). 
Nucleophilic attack by BTSP on an alkyl halide results in the displacement of the 
halide ion and formation of a new carbon-phosphorus bond. 
 
In the synthesis of alkylphosphinic acid compounds, shown in scheme 2.12, 
ammonium phosphinate was heated with 1.1 equivalents of HMDS for 2-3 hours 
at 110-120 qC to generate BTSP, which was then stirred at room temperature with 
the appropriate alkyl iodide. For the synthesis of mono-substituted 
alkylphosphinic acids, the reaction was terminated at this step by washing with 
aqueous acid to hydrolyse the silyl groups. However, for the synthesis of di-
substituted alkylphosphinic acids, more HMDS was added to the reaction solution 
at this point. Instead of acting as a silylating agent, HMDS now acts as a hindered 
base to deprotonate the intermediate and allow nucleophilic attack at a second 
alkyl iodide. After stirring with the second iodide, the silyl groups were 
hydrolysed with aqueous acid to liberate the di-substituted product. As with 
BTSPP, BTSP is pyrophoric so the reactions were performed under an inert 
atmosphere. 
 
Alkylphosphinic acids, like the phenylphosphinic acids, could not be purified by 
normal silica chromatography, so these reactions needed to be driven as far as 
possible towards completion. In addition to the problem of reactions being 
incomplete, the major possible problem with mono-substituted alkylphosphinic 
acid synthesis was the reaction proceeding too far, resulting in unwanted di-
substitution. The possible problems in the synthesis of di-substituted species were 
more diverse, however. 
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Scheme 2.12: Mechanism of the synthesis of mono- and di-substituted 
alkylphosphinic acids via the formation of BTSP. 
 
In addition to remaining ammonium phosphinate and the presence of mono-
substituted product, the synthesis of the asymmetric compounds could result in 
both symmetric and asymmetric di-substitution. To ascertain the extent of 
reactions, products were analysed by NMR spectroscopy. In 31P NMR spectra, 
ammonium phosphinate appeared as a single peak at G 9-10 ppm, while mono- 
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and di-substituted APAs appeared as single peaks at G 39-42 ppm and G 61-64 
ppm, respectively. If undesirable phosphorus peaks were evident, the reaction 
times and reagent quantities were adjusted accordingly in an attempt to rectify the 
problem. Fortunately, since ammonium phosphinate is water soluble, small 
amounts could be removed by aqueous washing if it was observed in the spectra. 
The results of the alkylphosphinic acid syntheses are described in section 2.3.3. 
 
2.2.4 Physical Measurements 
The physical characteristics of the successfully synthesized novel target 
compounds were fully evaluated by melting point analysis, NMR spectroscopy, 
mass spectroscopy and elemental analysis. These data and general experimental 
methodologies are described in appendix A. Representative NMR and mass 
spectra are shown in appendix B. 
 
 
2.3 Results and Discussion 
 
2.3.1 Aryl Ethanolamides 
The synthesis of the target aryl ethanolamide compounds was largely unsuccessful 
despite numerous attempts with varied reaction conditions. Of the fourteen target 
compounds, only five were synthesized successfully.  
 
Acid Chloride Strategy 
The results obtained from reactions using the acid chloride strategy are 
summarized in table 2.4. It is evident from these results that there is no definitive 
set of conditions that can be used for aryl ethanolamide synthesis and the reaction 
must be tailored to the individual carboxylic acid starting materials. For instance, 
of the successful syntheses, two of the four compounds required DMF catalysis 
whereas AE5 was successful with or without the catalyst. AE3 and AE4 are 
structurally very similar to AE5 and AE6, but the former compounds were not 
successfully synthesized despite attempts using similar conditions to those that 
proved successful for the latter. The successful synthesis of compound AE9 with a 
relatively high yield can be easily explained. The chlorine atom on the benzene 
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ring has an electron withdrawing effect and, therefore, makes the carboxylic acid 
and subsequent acid chloride more susceptible to nucleophilic attack. On the other 
hand, the failure to synthesize the methoxy derivatives may be due to these groups 
having an electron donating effect, thereby making the acid chloride less 
susceptible to nucleophilic attack. A similar effect caused by the double bonds in 
AE1 and AE2 may be responsible for their failure. 
 
 
Coupling Strategy 
The results of reactions performed using the EDC coupling strategy are shown in 
table 2.5. Although this strategy was not explored as thoroughly as the acid 
chloride strategy, it is apparent that there is no pattern relating to the success of 
synthesis and conditions used. The only successful reaction, AE13, was performed 
using DMAP and stirring overnight. This reaction time resulted in only a slightly 
increased yield when compared to stirring for 4 hours. AE1 and AE2 were totally 
unsuccessful, presumably due to the double bond adjacent to the acid functionality 
affecting the acid chloride reactivity. AE3 and AE4 are the most structurally 
similar compounds to the successfully synthesized AE13 and would be expected 
to be synthesized successfully too. The use of catalysis in the attempted syntheses 
of AE3 proved to have no beneficial effect. The aryl ethanolamide was formed 
after stirring overnight with and without catalyst, but analysis by TLC showed 
there were numerous, close impurities meaning purification by flash column 
chromatography was not possible. This was also the case in the synthesis of AE4. 
As with the acid chloride strategy, the electron donating effect of the methoxy 
groups of AE8 were likely to be the reason for the failed synthesis. 
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Compound 
Oxalyl 
Chloride 
(Equiv.) 
 
Time1 
 
Ethanolamine 
(Equiv.) 
 
Time 
 
DMF2 
(Equiv.) 
 
Outcome3 
AE1 1.91 1 hra 5.46 20 1.28 c
AE1 1.53 2 hrs 3.27 ¾ hr 0 c
AE2 1.38 1 hr 2.95 1½ hrs 0 c
AE2 1.38 ½ hr 2.95 ½ hr cat. d
AE3 1.4 ¾ hra 2.84 ¾ hr 0 e
AE3 1.4 ¾ hr 2.84 ½ hr 1.59 e
AE3 1.4 1¾ hrsb 2.84 2 hrs 1.59 d
AE3 1.14 ½ hra 2.84 1¾ hrs 1.11 d
AE4 1.27 1½ 2.71 ½ hr 1.42 d
AE4 1.27 1½ 2.71 ½ hr 0 f
AE5 1.4 1½ 3.0 1½ hrs 0 g (26 %)
AE5 1.4 1 hra 3.0 1¼ hrs cat. e
AE5 1.4 1 hra,b 3.49 ¾ hr cat. g (45 %)
AE6 1.4 1½ 3.0 1¾ hrs 0 g (62 %)
AE7 1.42 ½ hr 3.03 ¾ hr 0 e
AE8 1.27 1 hr 3.03 ¾ hr 0 c
AE8 1.27 1¼ hrsb 3.03 2 hrs 0 h
AE9 1.46 ½ hr 3.64 2 hrs 0 c
AE9 1.09 ½ hra 3.12 1½ hrs 1.22 g (71 %)
AE10 1.27 1 hr 3.03 ½ hr 0 h
AE11 1.27 1 hr 3.03 ¾ hr 0 c
AE12 1.42 1 hr 3.03 ½ hr 0 e
AE14 1.3 ¾ hrb 4.3 ¾ hr 0 h
AE14 1.3 3 hrsb 2.78 1 hr cat. g (49 %)
 
1. a = Solvent removed prior to addition of ethanolamine, b = inert atmosphere. 2. cat. = Catalytic 
amount, typically 2 drops. 3. c = Crude product formed, but not the desired AE, d = minute trace of 
ethanolamide protons, e = no product, f = impurity remained after columning, g = successful 
synthesis and purification (overall % yield), h = “product” was the starting material. 
 
Table 2.4. Results of reactions using the acid chloride strategy. 
HO
R R R R R R R
OH
R R RRMeO
OMe Cl
OMe
OMe MeO OMe
R
OH
R
AE2 AE3
N
H
OH
O
AE4 AE5 AE6 AE7
AE8 AE9
AE1
AE10 AE11 AE12 AE14 R =
 77
 
 
 
 
Compound 
EDC 
(Equiv.) 
Time1 
 
Ethanolamine
(Equiv.) 
Time2 Catalyst3 
(Equiv.) 
Outcome4 
AE1 2.9 1hr 5.46 o/n 0 a
AE2 1.39 ½ hr 4.43 1½ hrs 0 a
AE2 1.19 10 1.48 o/n 0 b
AE3 1.27 ¾ hr 2.84 ½ hr 0 b
AE3 1.21 0a 1.62 ¾ hr H, 1.31 b
AE3 1.11 1½ hrs 1.22 2 hrs D, cat. b
AE3 1.21 5 mins 1.22 o/n 0 c
AE3 1.27 10 1.22 o/n 0 c
AE3 1.27 ¼ hr 1.27 o/n D, cat. c
AE4 1.21 2½ hrs 2.71 ¾ hr 0 d
AE4 1.21 40 1.36 o/n 0 c
AE8 1.20 0a 3.03 2 hrs H, 1.43 a
AE8 1.20 25 1.82 o/n 0 b
AE13 1.11 0a 1.38 4 hrs D, cat. e (42 %)
AE13 1.11 ¼ hr 2.12 o/n D, cat. e (53 %)
 
1. a = EDC and ethanolamine added together. 2. o/n = Overnight. 3. H = HOBt, D = DMAP, cat. = 
catalytic amount (micro spatula tip). 4. a = Crude product formed, but not the desired AE, b = no 
product, c = numerous spots on TLC of crude product. Too close to separate, d =  1H NMR showed 
only a minute trace of ethanolamide protons, e = successful synthesis and purification (overall % 
yield). 
 
Table 2.5. Results of reactions using the EDC coupling strategy. 
 
 
 
2.3.2 Phenylphosphinic Acids 
Optimisation of these reactions took some time to achieve. Initial studies involved 
the attempted synthesis of PPA1 and these results are summarized in table 2.6. 
The methodology of Boyd et al. (1994) suggested that BTSPP should be stirred 
with the appropriate electrophile for 12-24 hours so, in attempts 1 and 2, butyl 
iodide and BTSPP were stirred together for 20½ hours. Neither reaction proved to 
be successful although, as expected, using 1.0 equivalents resulted in the reaction 
going further towards completion than 0.5 equivalents. Increasing the reaction 
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time and iodide concentration in attempts 3 and 4 showed a promising shift 
towards the product, but starting material still remained. It was postulated that this 
was because all of the phenylphosphinic acid was not being converted to BTSPP 
so, in attempts 5 and 6, reaction time with DIPEA and TMSCl was increased to 3 
hours and in attempt 5, the iodide reaction was refluxed at 50 qC in order to 
attempt to drive the reaction forwards. The fact that appreciable amounts of 
phenylphosphinic acid were still present after these reactions indicated that the 
determining factor was iodide reaction time. Attempts 7 and 8 were run in parallel 
with reaction times of 65 and 153 hours, respectively. Attempt 7 went very close 
to completion with a small amount of phenylphosphinic acid remaining, while 
attempt 8 resulted in a single product peak at G 45.42 in the 31P NMR spectrum. 
With this result in mind, the remaining PPA derivatives were attempted by 
reacting phenylphosphinic acid (14.1 mmol) with DIPEA (31.0 mmol) and 
TMSCl (31.5 mmol) for 3 hours and the appropriate electrophile for 7 days or 
more. The results of these reactions are summarized in table 2.7. 
 
Although the experimental conditions resulted in the desired products and 
disappearance of phenylphosphinic acid, there were still two factors affecting 
product purity.  In the literature, Boyd et al. (1996) suggested that washing with 
2M hydrochloric acid was sufficient to hydrolyse the remaining TMS groups. 
However, 1H NMR spectra of the crude products often revealed a strong TMS 
peak at approximately G 0 ppm. To hydrolyse these groups effectively, the crude 
material was resuspended in wet methanol, stirred for 1½ to 2 hours and the 
solvent then removed in vacuo. 
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Attempt DIPEA  (Equiv.) 
TMSCl 
(Equiv.) 
Time 
(hrs) 
Iodide 
(Equiv.) 
Time 
(hrs) Outcome 
1 2.2 2.18 2  0.5 21½  Phenylphosphinic acid present in approximate ratio of 4:3 with 
product. 
2 2.2 2.18 2  1 21½  Phenylphosphinic acid present in approximate ratio of 1:2 with 
product. 
3 2.2 2.18 2¼  1.5 48  Phenylphosphinic acid present in approximate ratio of 1:5 with 
product.  
4 2.2 2.18 2¼  2.0 48  Phenylphosphinic acid present in approximate ratio of 1:7 with 
product. 
5 2.2 2.18 3  1.5 20½1 Appreciable amount of phenylphosphinic acid remaining. 
6 2.49 2.52 3  1.5 20¾  Appreciable amount of phenylphosphinic acid remaining. 
7 2.2 2.18 21/3 2.0 65  Near completion. 
8 2.2 2.18 21/3 2.0 153 
 
Reaction complete, but excess iodide present. Impurity removed 
with base/acid wash. 31P peak at G 45.42. 
 
1. Refluxed at 50 qC. 
 
Table 2.6: Results of attempted PPA1 syntheses.
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Compound
Electrophile 
(Equiv.) 
Time 
(hrs) Outcome
1 Overall % 
Yield 
31P NMR 
(G) 
PPA1 2.0 153 a 74 45.42 
PPA2 2.0 163  a 66 47.63 
PPA3 2.04 164  b - - 
PPA4 1.98 211½  a 21 47.49 
PPA5 1.16 163 a 63 48.34 
PPA6 1.14 185¾  c - - 
PPA7 1.49 167½  d - - 
PPA7 1.49 259½  a 79 48.60 
PPA8 1.17 164  d - - 
PPA8 1.17 284½  a 68 46.86 
 
1. a = Pure product by 1H and 31P NMR after base/acid wash, b = 1H and 31P NMR indicates no 
phosphorus-containing product, c = no product, d = some phenylphosphinic acid remaining. 
 
Table 2.7: Results of attempted phenylphosphinic acid syntheses. 
 
 
The second problem encountered was that of alkyl iodide remaining in the crude 
product, evident from an excess number of protons in the 1H NMR spectra. To 
solve this, a work up procedure was developed to remove any impurities from the 
product. After initial washing with hydrochloric acid to partly hydrolyse the TMS 
groups, this aqueous phase was removed and replaced with 1M sodium hydroxide 
solution. As the alkylphosphinic acid products were acidic in nature, they were 
extracted into the basic aqueous layer, leaving any organic impurities in the 
solvent, which was then discarded. The product was then liberated by addition of 
excess 2M hydrochloric acid and redissolved in clean solvent. This procedure 
effectively removed impurities and resulted in clean products. 
As can be seen from table 2.7, the attempted syntheses of PPA3 and PPA6 failed. 
The use of 3-bromo-1-propanol in the attempted synthesis of PPA3 may have 
been an important factor as alkyl bromides are less reactive than their 
corresponding iodide. In addition, there may have been competition between 
carbons 1 and 3 in the nucleophilic attack by BTSPP, although this does not 
explain the total lack of any form of “product”. A possible reason for the failure of 
PPA6 is the production of propene gas as proposed in scheme 2.13. This would 
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explain the lack of success in this synthesis although, as in the synthesis of PPA3, 
regenerated phenylphosphinic acid should have been evident in the NMR spectra. 
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Scheme 2.13: Proposed mechanism to explain the failure of PPA6 synthesis. 
 
 
2.3.3 Alkylphosphinic Acids     
As mentioned in section 2.2.3, the main problem in the synthesis of 
alkylphosphinic acids is optimising the reaction conditions to obtain the desired 
product without the formation of unwanted substitutions. This was especially 
problematical in the synthesis of asymmetric, di-substituted phosphinic acids 
where it was theoretically possible to obtain two types of mono-substituted 
product and two types of symmetrical, di-substituted product as well as the target 
compound. Therefore, determining the optimum reaction conditions was vital for 
successful APA synthesis. 
 
 
Mono-Substituted Alkylphosphinic Acids 
 
Decylphosphinic Acid (APA1):   
The initial attempts at mono-substituted APA synthesis were on target compound 
APA1. The results for this compound are summarized in table 2.8. As can be seen 
in attempts 1 to 3, increasing the iodide reaction time increased the amount of di-
substituted product formed. Attempts 4 to 6 were performed in order to compare 
the HMDS silylating method with the TMSCl method employed for 
phenylphosphinic acid syntheses. 
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Attempt Silylating 
Method1 
Time 
(hrs) 
Iodide 
(Equiv.
Time 
(hrs) Outcome
2
 
1 a 2½  0.90 20  
d. Approximate 15:1 ratio of 
product to ammonium 
phosphinate. Large TMS peak. 
2 a 3  0.90 92  
d,f. No ammonium 
phosphinate remaining. 
Approximate 12:1 ratio of 
product to di-substituted. 
3 a 3  0.86 162  
d. As above, but approximately 
8:1. 
4 b 3  0.82 46  
d,f. Approximate 3:1 ratio of 
desired product to ammonium 
phosphinate. 
5 c 3  0.82 47  
e. Similar to attempt 4, but 
some di-substitution. 
6 a 3  0.82 47  
e. As above, though less di-
substitution. 
 
1.  a = 1.10 equivalents of HMDS, b = 2.20 equivalents of DIPEA for 15 mins then 2.20 
equivalents of TMSCl, c = 2.20 equivalents of NEt3 for 15 mins then 2.20 equivalents of TMSCl. 
2. d = Purification by base/acid extraction, e = washed with 2M HCl, f = stirred with methanol for 
1½-2 hrs to hydrolyse TMS groups. 
 
Table 2.8: Results of attempted syntheses of decylphosphinc acid (APA1). 
 
The reduced iodide concentration and intermediate reaction time employed proved 
to be more successful, and the results show that in the TMSCl reactions, 
triethylamine (NEt3) is a more effective base than DIPEA. However, the HMDS 
method resulted in less di-substituted product and, despite the fact that synthesis 
of pure APA1 was not achieved, this method appeared to be the best route to 
mono-substituted APAs. 
 
Hexadecylphosphinic Acid (APA2): 
The results of attempted APA2 synthesis are shown in table 2.9. The first 
attempted synthesis was carried out using less iodide than in the APA1 syntheses 
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in order to prevent di-substitution occurring. This strategy proved successful, 
although the overall yield was quite low. Attempts were made to rectify this in 
subsequent reactions by optimising reaction conditions. Attempt 2 appears to be 
anomalous as the desired product was not formed, while changing to the TMSCl 
silylating method in attempt 3 produced the desired product, although a large 
amount of ammonium phosphinate remained.  
 
 
Attempt Silylating 
Method1 
Time 
(hrs) 
Iodide 
(Equiv.
Time 
(hrs) Outcome
2
 
1 a 2  0.75 22¾  
c. Pure product obtained with 
20 % overall yield. 
2 a 3½  0.8 311  
c. Oil formed and did not 
crystallize on refrigeration. 
3 b 3  0.8 44½  
d,e. Significant amounts of 
ammonium phosphinate 
remaining. Stirring overnight 
with water did not remove it. 
4 b 3  0.8 48  
d,e,f. Pure product obtained 
with 7 % overall yield. 
5 b 3  0.87 66  
d,e,g. Pure product obtained 
with 11 % overall yield. 
6 a 3  0.9 189  
d,e,g. Pure product obtained 
with 26 % overall yield. 
 
1.  a = 1.10 equivalents of HMDS, b = 2.20 equivalents of DIPEA for 15 mins then 2.20 
equivalents of TMSCl. 2. c = Purification by base/acid extraction, d = washed with 2M HCl, e = 
stirred with methanol for 1½-2 hrs to hydrolyse TMS groups, f = sodium salt purification method, 
g = ethyl acetate wash. 
 
Table 2.9: Results of attempted syntheses of hexadecylphosphinic acid (APA2). 
 
At this point, two different purification methods were attempted. In attempt 4, it 
was noticed that when performing the basic extraction (as described for the PPA 
derivatives) on hexadecylphosphinic acid, a thick, white precipitate formed. This 
was assumed to be the insoluble sodium salt, so the precipitate was filtered off, 
dissolved in methanol and acidified with excess 2 M hydrochloric acid to yield the 
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alkylphosphinic acid, also a thick, white precipitate. The product was then 
resuspended in dichloromethane, washed, dried and the solvent removed to yield 
the pure product. However, the yield was low so, in the final two reactions, an 
attempt was made to find a solvent in which the impurities were soluble and the 
product insoluble. Hexane appeared to be the most suitable solvent, so it was used 
to wash the crude product to yield the pure alkylphosphinic acid in higher yields. 
 
 
Octadecylphosphinic Acid (APA3):  
These reactions were performed in parallel with those for APA2 and the results 
are summarized in table 2.10. 
 
Attempt Silylating 
Method1 
Time 
(hrs) 
Iodide 
(Equiv.)
Time 
(hrs) Outcome
2
 
1 a 3½  0.75 92  
c. No phosphorus peak evident 
in 31P spectrum. 
2 a 3½  0.80 312  
c. Small product peak plus 
ammonium phosphinate. 
3 b 3  0.80 44½  
d,e. Ammonium phosphinate 
remaining after work up.  
4 b 3½  0.89 48  
d,e,f. Pure product obtained 
with 4 % overall yield. 
5 b 3  0.89 66  
d,e,g. Pure product obtained 
with 15 % overall yield. 
6 a 3  0.92 138  
d,e,g. Pure product obtained 
with 26 % overall yield. 
 
1.  a = 1.10 equivalents of HMDS, b = 2.20 equivalents of DIPEA for 15 mins then 2.20 
equivalents of TMSCl. 2. c = Purification by base/acid extraction, d = washed with 2M HCl, e = 
stirred with methanol for 1½-2 hrs to hydrolyse TMS groups, f = sodium salt purification method, 
g = ethyl acetate wash. 
 
Table 2.10: Results of attempted syntheses of octadecylphosphinic acid (APA3). 
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Di-Substituted Alkylphosphinic Acids 
Synthesis of these compounds proved more problematical than the mono-
substituted alkylphosphinic acids. The first compound attempted, APA4, was the 
most straightforward as it was symmetrical and, therefore, there was no danger of 
unwanted di-substitutions. The results for this analogue are shown in table 2.11. 
The first attempt, stirring with each addition of iodide overnight, as described in 
the literature, was unsuccessful with no di-substituted product evident in the 31P 
NMR spectrum and some remaining ammonium phosphinate. It was thought that 
deprotonation of the second intermediate was not occurring effectively so, to try 
and rectify this, the reaction time of the second addition of HMDS was increased. 
This led to a slight improvement with some di-substitution evident, so reaction 
times at all stages were increased, resulting in a greater ratio of di-substituted 
product to mono-substituted by-product. To try and increase this ratio further, the 
second iodide reaction time was almost doubled in attempt 4, leading to a much 
improved ratio in favour of the desired product. In the final attempt, the silylating 
time was increased and a longer reaction time also applied to the first iodide. 
Although mono-substituted product was still evident, this reaction was the most 
effective of the five attempts. 
Despite the failure to synthesize APA4, the asymmetrical phosphinic acid 
derivatives were attempted beginning with APA5, also shown in table 2.11. The 
first reaction employed standard literature conditions but with longer reaction 
times for the two iodides. This resulted in a much more successful ratio of di-
substituted to mono-substituted products than the previous attempts with APA4. 
This was likely to be caused by the deprotonation of the second intermediate 
species being easier to achieve in this reaction due to the reduced electron 
donating effect of the butyl group in comparison to the decyl group. Increasing the 
iodide reaction times further in the second attempt led to an almost complete 
conversion to the di-substituted product, although some mono-substitution 
remained. 
It was now evident that total di-substitution was unlikely to be achieved in this 
one-pot reaction due to the fine line between mono-alkylating the ammonium 
phosphinate in the first step and creating unwanted, symmetrical di-substitution. 
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Compound HMDS (Equiv.) 
Time 
(hrs) 
First 
Iodide 
(Equiv.) 
Time 
(hrs) 
Base Used1
(Equiv.) 
Time 
(hrs) 
Second 
Iodide 
(Equiv.) 
Time 
(hrs) Outcome 
APA4 1.01 2  1.01 21  a, 1.01 2  1.01 21  
No di-substituted product. Mostly mono-
substituted with some ammonium 
phosphinate. 
APA4 1.10 2  1.09 22  a, 1.10 2½  1.09 24  
Small amount of di-substitution. No starting 
material remaining, mostly mono-
substitution. 
APA4 1.10 2½  1.09 66  a, 1.10 3  1.09 44½  
Approximate 3:2 ratio of mono- to di-
substituted species.  
APA4 1.10 3  1.06 68  a, 1.10 2  1.06 83½  
Approximate 1:3 ratio of mono- to di-
substituted species. 
APA4 1.10 4  1.06 93  a, 1.03 2½  1.06 70  
Approximate 1:4 ratio of mono- to di-
substituted species. 
APA5 1.10 2¾  
Butyl, 
1.11 
44  b, 1.10 3¾  Decyl, 1.06 43  
Approximate 1:7 ratio of mono- to di-
substituted species. 
APA5 1.04 3  
Butyl, 
1.10 
68  a, 1.06 2  Decyl, 1.06 83½  
Almost complete reaction. Small amount of 
mono-substitution remaining. 
 
1. a = HMDS, b = DIPEA. 
Table 2.11: Results of attempted syntheses of APA4 and APA5. 
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For the final two asymmetrical di-substituted alkylphosphinic acids, APA6 and 
APA7, the one-pot method was initially attempted with mixed success. In an 
attempt to remove the possibility of unwanted side-reactions in the synthesis of 
APA6 and APA7, it was decided that a different approach would be taken. As 
described above, the mono-substituted compounds hexadecylphosphinic acid 
(APA2) and octadecylphosphinic acid (APA3) were successfully synthesized and 
purified. Using these compounds as starting materials for the synthesis of APA6 
and APA7 and an analogous method to that employed in the synthesis of 
phenylphosphinic acid derivatives, unwanted substitutions would not be possible. 
The results of the attempted syntheses of APA6 and APA7 are shown in table 
2.12. In an attempt to silylate heaxadecylphosphinic acid, the DIPEA/TMSCl 
method was employed followed by the reaction with excess butyl iodide. 
Although not as effective as the initial result with the one-pot synthesis, this 
method did appear promising. In order to improve the amount of target compound, 
the iodide concentration was doubled to 3.06 molar equivalents. However, the 
result was opposite to that expected and, even when the reaction was refluxed with 
2.04 equivalents, the outcome was not as favourable as the initial reaction. 
Similarly, the attempted synthesis of APA7 by this route was also only a limited 
success. Based on the large proportion of starting materials remaining, it was 
thought that the deprotonation of these compounds by DIPEA was not occurring 
effectively due to the electron donating power of the hexadecyl and octadecyl 
substituents. Unfortunately, due to time constraints, it was not possible to 
investigate the outcome of these reactions using stronger bases in the 
deprotonation step. 
 
2.4 Summary 
 
In summary, five aryl ethanolamide, six phenylphosphinic acid and two 
alkylphosphinic acid target compounds were successfully synthesized (see table 
2.13). These target compounds were subsequently analysed for any 
cannabimimetic effects and the following chapters describe their evaluation at the 
CB1 and CB2 cannabinoid receptors, the anandamide transporter and fatty acid 
amide hydrolase. 
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Compound Silylating Method1 
First 
Iodide 
(Equiv.) 
Time 
(hrs) 
Base Used2
(Equiv.) 
Time 
(hrs) 
Second 
Iodide 
(Equiv.) 
Time 
(hrs) Outcome 
APA6 a 
Butyl, 
1.05 
93  a, 1.10 2½ hrs 1.10 70  
No ammonium phosphinate remaining. 
Approximate 1:9 ratio of mono- to di-substituted 
product. 
APA6 b - - - - 1.53 141  
Approximate 1:2 ratio of mono- to di-substituted 
product. 
APA6 b - - - - 3.06 143  
Approximate 13:1 ratio of mono- to di-substituted 
product. 
APA6 b - - - - 2.04 1393 
Approximate 1:1 ratio of mono- to di-substituted 
product. 
APA7 a 
Butyl, 
1.09 
117  b, 1.05 3½ hrs 1.10 168  
No phosphorus peak in 31P NMR spectrum. 
APA7 b - - - - 2.80 143  
Approximate 6:1 ratio of mono- to di-substituted 
product. 
 
1. a = 1.10 equivalents of HMDS at 110-120 qC for 3½ to 4 hours, b = DIPEA for 15 mins then TMSCl for 3 hrs using hexadecyl- or 
octadecylphosphinic acid as starting material. 2. a = HMDS, b = DIPEA. 3. Refluxed at 40 qC. 
 
Table 2.12: Results of attempted syntheses of APA6 and APA7. 
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Compound Structure Yield (%) 
AE5 
 
 
45 
AE6 
 
 
62 
AE9 
 
 
 
71 
AE13 
 
 
 
49 
AE14 
 
 
53 
PPA1  74 
PPA2  66 
PPA4  21 
PPA5  63 
PPA7  79 
PPA8  68 
APA2  26 
APA3  26 
 
 
 
 
Table 2.13: Summary of the successfully synthesized target compounds. 
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Chapter 3: 
 
CB1 Receptor Binding Studies 
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3.1 Introduction 
 
Radioligand binding assays have proved invaluable in the study of receptors. 
Competition assays are the most widely used of the radioligand binding 
techniques and enable the affinity of a drug for a receptor to be determined as well 
as the elucidation of receptor number and the kinetics of ligand-receptor 
interactions. Radioligand binding also enables the measurement of receptor 
activation upon drug binding and the accurate determination of receptor 
distribution within different tissues. In order to investigate the ability of the novel 
aryl ethanolamide and phosphinic acid compounds to bind to and activate the CB1 
receptor, two different radioligand binding assays were employed. 
 
3.1.1 Competition Assays 
Competition assays, sometimes referred to as displacement assays, are so called 
because they measure the ability of an unlabelled compound to compete for a 
binding site occupied by radiolabelled ligand. Radioligands bind specifically to 
receptors and non-specifically to other proteins and components of the assay 
system, so a means of determining the specific binding is required. This is 
achieved by incubating the radioligand and a cell or tissue preparation containing 
the receptor of interest with a high concentration of an unlabelled receptor ligand, 
thus displacing the specifically bound radioligand. The radioactivity of the 
remaining, non-specifically bound ligand can then be measured and specific 
binding calculated by subtracting this from the radioactivity in the absence of 
competing ligand. This type of assay was used to determine whether the aryl 
ethanolamide and phosphinic acid test compounds displayed affinity for the CB1 
receptor by displacing radiolabelled cannabinoid receptor ligands. 
 
3.1.2 GTP-J-S Binding Assays 
As shown in figure 1.2, when a G protein-coupled receptor is in its active state, 
GTP is bound to its GD subunit and, subsequently, signalling is terminated by 
hydrolysis of GTP to GDP by an inherent GTPase activity. GTP-J-S is a 
hydrolysis-resistant synthetic analogue of GTP. Therefore, when a GPCR is 
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activated by agonist binding in the presence of GTP-J-S, it displaces GDP and the 
G protein is persistently activated. To measure the extent of GPCR activation by a 
compound, [35S]-GTP-J-S binding assays can be used. The extent of receptor 
activation is determined by the difference between basal [35S]-GTP-J-S binding 
and binding in the presence of the compound. Non-specific binding of [35S]-GTP-
J-S is determined as described for competition assays, using a saturating 
concentration of unlabelled GTP-J-S. It was decided to investigate the effects of 
the test compounds on [35S]-GTP-J-S binding to brain membranes for two 
reasons. First, if any of the compounds displayed affinity for the CB1 receptor, the 
[35S]-GTP-J-S assay would indicate whether they were receptor agonists or 
antagonists. Second, if the compounds did not display CB1 receptor affinity, the 
[35S]-GTP-J-S assay would indicate whether they activated any other GPCRs in 
the brain. 
 
 
3.2 Experimental Methods 
 
3.2.1 Competition Assays 
Cultured cells transfected with CB1 are often used in cannabinoid research but, 
since the CB1 receptor is highly expressed in the CNS, membrane homogenates 
from rat cerebellum or whole brain were used in this work. This section describes 
the preparation of these tissues and their use in competition assays to investigate 
the affinity, if any, of the test compounds for the CB1 receptor. 
 
Membrane Preparation: 
Frozen cerebella or whole brains taken from male Wistar or hooded Lister rats 
were thawed, weighed and homogenized in 10 volumes of ice-cold buffer (50 mM 
Tris; pH 7.0) using a Polytron homogenizer. The homogenate was centrifuged at 
30,000g at 4 qC for 10 minutes, the supernatant layer was discarded and the pellet 
manually re-homogenized in ice-cold buffer using a glass/teflon homogenizer. 
The centrifugation and re-homogenization procedure was repeated twice more and 
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the final membrane pellet resuspended in 10 volumes of ice-cold buffer. Aliquots 
of the membrane homogenate were frozen at -20qC until required. 
Competition Assay Procedure: 
The assay procedure described below, a slight adaptation of that described by 
Compton et al. (1993), was used routinely within the School of Biomedical 
Sciences. In this procedure, the use of bovine serum albumin (BSA) in the buffers 
was necessary to overcome a particular problem encountered with the use of 
cannabinoids. These compounds are notoriously lipophilic and tend to adhere to 
glass and plastics. BSA acts as a carrier for the cannabinoids, keeping them in 
solution and reducing unwanted interactions with the assay vessel and membrane 
lipids. The assay protocol was initially verified by producing a concentration-
response curve for HU-210 displacement of [3H]-CP-55,940 from rat cerebellum 
membranes as follows: 
 
[3H]-CP-55,940 (180.0 Ci/mmol) was dissolved in drug buffer (50 mM Tris; pH 
7.0, 2 mM EDTA, 5 mM MgCl2, 5.0 mg/ml BSA) and the radioactivity of a 50 Pl 
sample measured using liquid scintillation spectroscopy. Dilutions were made to 
give 65,000 dpm per 50 Pl aliquot, resulting in an assay concentration of 
approximately 0.16 nM [3H]-CP-55,940. HU-210 was initially dissolved in 
ethanol to 200 times the desired assay concentration and then diluted 10 times in 
drug buffer. Aliquots (50 Pl) of radioligand solution were added to polystyrene 
test tubes followed by 50 Pl of blank buffer (drug buffer with 10 % v/v ethanol) or 
HU-210 solution and 850 Pl of assay buffer (50 mM Tris; pH 7.0, 2 mM EDTA, 5 
mM MgCl2, 0.2 mg/ml BSA). To initiate the assay, 50 Pl of membrane 
preparation were added to each tube, the tubes vortexed and incubated at 37 qC 
for 30 minutes. Membranes were harvested on to Whatman GF/B filter mats, pre-
soaked in drug buffer for 30 minutes, using wash buffer (50 mM Tris; pH 7.0, 2 
mM EDTA, 5 mM MgCl2, 0.5 mg/ml BSA) at 4 qC on a Brandel cell harvester. 
Individual filter circles were transferred to insert vials and 4 ml of Packard 
Emulsifier-Scintillator Plus added to each. After standing overnight, the vials 
were vortexed and radioactivity measured on an LKB Rackbeta liquid scintillation 
counter. Each assay condition was assayed in triplicate and non-specific binding 
determined in the presence of 10 PM HU-210.  
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Receptor Solubilization: 
As mentioned above, binding of radioligand to sites other than the receptor of 
interest is a problem encountered with this type of assay. In an attempt to increase 
the ratio of specific to non-specific radioligand binding, solubilization of the CB1 
receptor was attempted. In theory, this crude purification procedure should reduce 
the contribution of non-specific binding from the membrane preparation. 
Aliquots of rat cerebellum membrane homogenate were thawed, manually re-
homogenized using a glass/teflon homogenizer and kept on ice when not used. 
Solubilization of receptors was attempted by mixing 700 Pl of membrane 
preparation and 700 Pl of solubilization buffer (10 mM Tris; pH 7.0, 20 % w/v 
glycerol, 1 % w/v 3-[(3-Cholamidopropyl)dimethylammonio]-1-propane 
sulphonate (CHAPS)), vortexing three times over a 15 minute period and 
centrifuging at 36,000g at 4 qC for 15 minutes. The supernatant layer was 
removed and saved as soluble fraction 1 and the pellet re-suspended in 700 Pl of 
buffer (10 mM Tris; pH 7.0) by brief sonication using an MSE Soniprep 150 
ultrasonic disintegrator. Solubilization and centrifugation were repeated as 
described above and the supernatant saved as soluble fraction 2. 
 
To determine whether this solubilization procedure had been effective, the total 
and non-specific binding of 0.52 nM [3H]-SR 141716A, a selective CB1 receptor 
antagonist, (56.0 Ci/mmol) to untreated membranes and the two soluble fractions 
was compared. This was performed using the methodology described above with 
10 PM CP-55,940 to determine the non-specific binding of the radioligand. In 
addition, the effect of pre-soaking filter mats in drug buffer or polyethylenimine 
(PEI) solution (0.3 % w/v; pH 10.0) were compared, as PEI treatment has been 
shown to be effective for retention of soluble receptors, possibly due to an ionic 
charge effect (Bruns et al., 1983). All conditions were measured in triplicate and 
assays were repeated on a further occasion. 
 
Displacement of [3H]-CP-55,940 from CB1 by Test Compounds: 
The ability of the test compounds to bind to the CB1 receptor was assayed using 
the simple particulate homogenate and the protocol described above. [3H]-CP-
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55,940 was used as the radioligand, 10 PM HU-210 used to determine non-
specific binding and the test compounds were assayed at 1, 10 or 100 PM, 
depending on solubility. The compounds were initially dissolved in ethanol and 
diluted in drug buffer as previously described for HU-210. For these assays, 
whole rat brain membrane homogenate was used and each concentration of 
compound tested in triplicate using a minimum of two different tissue sources. 
 
Note: PPA1 became accidentally contaminated and was not used in the CB1 
receptor competition assay or the assays described hereafter. 
 
3.2.2 GTP-J-S Binding Assays 
As with the CB1 receptor displacement assay, the GTP-J-S binding assay was 
routinely used within the School of Biomedical Sciences. In this protocol, a slight 
variation of the method described by Traynor & Nahorski (1995), brain 
membranes were pre-treated with theophylline to reduce the basal level of [35S]-
GTP-J-S binding. The antagonist theophylline occupies the G protein-coupled 
adenosine A1 receptor (Bruns, 1981), which is activated by endogenous adenosine 
in the membrane homogenate. Pre-treatment with theophylline therefore reduces 
unwanted [35S]-GTP-J-S binding. However, unlike the CB1 displacement assays, 
the GTP-J-S binding assay protocol initially involved the use of BSA-free buffers.  
 
The assay was verified by producing a concentration response curve for HU-210-
stimulated [35S]-GTP-J-S binding to rat cerebella membranes. Assays with and 
without BSA in the buffers were performed in parallel to investigate whether 
including BSA would increase the signal to noise ratio. The tissue preparation and 
assay procedure are described below. 
 
Membrane Preparation: 
Frozen cerebella form male Wistar or hooded Lister rats were thawed, weighed 
and homogenized in 40 volumes of ice-cold buffer (50 mM Tris; pH 7.4, 100 mM 
NaCl, 10 mM MgCl2) using a Polytron homogenizer. The homogenate was 
centrifuged at 33,000g for 15 minutes at 4 qC, the supernatant discarded and the 
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pellet manually re-homogenized in ice-cold buffer using a glass/teflon 
homogenizer. The centrifugation and re-homogenization procedure was repeated 
twice more with the final pellet resuspended in 10 volumes of ice-cold buffer. 
Aliquots were frozen at -20 qC until required. 
 
General Assay Procedure: 
[35S]-GTP-J-S (20 mM, 1000 Ci/mmol) was diluted in assay buffer (50 mM Tris; 
pH 7.4, 100 mM NaCl, 10 mM MgCl2, ± 0.2 mg/ml BSA) to 893 nM. GTP-J-S 
was dissolved to 5 mM in distilled water and 50 Pl of this solution diluted to 500 
PM with 50 Pl of ethanol and 400 Pl of drug buffer (50 mM Tris; pH 7.4, 100 mM 
NaCl, 10 mM MgCl2, ± 5 mg/ml BSA). HU-210 was dissolved in ethanol to 500 
times the desired assay concentration and then diluted 10-fold in drug buffer. 
Aliquots of membrane homogenate were thawed and a membrane mixture was 
prepared with 150 Pl of theophylline solution (100 mM in distilled water), 150 Pl 
GDP solution (10 mM in distilled water) and 375 Pl membrane homogenate, made 
up to 15.6 ml with assay buffer. This mixture was vortexed and left to stand at 
room temperature for 20 minutes prior to its use in the binding assay. 
Aliquots of [35S]-GTP-J-S solution (460 Pl) were placed in polystyrene test tubes 
and 20 Pl of blank buffer (drug buffer with 10 % v/v ethanol), GTP-J-S solution 
or HU-210 solution were added in triplicate. The assay was initiated by adding 
520 Pl of membrane mixture and the tubes were vortexed and incubated at 25 qC 
for 45 minutes. Membranes were harvested on to Whatman GF/B filter mats and 
washed with distilled water at 4 qC on a Brandel cell harvester. Individual filter 
circles were then transferred to insert vials and 4 ml of Packard Emulsifier-
Scintillator Plus added to each. After standing overnight, the vials were vortexed 
and radioactivity measured on an LKB Rackbeta liquid scintillation counter. 
 
Comparison of GDP Concentrations: 
The preliminary results from the [35S]-GTP-J-S binding assays indicated that 
buffers containing BSA were the most effective, so they were adopted for the 
remaining assays. However, it was also decided to investigate the effect of GDP 
concentration on CP-55,940-stimulated binding of [35S]-GTP-J-S as this has 
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previously been shown to affect this assay (Griffin et al., 1998). Rat whole brain 
membranes were prepared in the same way as the cerebella membranes and the 
assay performed using GDP at 50 or 100 PM and CP-55,940 at concentrations 
between 5 nM and 1 PM. As the radioactivity present in the membranes in the 
initial assays was lower than expected, possibly due to radioactive decay, the 
assay concentration of [35S]-GTP-J-S was doubled to 0.82 PM and the amount of 
membrane homogenate used was also doubled. Otherwise, the procedure used was 
the same as described above. 
 
The Effect of Test Compounds on [35S]-GTP-J-S Binding to Brain Membranes: 
The comparison of GDP concentrations demonstrated that the use of 50 PM gave 
the higher binding above basal, so this concentration was used to assay the test 
compounds for their ability to stimulate [35S]-GTP-J-S binding to rat brain 
membranes. The assays were performed in the presence of 0.82 PM [35S]-GTP-J-S 
as described above, but with the following alterations. First, test compounds were 
initially diluted to 200 times the desired assay concentration in ethanol and then 
diluted 10-fold in drug buffer. Assay concentrations were 1, 10 or 100 PM with 50 
Pl of the solution added to the assay mixture. Second, CP-55,940 was used at 1 
PM as a positive control. Finally, the membrane mixture was prepared as 
described above, except that 600 Pl of brain membrane homogenate were used 
and 500 Pl of the mixture was added to each assay tube. All assays were 
performed using triplicate concentrations in two different brain membrane 
homogenates. 
 
 
3.3 Results and Discussion 
 
3.3.1 Competition Assays 
The initial competition assay of [3H]-CP-55,940 from rat cerebella membranes by 
HU-210 is represented in figure 3.1. These data clearly demonstrate that the assay 
procedure used was valid, with a concentration-dependent displacement of the 
radioligand by HU-210. From this data it was also possible to make a rough of 
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estimate of the Ki value of HU-210. Using the Cheng-Prusoff equation (Cheng & 
Prusoff, 1973), IC50 = Ki (1 + L/Kd) where L is the concentration of [3H]-CP-
55,940 and Kd is the dissociation constant of CP-55,940 at the CB1 receptor. The 
concentration of [3H]-CP-55,940 in the assay was 0.16 nM and, using GraphPad 
Prism, the IC50 of HU-210 was determined as 2.69 nM. From the literature, the Kd 
of CP-55,940 in rat cerebellum membranes was reported as 0.52 nM (Kearn et al., 
1999) and, hence, the Ki of HU-210 was calculated to be approximately 2.06 nM. 
Obviously this value was obtained from very limited experimental data but, in 
comparison to the Ki values for HU-210 summarized in table 1.2, is of the same 
order of magnitude suggesting that this assay was an effective measure of [3H]-
CP-55,940 displacement from the CB1 receptor. 
 
Figure 3.1: The displacement of specifically bound [3H]-CP-55,940 from rat 
cerebellum membranes by HU-210. Data are expressed as the mean r SEM of 
three determinations of displacement and were fitted by non-linear regression 
using GraphPad Prism. 
 
The results of the subsequent attempted solubilization of the CB1 receptor are 
shown in figure 3.2. As would be expected, there was very little difference 
between the specific and non-specific binding of [3H]-SR 141716A to the un-
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treated membranes when comparing buffer- and PEI-soaked filter mats. The 
amount of specifically bound radioligand was slightly higher using buffer-soaked 
filters with 31.1 ± 0.4 % specific binding compared to only 21.9 ± 1.6 % using 
PEI-soaked filters. When comparing the effect of filter pre-treatments on the 
soluble fractions, it is clear that the PEI-soaked filters retained a greater amount of 
the soluble protein. However, it is also apparent that the solubilization procedure 
greatly reduced the amount of bound radioligand and all but eliminated specific 
binding. This suggests that a large proportion of the membrane homogenate, 
including the CB1 receptor, was insoluble under these conditions. Repeated 
assays produced very similar results and, therefore, this approach was abandoned. 
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Figure 3.2: The effect of solubilization and filter pre-treatment on the total and 
non-specific binding of [3H]-SR141716A to rat cerebellum membranes. Data are 
expressed as the mean r SEM of three determinations of [3H]-SR141716A 
binding at each assay condition. 
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Using the original assay protocol with washed membranes, the affinity of the test 
compounds for the CB1 receptor was measured by their ability to displace [3H]-
CP-55,940. The results of these assays are shown in figures 3.3 and 3.4 and it is 
clear from these data that none of the compounds had a strong affinity for the CB1 
receptor, with high concentrations of compound being required to produce even a 
small percentage displacement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: The displacement of [3H]-CP-55,940 from rat brain membranes by 
aryl ethanolamide test compounds. Data are expressed as the mean ± SEM of 
three (AE5 and AE6) or four (AE9 and AE14) independent experiments. Each 
concentration of AE13 was assayed in two different membrane homogenates and 
the data is expressed as mean ± SEM of the triplicate concentrations from these 
single experiments. 
 
The aryl ethanolamides AE5 and AE6 proved to have the highest receptor affinity, 
displacing 30.4 and 30.2 % of the specifically bound radioligand, respectively, at 
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receptor can be roughly estimated using the Cheng-Prusoff equation. Assuming a 
Kd of 0.52 nM for CP-55,940 as described above, these two aryl ethanolamides 
have Ki values of >76.5 PM, very high when compared with the cannabinoid 
receptor ligands described in section 1.7.1. From this limited data it appears that, 
for the aryl ethanolamides, a single benzene ring and a spacer between it and the 
ethanolamide group confers greatest affinity. However, the large standard errors 
for most data prevent any firm conclusions being drawn for these compounds. 
 
 
 
Figure 3.4: The displacement of [3H]-CP-55,940 from rat brain membranes by 
phosphinic acid test compounds. Data are expressed as the mean ± range of two 
independent experiments (PPA2, PPA5, PPA7 and APA3) or the mean ± SEM of 
three independent experiments (PPA4, PPA8 and APA2). 
 
 
The phosphinic acids demonstrated even lower affinity for CB1 receptors than the 
aryl ethanolamides, with a maximum displacement of 18.1 % using PPA2 at 
100PM. The inactivity of the phosphinic acids is not entirely unexpected, 
however, as they were primarily designed as transition state enzyme inhibitors of 
FAAH rather than cannabinoid receptor ligands. 
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3.3.2 GTP-J-S Binding Assays 
The results of the initial assay to investigate the effect of including BSA in the 
buffers are shown in figure 3.5. It is apparent that with the use of BSA, the 
maximum percentage binding of [35S]-GTP-J-S above basal was greater than in 
the BSA-free assay. If BSA were acting as a carrier of HU-210 in the assay, the 
concentration-response curve should have been shifted to the left and the 
maximum [35S]-GTP-J-S binding should have been the same no matter which 
buffer was used. The fact that the curve was not shifted to the left, but that the 
maximum effect was increased is not easily explained. One possibility is that BSA 
is acting as an allosteric effector of the CB1 receptor G protein complex, 
increasing the overall signal compared to the BSA-free system. This would have 
important repercussions for cannabinoid research, as most in vitro work has been 
performed in the presence of BSA. The mechanism of this interaction requires 
further investigation. The increased [35S]-GTP-J-S binding afforded by BSA, 
however, led to the adoption of these assay conditions. 
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Figure 3.5: HU-210-stimulated [35S]-GTP-J-S binding to rat cerebellum 
membranes using normal (¹) and BSA (|) buffers. Data are expressed as the 
mean r SEM of three determinations of [35S]-GTP-J-S binding and were fitted by 
non-linear regression using GraphPad Prism. 
 103
The next investigation of assay conditions was the comparison of CP-55,940-
stimulated [35S]-GTP-J-S binding to rat whole brain membranes in the presence of 
50 or 100 PM GDP. These results are shown in figure 3.6. Again, it is clear that 
the concentration-response curve with 50 PM GDP displayed a greater maximum 
effect than that performed in the presence of 100 PM GDP. The curves, generated 
by GraphPad Prism, have maxima of 47.8 and 36.0 % [35S]-GTP-J-S binding 
above basal for 50 and 100 PM GDP, respectively. As the binding of guanine 
nucleotides to G proteins is a dynamic process, this result suggests that increasing 
the GDP concentration shifts the equilibrium in favour of GDP binding and, 
therefore, [35S]-GTP-J-S binding is reduced. For this reason, the lower 
concentration of GDP was used in subsequent assays as it was in the original 
assay. 
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Figure 3.6: CP-55,940-stimulated [35S]-GTP-J-S binding to rat brain membranes 
using 50 PM (¹) and 100 PM (|) GDP. Data are expressed as the mean r SEM 
of three determinations of [35S]-GTP-J-S binding and were fitted by non-linear 
regression using GraphPad Prism.  
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Since none of the test compounds showed any appreciable affinity for CB1 
receptors in the [3H]-CP-55,940 displacement assays, little effect would be 
expected for [35S]-GTP-J-S binding unless the compounds activate other GPCRs 
in the brain. The results of  [35S]-GTP-J-S binding assays with the test compounds 
are shown in figure 3.7. 
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Figure 3.7: The effect of test compounds on [35S]-GTP-J-S  binding to whole rat 
brain membranes. Data are expressed as the mean ± range of two independent 
experiments using different membrane homogenates, except the data for CP-
55,940 which is the mean ± SEM of thirteen assays. 
 
These results clearly show that, within error, none of the compounds activated 
GPCRs in rat brain or the CB1 receptor in particular. This latter point correlates 
with the result of the CB1 competition assays. Of course, the lack of increased 
[35S]-GTP-J-S binding compared to basal in the presence of these compounds 
does not rule out the possibility that they may be antagonists of other GPCRs. In 
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order to demonstrate this hypothetical effect, it would first be necessary to show 
that these compounds displace radioligands that are specific for other GPCRs 
from brain membranes. Due to the sheer number of such receptors, this would be a 
difficult and time-consuming task, well beyond the scope of this research.  
 
In summary, none of the target compounds showed any significant affinity for the 
CB1 cannabinoid receptor and did not activate any other GPCRs in the rat brain. 
The next chapter describes the development of a cannabinoid receptor competition 
assay in porcine spleen and the subsequent evaluation of the test compounds for 
CB2 receptor affinity. 
 
Chapter 4: 
 
CB2 Receptor Binding Studies 
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4.1 Introduction 
 
Most examples of CB2 binding assays in the literature have involved the use of 
transfected cells, while little work has been carried out on the native receptor. For 
this reason, porcine spleen membranes were used as a high density source of CB2 
receptors in order to develop CB2 receptor competition and agonist-stimulated 
GTP-J-S binding assays. After the initial characterization, these assays would then 
be used to examine the effects of the novel aryl ethanolamide and phosphinic acid 
test compounds. The spleen was chosen as it has been reported to have relatively 
high levels of CB2 expression (Galiègue et al., 1995), and pig spleen was chosen 
because of its size and, hence, the amount of tissue which could be readily 
prepared. The major problem in using spleen, or any other tissue preparation, 
instead of transfected cells is that the immune cells on which the CB2 receptor is 
expressed also express CB1 receptors (Schatz et al., 1997), albeit at much lower 
levels. Cannabinoid ligands will, therefore, bind to both receptors and the data 
produced will reflect overall cannabinoid binding, and not specifically CB2 
binding. For the test compounds, however, the effect of CB1 receptors should not 
be greatly relevant as none of the compounds tested had CB1 affinity and, 
therefore, any effects in these assays should be solely from CB2 receptors. The 
following section describes the preparation of porcine spleen membranes and their 
use in the development of the competition and GTP-J-S assays. 
 
4.2 Assay Development 
 
4.2.1 Competition Assays 
Membrane Preparation: 
Spleens from male or female Modern White hybrid pigs, less than 6 months old, 
were obtained from a local abattoir (G. Wood and Sons, Clipstone, Notts.). The 
tough, fibrous outer membrane was removed with forceps and the internal red 
pulp scraped out and placed in ice-cold buffer (50 mM Tris; pH 7.0, 2 mM EDTA, 
5 mM MgCl2). The tissue suspension was centrifuged at 2,000g at 4 qC for 10 
minutes, the supernatant was removed and the wet weight of tissue measured. The 
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tissue was then homogenized in 10 volumes of ice-cold buffer containing 10 % 
(w/v) sucrose using a Polytron homogenizer and the homogenate centrifuged at 
1,000g at 4 qC for 10 minutes. The supernatant was diluted with an equal volume 
of ice-cold, sucrose-free buffer and this mixture was then centrifuged at 33,000g 
at 4 qC for 15 minutes. The pellets were manually re-homogenized in ice-cold 
buffer using a glass/teflon homogenizer and the centrifugation and re-
homogenisation process was repeated twice more with the final re-
homogenisation in 40 volumes of buffer with respect to the original wet weight. 
Aliquots of the spleen membrane preparation were frozen at -20 qC until required. 
 
Preliminary Binding Assays: 
As the CB2 receptor density in the spleen membrane preparation was unknown, it 
was first necessary to determine the levels of total and non-specific binding using 
varying amounts of tissue in order to find the optimum conditions. The assay 
procedure was the same as that described for the CB1 competition assays, using 
0.18 nM [3H]-CP-55,940 as the radioligand and 10 PM HU-210 to determine non-
specific binding. Each determination of total and non-specific binding was 
performed in triplicate using 100 Pl of spleen membrane homogenate in a total 
assay volume of 1 ml. Where necessary, the tissue was diluted with buffer or 
concentrated by centrifugation at 9,000g at 4 qC for 5 minutes then re-suspension 
of the pellet in the appropriate volume of buffer. After incubation for 30 minutes 
at 37 qC, membranes were harvested as previously described using distilled water 
at 4 qC and the radioactivity then measured. As is evident from figure 4.1, 
increasing the tissue concentration resulted in an increase in the total binding of 
[3H]-CP-55,940 to the membranes. Similarly, an increase in non-specific binding 
would be expected but this was not evident. This resulted in a steady increase of 
specific binding peaking with 41.9 % specific binding in the 400 % concentrated 
tissue preparation. A possible reason for this was thought to be filter binding of 
the [3H]-CP-55,940. This potential problem is addressed below. 
Since specific cannabinoid binding to spleen membranes had been successfully 
demonstrated, the next assays performed in the assay development were 
concentration-response curves for CP-55,940 displacement of [3H]-CP-55,940. 
Duplicate assays were performed as above with triplicate concentrations of CP-
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55,940 and 100 Pl of 400 % spleen membrane homogenate. Non-specific binding 
was determined using 10 PM of the unlabelled ligand. The results of these 
experiments are shown in figure 4.2. 
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Figure 4.1: The effect of spleen membrane concentration on the binding of 
[3H]-CP-55,940. Data are expressed as the mean r SEM of three determinations of 
binding in the presence or absence of 10 PM CP-55,940. 
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 Figure 4.2: Displacement of [3H]-CP-55,940 from spleen membranes by 
CP-55,940. Data are expressed as the mean r SEM of three separate 
determinations of displacement for each concentration of CP-55,940. 
 
 
Although the displacement of [3H]-CP-55,940 did not reach 100 %, these assays 
clearly demonstrate a concentration-dependent displacement of the radioligand 
from porcine spleen membranes by CP-55,940. The possibility that the [3H]-CP-
55,940 was adhering to the filters was tested by examining the total and non-
specific “binding” in the absence of spleen membranes. It is apparent from figure 
4.3 that there was significant, albeit non-displaceable, binding of the radioligand 
to the filter mats and, in an attempt to rectify this, a centrifugation-based 
competition assay was performed to harvest the membranes. 
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Figure 4.3: The total and non-specific binding of [3H]-CP-55,940 in competition 
assays with and without spleen membranes. Data are expressed as the mean r 
SEM of three determinations of specific and non-specific binding in the presence 
or absence of spleen membranes. 
 
 
Centrifugation Assay: 
Assays were performed to determine total and non-specific binding of [3H]-CP-
55,940 to 0, 100, 200 and 400 % concentrations of spleen membrane homogenate, 
with 10 PM HU-210 to determine the non-specific binding. The procedure was 
performed in microcentrifuge tubes with triplicate determinations at each spleen 
concentration as described above. After incubation, the membranes were pelleted 
by centrifugation at 36,000g for 2 minutes at 4 qC to eliminate the use of filters. 
To remove free radioligand from the assay solution, the supernatant was aspirated 
and the pellets then washed with 1 ml of buffer (50 mM Tris; pH 7.0, 2 mM 
EDTA, 5 mM MgCl2). To digest the pellets, 50 Pl of aqueous NaOH solution (1 
M) was added to each before vortexing. The solutions were neutralized with 50 Pl 
of aqueous HCl solution (1 M) and 1 ml of scintillation fluid added to each tube. 
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After standing overnight, the tubes were vortexed and radioactivity was measured. 
As is shown in figure 4.4, this assay did not prove to be more advantageous than 
the filtration procedure. Despite the evidence of specific binding to the spleen 
homogenates, there was significant adherence of [3H]-CP-55,940 to the 
microcentrifuge tubes and this binding was displaceable by HU-210.  
 
In a further attempt to reduce unwanted binding of [3H]-CP-55,940, solubilization 
of the spleen membranes was performed. It was hoped that with CB2 being 
structurally dissimilar to CB1, the procedure would possibly be more successful 
than the previous attempts. This procedure was essentially the same as described 
for the CB1 receptor (section 3.2.1), except only one soluble fraction was 
obtained from the tissue. 
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Figure 4.4: The effect of spleen membrane concentration on the binding of 
[3H]-CP-55,940 in a centrifugation assay. Data are expressed as the mean r SEM 
of three determinations of specific and non-specific binding at each concentration 
of spleen membrane preparation. 
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Assays were performed to compare the binding of [3H]-CP-55,940 to 100 Pl of 
either untreated membrane homogenate, solubilized protein or a blank containing 
no tissue. The effect of pre-soaking filters in drug buffer and PEI solution was 
also examined and these results are shown  in figure 4.5. It is clear that there was 
significant binding of [3H]-CP-55,940 to both sets of filters and this binding was 
more than doubled in PEI-soaked filters compared to BSA-soaked. The fact that 
the non-specific “binding” in both blanks was greater than the total binding may 
be due to the high concentration of HU-210 employed displacing radioligand from 
the assay tube walls, therefore making more available to adhere to the filters. The 
level of [3H]-CP-55,940 binding to the filters makes it difficult to comment on the 
results from the membrane and soluble fraction assays with any confidence.   
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Figure 4.5: The effect of solubilization of spleen membranes and filter pre-
treatment on the total and non-specific binding of [3H]-CP-55,940. Data are 
expressed as the mean r SEM of three determinations of total and non-specific 
binding for each assay condition. 
 
PEI-soaked filters appeared to retain more membrane homogenate than BSA-
soaked filters. The soluble fractions, however, exhibited less specific binding of 
the radioligand than the un-treated membranes, suggesting that, as for CB1, CB2 
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was insoluble using these conditions. For this reason, attempts at solubilizing the 
CB2 receptor were abandoned at this point, as was the idea of pre-soaking filters 
in PEI as this seemed to promote non-specific [3H]-CP-55,940 filter binding. 
 
In this development procedure, membranes retained on filters had been rinsed 
with distilled water since this had been successful with the brain GTP-J-S binding 
assays. For the final assays in the development of the CB2 displacement assay, the 
use of cold water and wash buffer containing 0.5 mg/ml BSA to wash the 
membranes was compared. Assays were performed to investigate [3H]-CP-55,940 
binding with and without 100 Pl of un-diluted membrane homogenate as 
described above followed by harvesting on to Whatman GF/B filters, pre-soaked 
in drug buffer (containing 5 mg/ml BSA) for 30 minutes. 
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Figure 4.6: The effect of wash solution on the total and non-specific binding of 
[3H]-CP-55,940 to spleen membranes. Data are expressed as the mean r SEM of 
three determinations of total and non-specific binding for each assay condition. 
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It is evident from figure 4.6 that the use of wash buffer containing BSA caused a 
significant reduction in [3H]-CP-55,940 sticking to the filter mat and, in the 
presence of tissue, reduced non-specifically bound radioligand. Assuming that 
[3H]-CP-55,940 binds to the filter homogeneously, this effect should not 
detrimentally affect the outcome of binding assays. As a result of these initial 
assays, it was decided that centrifugation assays or solubilization of the tissue 
would not provide any advantage over the standard competition assay using a 
particulate membrane preparation. Investigation of cannabinoid and test 
compound binding to spleen membranes was, therefore, performed using 100 Pl 
of un-diluted membrane homogenate and the membranes then washed with BSA 
wash buffer at 4 qC as described for CB1 competition assays. 
 
4.2.2 GTP-J-S Binding Assay 
The GTP-J-S binding assay routinely used in the School of Biomedical Sciences 
had not been performed in spleen tissue, so some initial experiments were 
required to determine the optimum conditions. Total, non-specific and HU-210-
stimulated [35S]-GTP-J-S binding to spleen membranes was measured in triplicate 
using GDP concentrations of 12.5, 25, 50 and 100 PM. The procedure used was 
the same as that described for brain (section 3.2.2), with [35S]-GTP-J-S at an 
assay concentration of 0.45 PM and 250 Pl of spleen membrane homogenate used 
in the membrane mixture. HU-210 was used at 1 PM. The assay volume of 1 ml 
consisted of 480 Pl of [35S]-GTP-J-S solution, 20 Pl of either blank assay buffer, 
GTP-J-S solution or HU-210 solution and 500 Pl of membrane mixture.  
Figure 4.7 shows representative data from these experiments in comparison to a 
positive control of rat brain membranes using the same conditions. It is evident 
that, in the brain membranes, HU-210 caused an increase in [35S]-GTP-J-S 
binding. However, this was not observed in the porcine spleen membrane 
preparation, suggesting that the receptor density was simply too low for an 
effective GTP-J-S binding assay using this tissue. Previously published data 
investigating [3H]-CP-55,940 binding in peripheral tissues showed that, in the red 
pulp of the spleen, the specific binding of [3H]-CP-55,940 was 44 fmol/mg wet 
weight tissue compared to 143 fmol/mg in the brain (Lynn & Herkenham, 1994).  
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Figure 4.7: The effect of GDP concentration on HU-210-stimulated [35S]-GTP-J-
S binding to porcine spleen (A) and rat brain membranes (B). Data are expressed 
as the mean r SEM of three determinations of total, non-specific and HU-210-
stimulated binding at each concentration of GDP. 
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Another study, using RT-PCR to analyse the expression of cannabinoid receptors 
in different tissues showed that the brain contains 72 times more cannabinoid 
receptor mRNA compared to spleen (Schatz et al., 1997). With this in mind, the 
results of the spleen GTP-J-S binding assays are not unexpected, considering the 
fact that CP-55,940-stimulated binding of [35S]-GTP-J-S to brain membranes was 
only 30.4 % above basal (figure 3.7). This assay was not pursued further due to 
this lack of cannabinoid-stimulated GTP-J-S binding in porcine spleen 
membranes. 
 
 
4.3 Experimental Methods 
 
With the development of an effective cannabinoid competition assay using 
porcine spleen membrane homogenate, it was then possible to determine the 
receptor number in this tissue preparation, the binding affinity of a number of 
cannabinoid receptor ligands and the affinity, if any, of the test compounds for the 
CB2 receptor. The following sections describe how this was achieved. 
 
4.3.1 Determination of Receptor Number and Affinity for  
CP-55,940 
Competition assays where the competing compound employed is the same as the 
radioligand can be used to determine the receptor number (Bmax) and the affinity 
of the receptor for the radioligand (Kd) (DeBlasi, et al. 1989). According to the 
Cheng-Prusoff equation: 
IC50 = Kc (1 + L/Kh) 
where IC50 is the concentration of unlabelled compound required to displace 50 % 
of specifically bound radioligand, Kc and Kh are the dissociation constants of the 
unlabelled and radiolabelled ligands, respectively, and L is the concentration of 
radioligand (Cheng & Prusoff, 1973). Assuming that the radioligand and 
unlabelled ligand have equal receptor affinity (i.e. Kd), then Kc = Kh = Kd. 
Therefore, using the Cheng-Prusoff equation: 
        IC50 = Kd (1 + L/Kd) 
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                           = Kd + L             (a) 
so    Kd  = IC50 - L         (b) 
Also, according to the law of mass action: 
         Bmax = B0 (Kd + L)/L 
where B0 is the specific binding of the radioligand. Substituting (a): 
                                                    Bmax = B0 IC50/L            (c) 
Since B0 and IC50 can be determined experimentally, equations (b) and (c) can be 
used to define Bmax and Kd.  
 
It would have been desirable to perform these assays with a CB2-specific 
radioligand and corresponding unlabelled ligand, but these were not available 
when this work was performed. Instead, it was decided to define binding to both 
cannabinoid receptors using [3H]-CP-55,940 which possesses almost equal 
affinity for CB1 and CB2 (Showalter et al., 1996). Assays were performed to 
measure the displacement of a single concentration of [3H]-CP-55,940 from 
spleen membranes by increasing concentrations CP-55,940 (0.03 to 300 nM) 
using the protocol described below. Each drug concentration was assayed in 
triplicate and each assay was performed in spleen membrane homogenates from 
three different animals. The adaptation of the assay was carried out to allow for 
the use of repeat dispensing pipettes, but drug solutions and buffers (containing 
BSA) were made up as described previously.  
 
General Assay Procedure: 
[3H]-CP-55,940 (180.0 Ci/mmol) was dissolved in drug buffer (50 mM Tris; pH 
7.0, 2 mM EDTA, 5 mM MgCl2, 5.0 mg/ml BSA) to a concentration of 3.25 nM 
and then diluted to 0.65 nM in assay buffer (50 mM Tris; pH 7.0, 2 mM EDTA, 5 
mM MgCl2, 0.2 mg/ml BSA). Aliquots (250 Pl) were placed in polystyrene test 
tubes with 500 Pl of assay buffer and 50 Pl of blank buffer or unlabelled drug 
solution then added. Assays were initiated by addition of 200 Pl of spleen 
membrane homogenate (diluted 1:1 with assay buffer), the tubes vortexed and 
then incubated at 37 qC for 30 minutes. Non-specific binding of the radioligand 
was determined using HU-210 at a concentration of 10 PM. Membranes were 
harvested on to Whatman GF/B filter mats, pre-soaked in drug buffer for 30 
118 
minutes, using wash buffer (50 mM Tris; pH 7.0, 2 mM EDTA, 5 mM MgCl2, 0.5 
mg/ml BSA) at 4 qC on a Brandel cell harvester. Individual filter circles were 
placed in insert vials, 4 ml of Packard Emulsifier-Scintillator Plus added to each 
and left overnight. The vials were then vortexed and radioactivity measured on an 
LKB Rackbeta liquid scintillation counter. For accurate determination of the [3H]-
CP-55,940 assay concentration, the mean value of radioactivity from three 250 Pl 
aliquots of radioligand solution was determined and the assay concentration 
calculated. 
 
Protein Concentration Assay: 
In order to determine Bmax, it was necessary to determine the protein concentration 
in the spleen membrane homogenates used in the assays. This was achieved using 
a variation of the method described by Bradford (1976): 
 
Aliquots of each spleen membrane homogenate were diluted to 4, 2, 1 and 0.5 % 
of the original with buffer (50 mM Tris; pH 7.0, 2 mM EDTA, 5 mM MgCl2) 
containing NaOH at a final concentration of 0.5 M in each solution. These 
solutions were assayed against BSA standards from 1.95 Pg/ml to 4 mg/ml, each 
containing the same concentrations of buffer and NaOH as the spleen samples. 
Triplicate aliquots of the standards and quadruplicate aliquots of the spleen 
membrane samples (10 Pl) were placed on a 96 well plate with 12 blanks of buffer 
containing 0.5 M NaOH. Coomassie blue dye (200 Pl) was added to each well 
and, after allowing a minimum of 2 minutes for the colour to develop, optical 
densities were measured at a wavelength of 595 nm using a Dynation MRX 
microplate reader. The protein concentrations of the samples were calculated by 
fitting the sample optical densities to the BSA standard curve generated by non-
linear regression (one site binding) using GraphPad Prism. 
 
Coomassie Blue Dye: 
Coomassie Brilliant Blue G (100 mg) was dissolved in 50 ml of 95 % ethanol and 
100 ml of 85 % orthophosphoric acid added. The solution was made up to 1 litre 
with distilled water, filtered and stored in a well stoppered bottle at room 
temperature. 
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 Data Analysis: 
The amount of radioligand bound to the membranes was calculated and expressed 
as fmol/mg protein. This was plotted against the concentration of unlabelled CP-
55,940  (log M) and a sigmoidal dose-response curve for each homogenate was 
generated by non-linear regression using GraphPad Prism. B0 values were 
determined by subtracting the minimum from the maximum of each curve and 
these, along with the IC50 values generated by the program, were used to calculate 
Bmax and Kd values for each tissue homogenate. The final values were expressed 
as the means ± SEMs of the three assays. As the spleen membranes contained 
both CB1 and CB2, the Bmax and Kd represent the total number of cannabinoid 
binding sites and the affinity of combined spleen cannabinoid receptors for CP-
55,940. 
 
4.3.2 Determination of Ki Values for Other Cannabinoid Ligands 
When the Kd had been determined for [3H]-CP-55,940 binding to porcine spleen 
cannabinoid receptors, it was possible to determine the equilibrium binding 
constants (Ki) for other cannabinoid ligands in this tissue preparation. In the 
Cheng-Prusoff equation, the Kd of CP-55,940 is equivalent to Kh, and Ki is 
equivalent to Kc, so: 
IC50 = Ki (1 + L/Kd) 
Rearranging gives: 
Ki = IC50/(1+ L/Kd) 
Assays were performed to generate concentration-response curves of [3H]-CP-
55,940 displacement from spleen membranes by HU-210, SR141716A, SR144528 
and anandamide. The assays were performed in triplicate as described above but, 
since anandamide is hydrolysed by FAAH, assays were performed to compare its 
ability to displace [3H]-CP-55,940 from normal and PMSF-treated membranes. 
This PMSF pre-treatment was performed as described below. 
 
 
Treatment of Spleen Membranes with PMSF: 
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PMSF was dissolved in ethanol to a concentration of 6 mM and then diluted 10 
times in assay buffer. Equal volumes (3.5 ml) of spleen membrane homogenate 
and either PMSF solution or assay buffer containing 10 % ethanol were vortexed 
together, incubated at room temperature for 30 minutes and then centrifuged at 
19,000g for 2 minutes. The supernatant was aspirated, the pellet washed with 5 ml 
of assay buffer and then re-suspended in the original volume of buffer. 
 
Data Analysis: 
The percentage displacement of specifically bound [3H]-CP-55,940 from the 
membranes was plotted against the concentration of unlabelled cannabinoid (log 
M) and a sigmoidal concentration-response curve generated by non-linear 
regression using GraphPad Prism. The IC50 value generated by the program was 
used to calculate the Ki value for that compound and the final Ki value was 
determined by calculating the mean ± SEM for the three individual assays. The Ki 
for CP-55,940 was also determined in this way using the data generated in the CP-
55,940 versus [3H]-CP-55,940 assays. 
 
4.3.3 Determination of the Affinity of Test Compounds for the 
CB2 Receptor 
The affinity of the test compounds for the CB2 receptor was determined by their 
ability to displace [3H]-CP-55,940 from porcine spleen membranes. Each 
compound was assayed as described above (section 4.3.1) using triplicate 
concentrations of either 10 or 100 PM in three different spleen membrane 
homogenates. 
 
4.4 Results and Discussion 
 
4.4.1 Determination of Receptor Number and Affinity for  
CP-55,940 
The results of [3H]-CP-55,940 displacement from spleen membranes by CP-
55,940 are shown in figure 4.8. The combined data from the three assays 
produced a Kd for [3H]-CP-55,940 of 1.55 ± 0.34 nM, and a Bmax of 678.5 ± 129.5 
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fmol/mg protein and these values compare well with data in the literature (table 
4.1), especially the results of Hillard et al. (1999) which were also obtained using 
native spleen cannabinoid receptors, albeit from the rat. The small differences 
between the values described here and the other cited literature values are readily 
explained. The fact that the Bmax in the spleen membranes is lower than that 
reported by other groups, excluding Hillard et al., is likely to be due to this work 
being done using the endogenous receptor as opposed to transfected receptors 
where the receptor number is artificially high. Therefore, no direct comparisons 
can be made between this work and the Bmax values described in the literature. As 
Kd is a property of the receptor, the Bmax has no bearing on it. One possible reason 
for the difference in Kd values is the presence of CB1 in the spleen membranes 
used in this work. However, in species other than the pig, it is known that the CB1 
receptor is expressed at much lower levels than the CB2 receptor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Displacement of specifically bound [3H]-CP-55,940 from spleen 
membranes by CP-55,940. Data are expressed as the mean ± SEM of three 
independent experiments. 
 
 
The lower affinity of the receptor population for CP-55,940 described here is 
likely to be caused by species variation. The only CB2 receptors that have been 
cloned at this time are the human, rat and murine receptors. The murine receptor 
(mCB2) is 13 amino acids shorter than the human equivalent (hCB2) with the two 
sharing 82 % overall identity. In binding studies with the hCB2 and mCB2 
receptors expressed in COS-3 cells, [3H]-CP-55,940 was displaced by CP-55,940 
with IC50 values of 3.2 ± 0.8 nM and 5.6 ± 0.5 nM for the two receptors, 
respectively. This indicates that mCB2 has a slightly lower affinity for CP-55,940 
than hCB2 (Shire et al., 1996). It has also recently been shown that the cloned rat 
CB2 receptor exhibits a different binding profile for a number of cannabinoid 
receptor ligands in comparison to the hCB2 and mCB2 receptors (Griffin et al., 
2000). It is likely that the porcine CB2 receptor also exhibits a slightly different 
binding profile compared to the human, rat and mouse CB2 receptors, explaining 
the slight variation between the Kd in porcine spleen membranes and the data 
summarized in table 4.1, using cells transfected with hCB2. 
 
 
Kd 
(nM) 
Bmax 
(pmol/mg 
protein) 
 
Receptor Source 
0.49 ± 0.11 4.69 ± 0.58 hCB2 in CHO cells (Rinaldi-Carmona et al., 1998)
0.88 ± 0.09 1.55 ± 0.39 hCB2 in HEK-293 cells (Tao et al., 1999) 
0.96 ± 0.24 2.42 ± 0.38 
hCB2 in CKL cells (CHO with krox24 reporter) 
(Portier et al., 1999) 
0.46 ± 0.06 2.88 ± 0.19 
hCB2 in CCL cells (CHO with cAMP reporter) 
(Portier et al., 1999) 
0.64 r 0.05 27.4 r 6.15 rCB2 in HEK-293 cells (Griffin et al., 2000) 
0.73 r 0.20 9.9 r 1.60 mCB2 in HEK-293 cells (Griffin et al., 2000) 
0.87 r 0.08 5.8 r 0.67 hCB2 in HEK-293 cells (Griffin et al., 2000) 
2.8 r 0.4 0.57 r 0.02 Rat spleen membranes (Hillard et al., 1999) 
 
Table 4.1: Previously reported Kd and Bmax values determined by CP-55,940 
displacement of [3H]-CP-55,940 from the CB2 receptor. 
4.4.2 Determination of Ki Values for Other Cannabinoid Ligands 
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The results of cannabinoid displacement of [3H]-CP-55,940 from spleen 
membranes are shown in figure 4.9. These data show that, in this system, the 
affinities of the compounds is in the order HU-210 > CP-55,940 > SR144528 > 
SR141716A > anandamide. It is also clear that pre-treatment of the spleen 
membranes with PMSF had no effect on the ability of anandamide to displace 
[3H]-CP-55,940. This suggests that FAAH is not present in the spleen or that the 
levels are too low to significantly hydrolyse anandamide in the time available 
during the assay. Data from Katayama et al. (1997) indicates that FAAH activity 
with respect to anandamide hydrolysis is 0.13 ± 0.06 nmol/min/mg protein in rat 
spleen compared to 4.36 ± 0.28 nmol/min/mg in the liver. Despite the inevitable 
species variation, this difference in distribution is likely to be similar in the pig. 
In table 4.2, the Ki values obtained in these experiments are compared with those 
published in the literature. It is evident that the values obtained using porcine 
spleen membranes are consistent with the literature values, although most of these 
were determined using cells transfected with hCB2. The only two compounds that 
appear significantly different, however, are the two antagonists, SR141716A and 
SR144528. The reasons for these differences are likely to be due to the fact that 
these were the only receptor-selective compounds tested. The presence of CB1 in 
the spleen membranes is likely to have caused the lower than expected Ki value 
for SR141716A while, at the same time, causing a higher than expected Ki value 
for SR144528. However, Rinaldi-Carmona et al. (1998) determined that 
SR144528 had a Ki value of 0.30 ± 0.38 nM in rat spleen microsome membranes 
compared to 4.55 ± 1.1 nM in this work. Since both preparations contained CB1 
and CB2, it is most likely that the differences in the values are due to inter-species 
differences in receptor structure and binding. 
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 Figure 4.9: The displacement of [3H]-CP-55,940 from porcine spleen membranes 
by various cannabinoid ligands. A. HU-210 (¹), CP-55,940 (¼), SR144528 (~) 
and SR141716A (|). B. The effect of membrane pre-treatment with PMSF (|) 
compared to un-treated membranes (¹). Data are expressed as the mean ± SEM 
of three independent experiments.
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Compound Ki (nM) Literature Ki (nM) Receptor Source 
 
CP-55,940 
 
1.55 r 0.31 
0.69 ± 0.02 
2.55 ± 0.19 
7.2 ± 2.4 
0.75 ± 0.08 
0.64 r 0.06 
0.73 r 0.20 
hCB2 in CHO cells (Showalter et al., 1996) 
hCB2 in mouse AtT-20 cells (Felder et al., 1995) 
Rat spleen sections (Lynn & Herkenham, 1994) 
hCB2 in HEK-293 cells (Tao et al., 1999) 
rCB2 in HEK-293 cells (Griffin et al., 2000) 
mCB2 in HEK-293 cells (Griffin et al., 2000) 
HU-210 1.02 r 0.24 0.22 ± 0.18 0.60 ± 0.13 
hCB2 in CHO cells (Showalter et al., 1996) 
hCB2 in mouse AtT-20 cells (Felder et al., 1995) 
SR141716A 236.7 r 25.1 702 ± 62 973 ±280 
hCB2 in CHO cells (Showalter et al., 1996) 
hCB2 in mouse AtT-20 cells (Felder et al., 1995) 
 
SR144528 
 
4.55 r 1.1 
0.30 ± 0.38 
0.60 ±0.13 
0.30 r 0.14 
0.08 r 0.02 
Rat spleen microsome membranes (Rinaldi-Carmona et al., 
1998) 
hCB2 in CHO cells (Rinaldi-Carmona et al., 1998) 
rCB2 in HEK-293 cells (Griffin et al., 2000) 
mCB2 in HEK-293 cells (Griffin et al., 2000) 
Anandamide 
 
 
693 r 26 
641 r 178 (PMSF) 
371 ± 102 
1940 ± 240 
306 ± 48 
1930 
> 10 PM 
hCB2 in CHO cells (Showalter et al., 1996) 
hCB2 in mouse AtT-20 cells (Felder et al., 1995) 
hCB2 in HEK-293 cells (Tao et al., 1999) 
Mouse spleen membranes (Lin et al., 1998) 
rCB2 in HEK-293 cells (Griffin et al., 2000) 
 
 
Table 4.2: The Ki values of cannabinoid receptor ligands at porcine spleen cannabinoid receptors in comparison to Ki values from the literature. 
The values for porcine spleen are represented as the mean r SEM of three independent experiments. 
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4.4.3 The Affinity of Test Compounds for Porcine Spleen 
Cannabinoid Receptors 
 
The results of [3H]-CP-55,940 displacement from porcine spleen membranes by 
the novel test compounds are shown in figure 4.10. 
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Figure 4.10: The displacement of [3H]-CP-55,940 from porcine spleen 
membranes by aryl ethanolamide and phosphinic acid test compounds. Data are 
expressed as the mean ± SEM of three independent experiments. 
 
It is apparent from these results that none of the test compounds had any affinity 
for the CB2 receptor and, unlike the results at the CB1 receptor, no speculation 
can be made about any structure-activity relationships. However, despite these 
disappointing results, the cannabinoid binding profile of porcine spleen 
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cannabinoid receptors has been characterized and shown to be similar to the 
binding profiles of the cloned human, rat and murine CB2 receptors. The next 
chapter describes the investigation of the effect of these compounds on the 
anandamide transport mechanism. It was hoped that the lack of affinity of the test 
compounds for the receptors would not preclude activity at this target. Indeed, the 
anandamide transport inhibitor AM404 possesses only low affinity for the CB1 
cannabinoid receptors with a Ki value of 1.76 ± 0.14 PM (Beltramo et al., 1997). 
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Chapter 5: 
 
Anandamide Uptake Studies 
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5.1 Introduction 
 
In order to explore the effects of the aryl ethanolamides and phosphinic acids on 
anandamide uptake, a cell line possessing the endocannabinoid transporter was 
required. The mouse neuroblastoma cell line N18TG2 was available in the School 
of Biomedical Sciences and, although previously shown to accumulate [3H]-
anandamide (Deutsch & Chin, 1993), the anandamide transport system has not 
been fully characterized in this cell type. The following section describes the 
culture of these cells, the uptake experiments used to determine the presence of 
the anandamide transport system and subsequent studies to investigate the effect 
of the novel test compounds 
 
5.2 Experimental Methods 
 
5.2.1 Cell Culture 
The cell culture work was performed in a laminar flow cabinet using sterile 
techniques throughout. All solutions were sterile unless otherwise stated and were 
pre-warmed to 37 qC in order to prevent the cells being exposed to temperature 
shock. 
 
Initial Cell Culture: 
N18TG2 cells were thawed from storage at -80 qC, suspended in culture medium 
(90 % DMEM, 9 % FBS and 1 % 200 mM L-glutamine) and, to remove the 
freezing solution, were centrifuged at 400g for 15 minutes. The supernatant was 
aspirated, the pellet re-suspended in 10 ml of culture medium and the suspension 
transferred to a 25 cm2 culture flask. The cells were then incubated at 37 qC in an 
atmosphere of 95 % O2 and 5 % CO2. When the cells had reached confluence, 
they were dislodged from the flask with 5 ml of trypsin solution (0.25 % w/v). 
This solution was not sterile, so it was added to the flask through a 0.2 Pm filter in 
order to remove any microbial contaminants. The cell suspension was transferred 
to a universal tube and the flask washed with 5 ml culture medium which was 
combined with the cell suspension and centrifuged at 400g for 5 minutes. The 
supernatant was aspirated and the tube “flicked” to break up the cell pellet which 
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was then re-suspended in 5 ml of culture medium and transferred to a 75 cm2 
culture flask. A further 5 ml of medium was added to the flask to give an overall 
split of 1:3 and the cells were incubated as described above. 
 
Cell Viability Test: 
In order to test the viability of the cells, trypan blue dye was used. This is an 
exclusion dye which is only taken up by dead or dying cells, turning them blue. 
Equal volumes of cell suspension and dye were mixed together and 10 Pl of the 
mixture placed on a counting chamber and examined using phase contrast 
microscopy. The number of colourless, viable cells and dead or dying cells were 
counted in a 25 by 25 grid and percentage viability calculated.  
 
Cell Maintenance: 
It was observed that EDTA was at least as effective as trypsin at dislodging the 
cells so, when the cells had reached confluence, the culture medium was aspirated 
and the cells dislodged from the flask with 10 ml of EDTA solution (0.5 mM in 
Dulbecco’s PBS). As with the trypsin solution, this solution was not sterile, so it 
too was added to the flask through a 0.2 Pm filter. The cell suspension was then 
transferred to a universal tube, and the flask washed with 5 ml of culture medium 
which was combined with the cell suspension. The tube was then centrifuged at     
400g for 5 minutes, the supernatant aspirated and the cell pellet re-suspended in 6 
ml of medium. A 1:3 split was performed by transferring 2 ml of the suspension 
back to the original culture flask and making the volume up to 10 ml with culture 
medium. The remaining 4 ml of cell suspension was split in to two new flasks in a 
total volume of 10 ml per flask and all three flasks incubated as described above. 
Cells were passaged every 2 to 3 days, or when confluent, and new culture flasks 
were used after every third or fourth passage to prevent the selection of cells that 
were resistant to EDTA treatment. 
 
Cell Plating: 
When cells were required for anandamide uptake assays, a 1:3 split was 
performed and the remaining 4 ml of cell suspension was made up to 25 ml with 
culture medium. The cell suspension was then plated at 1 ml per well on a 24 well 
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culture plate and incubated as described above.  
 
Cell Storage: 
In case the cells became infected, it was necessary to have a supply of frozen, 
healthy cells that could be thawed and cultured. To achieve this, at passage 2, the 
cells were dislodged, transferred to a universal tube and the flask washed as 
described above. 5 ml of the suspension were transferred to a second universal 
tube with 5 ml of medium, resulting in this tube containing one third of the cells. 
The cells were then pelleted and the second tube used for a 1:3 split. The pellet 
from the first tube was re-suspended in 4 ml of freezing solution (10 % DMSO, 90 
% FBS) and 1 ml aliquots were gradually lowered in to liquid nitrogen for storage. 
 
5.2.2 Anandamide Uptake Assays 
The high-affinity anandamide transporter described in rat neurones and astrocytes 
by Beltramo et al. (1997) is temperature-dependent, saturable and inhibited by 
AM404 and the prostaglandin E2 transport inhibitor bromocresol green. In order to 
establish the presence of the uptake mechanism in N18TG2 cells, it was necessary 
to perform assays to demonstrate these characteristics. The effect of temperature 
and inhibitors on anandamide accumulation in to the cells was examined by 
performing anandamide concentration-response assays to measure its 
accumulation at 0 qC and at 37 qC in the absence or presence of AM404 and 
bromocresol green. An anandamide concentration-response assay was also 
performed at 37 qC in a cell-free system to determine whether experiments would 
be affected by adherence of the anandamide to the culture plate. This assay was 
performed in the absence or presence of AM404 to ascertain whether any 
adherence was displaceable by this inhibitor. Finally, the effect of time on 
anandamide uptake by N18TG2 cells was examined by performing time course 
assays using a single concentration of anandamide in the absence or presence of 
AM404. 
 
For these assays, cells were incubated with unlabelled anandamide containing 0.5 
% (v/v) of [3H]-anandamide (223 Ci/mmol) as a tracer. The amount of 
anandamide accumulated could then be calculated by lysing the cells and 
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measuring the radioactivity present in the lysate. The aqueous solutions of 
anandamide used in the assays contained 2-hydroxy-E-cyclodextrin (E-CD) as this 
has previously been shown to improve anandamide’s solubility (Jarho et al., 
1996). Also, since these cells express the CB1 receptor, it was necessary to 
displace any membrane-bound anandamide by washing the cells with BSA-
containing buffer before lysis to prevent it affecting the results. 
 
General Assay Procedure: 
N18TG2 cells were grown to confluence on 24 well culture plates as described 
above and placed on a plate warmer at 37 qC. The culture medium was aspirated 
and replaced with 500 Pl of Tris-Krebs’ buffer (20 mM Tris; pH 7.4, 130 mM 
NaCl, 5 mM KCl, 1.2 mM MgCl2, 2.5 mM CaCl2, 10 mM glucose) pre-warmed to 
37 qC and the cells allowed to equilibrate for at least 10 minutes. The buffer was 
then aspirated and replaced with 500 Pl of pre-warmed assay buffer (Tris-Krebs’ 
with 1 % (w/v) E-CD) containing the appropriate concentrations of anandamide 
and [3H]-anandamide. The cells were incubated for 10 minutes and the 
incubations terminated by aspiration of the buffer. The cells were then washed 
carefully with 2 x 500 Pl of Tris-Krebs’ buffer containing 0.1 % (w/v) BSA at 
room temperature and lysed with 500 Pl of aqueous HCl solution (1 M). The 
lysates were transferred to scintillation vials and each well washed with 500 Pl of 
distilled water which was combined with the corresponding lysate. 8 ml of 
scintillation fluid was added to each tube, the tubes vortexed and radioactivity 
measured on an LKB Rackbeta liquid scintillation counter. 
 
Comparison of Anandamide Uptake at 0 and 37 qC: 
Assays were performed as described above with triplicate anandamide 
concentrations of 6.25 to 100 nM containing 0.03 to 0.5 nM [3H]-anandamide. For 
the assay at 0 qC, the culture plate, Tris-Krebs’ buffer and assay buffers were 
cooled on ice. The 37 qC assay was performed in the presence or absence of 
AM404 and bromocresol green at 10 PM and 20 PM, respectively. 
 
Cell-Free Assay: 
The assay was performed as above with duplicate anandamide concentrations in 
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the presence or absence of 10 PM AM404. 
 
Time Point Assay: 
This assay was performed essentially as above using 50 nM anandamide 
containing 0.25 nM [3H]-anandamide with or without 10 PM AM404. Assay 
durations of 5, 10, 20 and 40 minutes were employed. 
 
When the transport mechanism had been studied, the aryl ethanolamides and 
phosphinic acids were included in the general assay to investigate whether they 
affected anandamide accumulation. The compounds were dissolved in ethanol and 
assay solutions made up with 50 nM anandamide containing 0.25 nM [3H]-
anandamide and 10 PM of the test compound with a final ethanol concentration of 
0.5 %. Duplicate assays were performed as described above, except that the 
incubations continued for 20 minutes, with triplicate concentrations each of a 
blank containing anandamide only, a positive control of anandamide containing 
10 PM AM404 and the test compounds. 
 
Data Analysis: 
The mean ± SEM anandamide accumulation was plotted against anandamide 
concentration or time and curves were generated by non-linear regression (one site 
binding) using GraphPad Prism. To determine the significance of inhibition by 
AM404 and bromocresol green, the data from assays using these compounds was 
compared to the control conditions using un-paired t tests. For the test compound 
assays, the accumulation in the presence of test compound was compared to that 
of the control containing anandamide only and the percentage inhibition 
calculated. 
 
5.2.3 Protein Concentration Assay 
In order to calculate the rate of anandamide accumulation by the cells 
(pmol/min/mg protein), it was necessary to determine the amount of protein in the 
wells of the culture plates. N18TG2 cells were grown to confluence on a 24 well 
plate as described above and the plate placed on a plate warmer at 37 qC. Since 
the culture medium was protein-rich, it was necessary to remove as much as 
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possible to prevent it affecting the assay for cellular protein. To achieve this, the 
medium was aspirated and the wells then washed with 1 ml of pre-warmed Tris-
Krebs’ buffer which was replaced with a further 1 ml of buffer. 1 ml of aqueous 
NaOH solution (1 M) was then added to each well and left for 10 minutes to allow 
the cellular protein to be digested. BSA standards from 1.95 Pg/ml to 4 mg/ml 
were assayed in triplicate, each containing the same concentrations of NaOH and 
Tris-Krebs’ buffer as the samples. The assay procedure and calculation of protein 
concentration was the same as described in section 4.3.1. 
 
5.3 Results and Discussion 
 
5.3.1 Cell Viability 
Cell viability was tested after the initial culture from frozen and after passage 
number 7. The initial viability was approximately 75 %, increasing to a mean of 
92 ± 1.5 % in the three flasks tested after passage 7. 
 
5.3.2 Characterization of Anandamide Uptake 
The data from the preliminary anandamide uptake assays were expressed as 
pmol/min/well due to an unforeseen problem with the protein concentration assay. 
The comparison of anandamide uptake at 0 and 37 qC, shown in figure 5.1, 
demonstrated that there was a temperature- and concentration-dependent 
accumulation of anandamide in the N18TG2 cells, indicating the presence of the 
anandamide transporter. In addition, this accumulation was significantly inhibited 
by the anandamide transport inhibitor AM404, further supporting this 
interpretation. Performing the uptake assay in the absence of cells (figure 5.2) 
showed a concentration-dependent adherence of anandamide to the plastic of the 
culture plate, which was displaced by AM404. However, the amount of 
anandamide that adhered to each well was very small in comparison to that 
accumulated by the cells, and this effect was ignored in subsequent assays. 
Confirming the results of Beltramo et al. (1997) in rat neurones and astrocytes, 
figures 5.3 shows that anandamide uptake was time-dependent in N18TG2 cells. 
However, contradicting the results of Beltramo et al, figure 5.4 shows that 
anandamide accumulation by N18TG2 cells was not significantly inhibited by 
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bromocresol green. Un-paired t-tests comparing anandamide accumulation in the 
absence and presence of this compound (20 PM) gave P values of > 0.1 at all 
anandamide concentrations. 
  
Although the scope of these experiments was limited, the results clearly show that 
N18TG2 cells possess a temperature- and time-dependent anandamide uptake 
mechanism that is inhibited by AM404. However, it is apparent from the graphs 
that the range of anandamide concentrations used was not sufficient to allow the 
determination of Vmax. It is also evident that there was inconsistency between the 
experiments. This can be seen when comparing the rates of anandamide uptake in 
the absence of inhibitor in figures 5.1 and 5.4. The most likely reasons for this 
inconsistency are variations in the confluency of the cells and slight differences in 
the culture medium used in the different passages. It is clear though, that in order 
to properly characterize the kinetics of this uptake mechanism in this cell type, 
numerous repeats of these assays should be performed. 
 
Since Vmax was not determined, these preliminary results can not be compared 
directly with those of Beltramo et al. However, it does appear that there are 
differences in the kinetics of the uptake mechanism of N18TG2 cells compared to 
that of rat neurones and astrocytes. In these cells, Km values were determined as 
32 nM and 320 nM, respectively. In comparison, it is apparent from figures 5.1 
and 5.4 that the Km for N18TG2 lies between these two values. There is also a 
difference between the time courses in rat neurones and astrocytes when 
compared with N18TG2 cells. Beltramo et al. found that anandamide 
accumulation reached 50 % of the maximal rate within about 4 minutes. In 
contrast, figure 5.3 shows that in the N18TG2 cells, this time is much greater. 
This is possibly due to variation in the transporter number between the different 
cell types. 
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Figure 5.1: Accumulation of anandamide by N18TG2 cells at 0 qC 
(¹) and at 37 qC in the absence (|) and presence (~) of 10 PM 
AM404. Data are expressed as the mean r SEM of six (0 qC) or three 
(37 qC) determinations of uptake, and were fitted by non-linear 
regression (one-site binding) using GraphPad Prism. Rates of 
anandamide uptake at 37 qC in the presence and absence of AM404 
were compared using un-paired t-tests (** P < 0.01, *** P < 0.001). 
Figure 5.2: Adherence of anandamide to the plastic of a culture 
plate at 37 qC in the absence (¹) and presence (|) of 10 PM 
AM404. Data are expressed as the mean r range of two 
determinations of uptake at each concentration and were fitted by 
non-linear regression (one-site binding) using GraphPad Prism. 
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Figure 5.4: The accumulation of anandamide by N18TG2 
cells at 37 qC in the absence (¹) and presence (|) of 20 
PM bromocresol green. Data are expressed as the mean r 
SEM of three determinations of uptake at each 
concentration and were fitted by non-linear regression 
(one-site binding) using GraphPad Prism. Rates of 
anandamide uptake in the presence and absence of 
bromocresol green  were compared using un-paired t-tests.  
Figure 5.3: The effect of incubation time on anandamide 
uptake by N18TG2 cells at 37 qC in the absence (¹) and 
presence (|) of 10 PM AM404. Data are expressed as the 
mean r SEM of three determinations of uptake at each time 
point and were fitted by non-linear regression (one-site 
binding) using GraphPad Prism. 
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5.3.3 The Effect of Test Compounds on Anandamide Uptake 
As the results described above indicated that N18TG2 cells possess an 
anandamide transport system, the effect of the aryl ethanolamides and phosphinic 
acids on uptake were investigated. The results in figure 5.5 show that, when 
compared to the anandamide control, AM404 inhibited anandamide uptake by 
30.3 ± 10.0 % at a concentration of 10 PM, while none of the other compounds 
tested had any inhibitory effect at the same concentration within experimental 
error. The only compound that showed any activity was PPA2. This compound 
has a long carbon chain and a benzene ring and therefore, structural similarities 
with AM404, but this could also be claimed for PPA5 and PPA7. Therefore, it is 
likely that this compound had no real effect on anandamide uptake, though studies 
at higher concentrations would be required to confirm this. It is possible, however, 
that there are multiple endocannabinoid transport systems. If this were the case, 
the relatively poor inhibition of anandamide uptake by AM404 and bromocresol 
green could be due to potent inhibition of a single transporter. It is therefore 
hypothetically possible that one or more of the test compounds could demonstrate 
this selectivity. 
 
Although the test compounds failed to bind to either CB1 or CB2 and to affect 
anandamide uptake, the next chapter describes the investigation of their potential 
effects on FAAH using a novel spectrophotometric assay for FAAH activity. It 
was hoped that this would be the most likely successful target for these 
compounds due to the known inhibition by ibuprofen and other NSAIDs and the 
similarities between the alkylphosphinic acids and existing FAAH inhibitors. 
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Figure 5.5: The effect of the test compounds and AM404 on anandamide accumulation in to N18TG2 cells. All 
compounds were assayed at 10 PM and data represent the mean ± SEM of six determinations of uptake for the test 
compounds and 12 determinations for AM404. 
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Chapter 6: 
 
Fatty Acid Amide Hydrolase 
Studies 
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6.1 Introduction 
 
6.1.1 Existing Assays for Fatty Acid Amide Hydrolase Activity 
The majority of assays for FAAH activity described in the literature involve the 
use of either radiochemicals, chromatography, or both. In radiochemical FAAH 
assays, a radiolabelled substrate is incubated with the enzyme and, after extraction 
of reaction products from the mixture, the radioactive reaction product is 
separated from any remaining labelled substrate. This separation is achieved by 
TLC (Deutsch & Chin, 1993), mini-column chromatography (Desarnaud et al., 
1995) or reverse-phase high performance liquid chromatography (RP-HPLC) (van 
der Stelt et al., 1997; Maccarrone et al., 1999), followed by measurement of the 
radioactivity present in the relevant band, fraction or peak. Alternatively, if an 
ethanolamide FAAH substrate is used, the compound can be radiolabelled with 
14C on the ethanolamine portion. After incubation of this substrate with the 
enzyme, addition of an organic solvent causes the ethanolamine to partition in the 
aqueous phase, while any unreacted substrate is retained in the organic phase. The 
aqueous phase is then removed and liquid scintillation counting is performed, 
eliminating the use of chromatography (Omeir et al., 1995).  
The other commonly used FAAH assays are based purely on chromatography. 
The first methodology involves the incubation of an unsaturated FAAH substrate 
with the enzyme followed by extraction of the reaction products. RP-HPLC is 
then used to separate and quantify substrate and products by detection of the 
carbon-carbon double bonds (Lang et al., 1996). The second method is another 
HPLC-based assay in which an ethanolamide substrate is incubated with FAAH 
and the products then extracted from the assay mixture. The ethanolamine 
produced by the reaction is derivatized by reaction with o-phthaldialdehyde to 
form an isoindole which can then separated by RP-HPLC and detected at a 
wavelength of 230 nm (Qin et al., 1998). 
 
All of these assays have drawbacks in that they are either expensive due to the use 
of radiolabelled substrates, time-consuming because of the chromatographic 
analysis, or both. These problems are especially compounded by the need to assay 
multiple samples, but only two examples of FAAH assays exist in the literature 
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that do not possess either of these drawbacks. First, the activity of FAAH has been 
measured using an ion-specific electrode to detect the ammonia generated by 
oleamide hydrolysis (Patterson et al., 1996). Second, a fluorescent displacement 
assay has been described which measures either the arachidonic acid or oleic acid 
generated by hydrolysis of anandamide or oleamide, respectively (Thumser et al., 
1997). In this method, the generation of the fatty acid displaces DAUDA (11-(5-
dimethylamino naphthalenesulphonyl)-undecanoic acid), a fluorescent fatty acid 
analogue, from fatty acid binding protein (FABP) and the decrease in fluorescence 
is used to determine the rate of hydrolysis by FAAH. Both of these methods have 
drawbacks, however. The ammonia electrode method involves the use of large (10 
ml) assay volumes due to the physical size of the electrode. The fluorescence 
assay has two problems associated with it. First, the FABP must be extracted from 
either rat liver or E. coli expressing the recombinant protein, then purified and 
delipidated for use in the assay. Second, because anandamide and oleamide also 
bind to the FABP, the assay system requires calibration in order to discount the 
effects of these ligands binding to the FABP. 
 
6.1.2 A Novel FAAH Assay 
Due to the drawbacks of existing assays, it was decided that a totally novel 
approach would be taken to develop an effective, cheap and rapid FAAH assay 
that could be performed without specialized equipment. To achieve this, a 
spectrophotometric assay was developed using the first known substrate of 
FAAH, oleamide. To measure the rate of ammonia generation upon oleamide 
hydrolysis, a dual-enzyme assay was proposed using FAAH and L-glutamate 
dehydrogenase (GDH) as shown in scheme 6.1. 
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Scheme 6.1: Dual-enzyme assay to measure the ammonia generated by FAAH-
catalysed oleamide hydrolysis. 
 
As shown above, GDH catalyses the condensation of D-ketoglutarate (D-KG) and 
ammonia to form glutamate, using NADH as a co-factor. NADH has a high molar 
extinction at 340 nm and, therefore, its oxidation to NAD+ can readily be followed 
using a spectrophotometer. Since ammonia and NADH are equimolar in this 
reaction, the ammonia generated by FAAH-catalysed hydrolysis of oleamide and 
the reduction in absorbance at 340 nm are directly proportional. The following 
section describes how this theoretical assay system was developed and optimized. 
 
 
6.2 Assay Development 
 
6.2.1 Glutamate Dehydrogenase Reaction 
Before attempting to combine the two enzymes in one assay, it was first necessary 
to optimize the conditions of the GDH assay. Using commercially available 
bovine L-glutamate dehydrogenase, the method of Bergmeyer & Beutler (1985) 
was adapted for use in cuvettes as shown in table 6.1. These adapted conditions 
L-Glutamate 
dehydrogenase 
FAAH 
D-Ketoglutarate
Glutamate 
Oleic acid 
Oleamide 
NADH
NAD+ 
NH3 
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will henceforth be referred to as the “normal” assay conditions. ADP was present 
in this assay system as it is a known allosteric activator of GDH. 
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Triethanolamine 
D-Ketoglutarate 
ADP 
155 mM 
11 mM 
0.56 mM 
 
1.00 
156 mM 
11 mM 
0.67 mM 
 
140 
E-NADH 
NaHCO3 
186 PM 
3.70 mM 
0.10 222 PM 
3.75 mM 
14 
GDH* 7.4 kU/dm3 0.02 6.7 kU/dm3 2 
Water - 2.00 - 244 
Ammonia 
sample 
up to 150 PM 0.10 160 PM 50 
Total Volume  3.22 ml  450 Pl 
 
Table 6.1: Assay components, volumes and concentrations for the glutamate 
dehydrogenase reaction. * 1 Unit = the amount of enzyme that will oxidize 1.0 
Pmole of D-KG in the presence of  ADP at 25 qC, pH 7.8. 
 
Another factor known to affect GDH activity is the magnesium ion concentration, 
although there are conflicting accounts of its effects. For example, Fahien et al. 
(1990) reported that, in the absence of ADP, Mg2+ inhibited bovine GDH activity 
while, in the presence of ADP, Mg2+ behaved as an activator. However, Bailey et 
al. (1982), also using bovine GDH, showed that, up to 5 mM, Mg2+ had no effect 
on GDH activity or the role of ADP in its regulation.  
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Preliminary Assays 
With the conflicting accounts of the effect of ADP and Mg2+, it was necessary to 
investigate the effects of these factors by performing assays in their presence and 
absence. To confirm that the assay concentrations used by Bergmeyer & Beutler 
were indeed the most effective, assays were also performed with varying amounts 
of D-ketoglutarate, NADH and GDH in comparison to the normal assay 
conditions. 
 
Normal Assay Procedure: 
Assay solutions were made up by placing 140 Pl of solution A (71.4 mM D-
ketoglutarate, 4.3 mM ADP, 500 mM triethanolamine; pH 8.0), 14 Pl of solution 
B (7.1 mM E-NADH, 120.6 mM NaHCO3), 2 Pl of GDH solution (1600 kU/dm3, 
50 % glycerol solution) and 244 Pl of distilled water in acrylic cuvettes. 
Solutions were stirred and gently shaken for at least 10 minutes to allow 
equilibration prior to placing the cuvettes in a Beckman DU650 
spectrophotometer. Absorbance was monitored at 340 nm until constant and the 
reactions then initiated by the addition of 50 Pl of ammonium acetate solution (1.4 
mM) to give an assay concentration of 160 PM. Solutions were mixed by stirring 
and absorbance automatically measured every 38 seconds for up to 30 minutes. 
Each assay was conducted at room temperature and consisted of four test cuvettes 
and two cuvettes containing a blank of distilled water added in place of 
ammonium acetate solution. 
 
Variation of Assay Conditions: 
Assays were performed as described above with the following variations in the 
assay conditions: high (1.1 mM) or low (0.4 mM) NADH, high (22.2 mM) or low 
(1.1 mM) D-KG, high (66.7 kU/dm3) or low (0.7 kU/dm3) GDH, 1 mM Mg2+  with 
ADP, 1 mM Mg2+ without ADP or the absence of both Mg2+ 
 
and ADP. For assays 
containing Mg2+, the distilled water in the normal assay was replaced with MgCl2 
solution (1.8 mM). 
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Results: 
The results in figures 6.1 and 6.2 show the effect of altering D-KG, NADH and 
enzyme concentrations on the rate of the GDH reaction. It is clear that lower than 
normal concentrations of these species reduced the reaction rate. As expected, 
increasing the amount of enzyme increased the rate, but a higher than normal 
concentration of D-KG did not affect the reaction. Unfortunately, due to the 
absorbance reading going off the scale of the spectrophotometer, a higher 
concentration of NADH could not be assayed. The effects of ADP and Mg2+ on 
the GDH reaction are shown in figure 6.3 and table 6.2. These data confirm the 
activation of glutamate dehydrogenase by ADP and show that Mg2+ has an 
inhibitory effect on the reaction rate. The initial reaction rate in the presence of 
ADP (i.e. normal assay conditions) is double that of the assay in its absence. 
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Figure 6.1: Representative data from a single experiment, showing the effect of 
different concentrations of D-ketoglutarate and NADH on the rate of the GDH 
reaction. Blank (¹), normal assay conditions (|), high D-KG (~), low D-KG 
(¼) and low NADH (”). For visualisation, all data were normalized so that the 
absorbance reading at 0 seconds was 2.0. 
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Figure 6.2: Representative data from a single experiment, showing the effect of 
different concentrations of enzyme on the rate of the GDH reaction. Blank (¹), 
normal assay conditions (|), high GDH (~) and low GDH (¼). For visualisation, 
all data were normalized so that the absorbance reading at 0 seconds was 2.0. 
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Figure 6.3: Representative data from a single experiment, showing the effect of 
the presence or absence of ADP and Mg2+ on the rate of the GDH reaction. Blank 
(¹), normal assay conditions (|), +ADP/+Mg2+ (~), -ADP/-Mg2+ (¼) and -
ADP/+Mg2+ (”). For visualisation, all data were normalized so that the 
absorbance reading at 0 seconds was 2.0. 
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Conditions Rate (Abs/sec) Relative Rate 
Normal (+ADP/-Mg2+) -1.02 x 10-3 1 
-ADP/-Mg2+ -5.13 x 10-4 0.50 
+ADP/+Mg2+ -3.86 x 10-4 0.38 
-ADP/+Mg2+ -2.21 x 10-4 0.22 
 
Table 6.2: The effect of ADP and Mg2+ on initial GDH reaction rate. Rates were 
determined by linear regression (0 to 228 seconds) of the data from figure 6.3 
using GraphPad Prism and the blank rate subtracted from each. 
 
When ADP and 1 mM Mg2+ were both present, the initial rate was approximately 
one third that of the normal assay, showing the negative effect of the ADP-metal 
complex. However, with Mg2+ alone, the inhibitory effect was even greater, with 
the initial rate reduced to one fifth of the optimum. 
 
These results demonstrate that the assay conditions adapted from Bergmeyer & 
Beutler were indeed optimal for this assay. The reaction rate could have been 
dramatically increased by increasing the enzyme concentration but this would be 
unnecessary and wasteful. In contrast to the results of Fahien et al. (1990), these 
results showed that the ADP/Mg2+ complex was not activating, but inhibitory. 
This also contradicts the findings of Bailey et al. (1982) who found Mg2+ did not 
alter either the activity of GDH or the effect of ADP. With these results in mind, 
the assay conditions shown in table 6.1 were adopted for the subsequent assays.  
 
Ammonium Acetate Concentration-Response Assay 
To show that the GDH assay could be used to detect variable concentrations of 
ammonia, an ammonium acetate concentration-response assay was performed. 
The protocol was as described for the normal assay procedure, using ammonium 
acetate at assay concentrations between 1 and 160 PM. Each concentration was 
assayed in duplicate against blanks containing water only. Reaction rates were 
linear up to at least 5 minutes, so the initial rate at each concentration was 
determined by linear regression of the data from 0 to 304 seconds using GraphPad 
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Prism. Reaction rates were plotted against concentration and the results of this 
assay are shown in figure 6.4. These data clearly show that, as expected, the rate 
of GDH reaction was dependent on ammonium acetate concentration and was 
linear using these assay conditions. With this demonstration, it was then possible 
to combine GDH and FAAH in one assay to test the proposed spectrophotometric 
FAAH assay. 
 
 
Figure 6.4: Representative data showing the effect of increasing ammonium 
acetate concentration on the rate of GDH-catalysed glutamate formation. Data are 
expressed as the mean ± range of two determinations of rate and were fitted by 
linear regression using GraphPad Prism. 
 
 
6.2.2 FAAH Assays 
Preliminary Assays 
FAAH is highly expressed in the brain (Desarnaud et al., 1995) and liver 
(Katayama et al., 1997) so, due to the immediate availability of rat liver 
microsomes, liver was chosen for this work. The first attempt at combining the 
two enzyme sources in one assay was unsuccessful as the absorbance was off the 
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scale of the spectrophotometer, probably due to light scattering by the cloudy 
assay solution. To overcome this, the microsomes were solubilized as described 
below and the assays repeated. 
 
Tissue Solubilization: 
Frozen rat liver microsomes (13.25 mg protein/ml in 250 mM sucrose, 5 mM 
EDTA, 20 mM Tris; pH 8.0) were prepared by an adaptation of the method 
described by Kamath et al. (1971) and kindly provided by Mr Kishan Jassi. Equal 
volumes of thawed microsome preparation and microsome buffer containing 1 % 
(w/v) of the detergent t-octylphenoxypolyethoxy ethanol (TX-100) were placed on 
ice and vortexed three times over a period of 15 minutes, then centrifuged at 
9,000g for 5 minutes at 4 qC. The supernatant, containing the soluble protein, was 
removed and used in the subsequent assays. 
 
FAAH Assay Procedure: 
Assay solutions were made up by placing 140 Pl of solution A, 14 Pl of solution 
B, 2 Pl of enzyme solution and 40 Pl of solubilized microsomes in acrylic cuvettes 
and making the volume up to 448 Pl with microsome buffer. The procedure used 
was then exactly as described above for the GDH reaction with the assay initiated 
by adding 2 Pl of ethanolic oleamide stock (36 mM), giving an assay 
concentration of 160 PM. Blank cuvettes contained the same assay components as 
the test cuvettes, but 2 Pl of ethanol was added instead of oleamide solution. 
 
The results of the initial FAAH assay are shown in figure 6.5. This example of 
typical experimental data demonstrates that the reaction rate in the blank and test 
sample were linear for the duration of the assay. The blank showed a small 
decrease in absorbance due to the inevitable presence of endogenous ammonia in 
the microsome preparation, but this was eclipsed by the much larger reaction rate 
in the presence of oleamide. These data indicate that oleamide was hydrolysed by 
FAAH, with the resulting ammonia utilized by GDH. The linearity of these data 
may be due to the FAAH reaction being the rate-limiting step in this system, 
presumably because the pH and temperature of the assay were not optimal for this 
enzyme.  
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Figure 6.5: Representative experimental data from the preliminary FAAH assays 
using solubilized rat liver microsomes with an ethanolic blank (~) or 160 PM 
oleamide (¼). Data were fitted by linear regression using GraphPad Prism. 
 
Oleamide Concentration-Response Assay 
To demonstrate further that this assay was working as predicted, a limited 
oleamide concentration-response assay was performed. The procedure was as 
described for the preliminary FAAH assay, with oleamide at assay concentrations 
of 10 to 320 PM. Each concentration was assayed in duplicate against ethanolic 
blanks. 
 
Data Analysis: 
As with the previous assays, the rate of oleamide hydrolysis was linear for the 
duration of the experiments, so rates were determined by linear regression of the 
data from 0 to 4560 seconds. The rate of reaction in nmol/min was then calculated 
as described below and the data fitted by non-linear regression using GraphPad 
Prism. 
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The absorbance of a chromophore is linked to its concentration by the Beer-
Lambert equation: 
A = H c l 
where A = absorbance, H = the molar extinction coefficient, c = the concentration 
of the chromophore and l = the path length of the cuvette. In this system, the 
molar extinction coefficient of NADH = 6220 M-1 cm-1 and the path length of the 
cuvette = 1 cm. Therefore, 
A = 6220 c 
 
As the absorbance in these assays decreased with time, the slopes generated by 
GraphPad Prism were negative with units of A/sec so: 
-1(slope x 60) = 6220 c/min 
c/min = -1((slope x 60)/6220) 
Finally, to convert the rate from moles/dm3/min to nmol/min: 
nmol/min = -1((Slope x 60 x 450x10-6 x 1x109)/6220) 
= -1((Slope x 27x106)/6220) 
 
Results: 
The results of the preliminary oleamide concentration-response assay are shown 
in figure 6.6. These data show that the rate of oleamide hydrolysis was 
concentration -dependent, confirming that this assay may be an effective method 
to measure FAAH activity. 
 154
0 40 80 120 160 200 240 280 320
0.0
0.1
0.2
0.3
0.4
0.5
Oleamide (µM)
R
at
e 
o
f O
lea
m
id
e H
yd
ro
lys
is 
(nm
o
l/m
in)
 
 
Figure 6.6: The effect of concentration on FAAH-catalysed oleamide hydrolysis 
by solubilized rat liver microsomes using a spectrophotometric FAAH assay. The 
data represent the mean ± range of two determinations of rate and were fitted by 
non-linear regression using GraphPad Prism. 
 
Comparison of Rat Liver Microsomes and Liver Plasma Membranes 
To simplify the overall assay procedure, it was decided that rat liver membranes 
would be assayed for FAAH activity as their preparation is simpler than that of 
microsomes. Therefore, the rate of hydrolysis of 160 PM oleamide by FAAH was 
compared in solubilized preparations from rat liver microsomes and rat liver 
membranes to determine whether the membranes were a viable FAAH source.  
 
Assay Procedure: 
Rat liver membranes were prepared as described for the brain membrane 
preparation in section 3.2.1, and kindly provided by Professor David Kendall. 
Assays were performed as described for the previous rat liver microsome FAAH 
assays, with 40 Pl of solubilized microsomes or membranes in duplicate against 
blanks containing ethanol instead of oleamide solution. Slopes were generated as 
previously described  using data from 0 to 1026 seconds and the rate of oleamide 
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hydrolysis calculated as nmol/min/mg protein. The microsome preparation was 
provided at a known protein concentration of 13.25 mg/ml and the protein 
concentration of the membrane preparation was determined using the adapted 
method of Bradford (1976), as described in section 4.3.1. The protein 
concentrations used to determine the rate of oleamide hydrolysis in each tissue 
preparation were the pre-solubilization concentrations. 
 
Results: 
 The results of this assay are shown in figure 6.7. It is clear from this figure that 
there was no difference in the FAAH activity present in solubilized rat liver 
membrane or microsome preparations. Although the protein concentrations used 
to determine rates were the pre-solubilization concentrations, it is reasonable to 
assume that the efficiency of FAAH solubilization by TX-100 was the same in 
both preparations. In light of these results, it was decided that, because of the ease 
of preparation, rat liver membranes would be used instead of rat liver microsomes 
in subsequent assays. 
 
Figure 6.7: Comparison of the rate of FAAH-catalysed hydrolysis of 160 PM 
oleamide in solubilized preparations of rat liver microsomes and membranes. Data 
represent the mean ± range of two determinations of rate. Protein concentrations 
were determined prior to solubilization of the tissue preparations. 
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Crude Purification of FAAH Activity 
In an attempt to enrich the FAAH activity in the liver membrane homogenate, a 
crude purification procedure was employed using a BioRad Econo-Pac High Q 
anion exchange column.  
 
Purification and Assay Procedures: 
Distilled water was passed through the column for 1 hour at 1 ml/min followed by 
column buffer (1 mM EDTA, 0.1% (w/v) TX-100, 20 mM HEPES; pH 7.2) for 2 
hours at 1 ml/min. Rat liver membrane homogenate was solubilized as described 
at the beginning of this section, using an equal volume of solubilization buffer (1 
mM EDTA, 1% (w/v) TX-100, 20 mM HEPES; pH 7.2). The solubilized protein 
solution (5 ml) was then passed through the column at 1 ml/min. A linear gradient 
of 50 mM to 1 M ammonium acetate was employed to desorb bound material, 
which was collected as 32 x 2.5 ml fractions. FAAH assays were then performed 
using 50 Pl aliquots of the samples with column buffer making up the bulk of the 
assay volume. In these assays, all cuvettes contained oleamide at a concentration 
of 160 PM and, in the blanks, the tissue was replaced by 50 Pl of buffer.  
 
Results: 
From the results shown in figure 6.8, it is apparent that FAAH activity was not 
eluted as a sharp band, with activity present in fractions 4 to 11. A subsequent 
experiment (figure 6.9) showed that fraction 6 contained the highest FAAH 
activity, possessing an oleamide hydrolysis rate of 0.72 ± 0.01 nmol/min. 
Significant enzyme activity was also evident in fractions 4, 5, 7 and 8. However, 
with the failure of this procedure to separate the FAAH activity in to a single 
fraction, no further purification was attempted. For simplicity, it was decided to 
routinely use solubilized homogenate without an additional purification step. 
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Figure 6.8: The FAAH activity present in the alternate fractions collected during 
the attempted purification of the enzyme using an ion exchange column. 
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Figure 6.9: The FAAH activity present in fractions 4-8, collected during the 
attempted purification of the enzyme using an ion exchange column. 
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FAAH Assays Using Rat Liver Crude Particulate Fraction 
To simplify further the overall procedure, it was decided to attempt FAAH assays 
with the crude particulate fraction (CPF) of rat liver. The preparation of this tissue 
homogenate, more straightforward than liver membrane preparation, and its 
subsequent use in FAAH assays is described below. 
 
 
Preparation of Rat Liver Crude Particulate Fraction (CPF): 
Freshly dissected liver from Wistar or hooded Lister rats was roughly chopped 
with scissors, weighed and homogenized in 10 volumes of ice-cold buffer (1 mM 
EDTA, 50 mM Tris; pH 7.4) using a Polytron homogenizer. The homogenate was 
centrifuged at 1,000g for 5 minutes at 4 qC, and the supernatant was then 
centrifuged at 36,000g for 20 minutes at 4 qC. The resulting pellet was then 
suspended in 4 volumes (original wet weight) of ice-cold buffer and manually re-
homogenized with a glass/teflon homogenizer. Aliquots of the CPF (1 ml) were 
frozen at -80 qC until required. 
 
Assay Procedure: 
Assays were performed to assess the FAAH activity in solubilized preparations 
from rat liver CPF. Solubilization was performed as described above using equal 
volumes of rat liver CPF and buffer (1 mM EDTA, 50 mM Tris; pH 7.4) 
containing 1 % (w/v) TX-100 and 100 Pl of the soluble protein was used in each 
assay. The assay procedure was as described above, with CPF buffer as the bulk 
of the assay volume. The hydrolysis of 160 PM oleamide was measured in 
quintuplicate against blanks containing no oleamide and rates determined as 
previously described.  
 
Results: 
The rate of oleamide hydrolysis in this solubilized tissue was calculated as 0.98 ± 
0.08 nmol/min, i.e. greater than that in soluble liver microsomes or membrane 
homogenate. Subsequently, an oleamide concentration-response assay was 
performed with oleamide at 1 to 160 PM, with each concentration assayed in 
duplicate. To calculate the rate of hydrolysis of oleamide in this assay, the protein 
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concentration of the solubilized tissue was measured using an adaptation of the 
method of Bradford (1976) as described in section 4.3.1. Rates were then 
expressed as nmol/min/mg protein and the results are shown in figure 6.10. These 
data demonstrate that, as in solubilized rat liver membranes, there was a 
concentration -dependent FAAH activity in solubilized preparation of rat liver 
CPF.  
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Figure 6.10: Representative data showing the effect of oleamide concentration on 
its FAAH-catalysed hydrolysis using solubilized rat liver crude particulate 
fraction. Data represent the mean ± range of two determinations of hydrolysis rate 
and were fitted by non-linear regression using GraphPad Prism. 
 
 
All of the results described above demonstrate that the novel assay combining 
FAAH and GDH does work, largely as predicted. The next section describes the 
detailed validation of this assay system. 
 
 
 
 
6.3 Assay Validation 
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To ensure that this assay system was a valid method of measuring FAAH activity, 
it was necessary to demonstrate that the enzyme kinetics measured were 
comparable with those reported using existing assays and that activity was 
concentration-dependently inhibited by known FAAH inhibitors.  
 
6.3.1 Oleamide Concentration-Response Assays 
Although these assays had been performed as part of the assay development 
process, they were of limited value due to the low number of replications and 
variations in the assay conditions. To rectify this, assays were performed using the 
following, definitive, protocol. 
 
FAAH Assay Procedure: 
Assay solutions were made up by placing 140 Pl of solution A (71.4 mM D-
ketoglutarate, 4.3 mM ADP, 500 mM triethanolamine; pH 8.0), 14 Pl of solution 
B (7.1 mM E-NADH, 120.6 mM NaHCO3), 2 Pl of GDH solution (1600 kU/dm3, 
50 % glycerol solution), 192 Pl of CPF buffer (1 mM EDTA, 50 mM Tris; pH 7.4)  
and 100 Pl of solubilized preparation of rat liver CPF in acrylic cuvettes. 
Solutions were stirred, gently shaken for at least 10 minutes to allow equilibration 
and then the cuvettes were placed in a Beckman DU650 spectrophotometer. 
Absorbance was monitored at 340 nm until it was constant and the reactions were 
initiated by the addition of 2 Pl of ethanolic oleamide solution. Solutions were 
mixed by stirring and absorbance automatically measured every 38 seconds for up 
to 2500 seconds. Each assay was conducted at room temperature and consisted of 
five test cuvettes and one cuvette containing a blank of ethanol instead of 
oleamide solution. Oleamide was assayed at concentrations ranging from 3.75 to 
120 PM, with each concentration measured in triplicate. Three assays were 
performed using liver CPF from three separate rats. 
 
 
 
Data Analysis: 
 161
The protein concentration of each solubilized tissue was determined as described 
previously and slopes were calculated for each assay by linear regression of the 
data (0 to 494 seconds) using GraphPad Prism. The slope of the blank was then 
subtracted from that of the test samples and the rate of oleamide hydrolysis 
calculated using the equation described in section 6.2.2. Rates were then plotted 
against concentration and the data fitted by non-linear regression to a rectangular 
hyperbola using GraphPad Prism. 
 
The two defining values usually quoted when referring to enzyme kinetics are 
Vmax, the maximum rate, and Km, the Michaelis constant, which is the 
concentration of substrate at which the reaction rate is half the Vmax. Non-linear 
regression analysis of the data by GraphPad Prism generated Km and Vmax values 
for each experiment. The means ± SEMs of these data were calculated from three 
experiments. 
 
Results: 
The combined data from the three experiments are shown in figure 6.11. The Vmax 
and Km values for oleamide hydrolysis by FAAH were calculated as 5.73 ± 0.44 
nmol/min/mg protein and 103.8 ± 13.0 PM, respectively and data described in the 
literature are shown in table 6.3 for comparison. Although Vmax values for 
oleamide hydrolysis by FAAH have not been reported in the literature, the rate at 
a single concentration has been determined in comparison to that of anandamide. 
Using purified FAAH, the rate of hydrolysis of 100 PM oleamide was shown to be 
242 ± 20 nmol/min/mg protein compared to 333 ± 30 nmol/mg/protein with 100 
PM anandamide (Cravatt et al., 1996). This demonstrates that, although 
anandamide is the preferred substrate of the enzyme, the rate for oleamide 
hydrolysis is similar to that for anandamide. In comparison with the Vmax values in 
table 6.3, the maximum rate described for these experiments is of the same order 
of magnitude. 
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Figure 6.11: The effect of concentration on FAAH-catalysed oleamide hydrolysis 
in solubilized rat liver crude particulate fraction. Data are expressed as the mean ± 
SEM of three independent experiments. 
 
 
However, the Km value of 103.8 ± 13.0 PM obtained with the present assay was 
higher than the previously reported data, but of the same order of magnitude. 
These differences may well be due to pH and temperature effects. Although the 
Vmax was defined using this spectrophotometric assay, the concentration of 
oleamide required to achieve this may have been greater than that needed to 
achieve the maximum rate under the optimum conditions. For this reason, the 
concentration necessary to achieve half the maximal rate, i.e. Km, would also be 
higher. These results suggest that this spectrophotometric assay of FAAH activity 
was effective but, to confirm this, it was necessary to validate further the assay by 
studying the effects of known FAAH inhibitors. This validation procedure is 
described in the following section. 
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Tissue 
 
Substrate 
Km 
(PM) 
Vmax 
(nmol/min
/mg 
protein) 
 
Reference 
Rat brain 
microsomes 
Anandamid
e 
12.7 ± 
1.8 
5.63 ± 0.20 Desarnaud et al., 1995 
Over-
expression in 
COS-7 cells 
Anandamid
e 
18 132 
 
Kurahashi et al., 1997 
 
Rat brain 
microsomes 
Anandamid
e 
2.78 ± 
0.51 
1.40 ± 0.06 Lang et al., 1999 
Human brain 
Anandamid
e 
2 ± 0.2 
0.800 ± 
0.075 
Maccarrone et al., 1998 
Solubilized rat 
liver plasma 
membranes 
Oleamide 31 ± 3 N.D. Patricelli et al., 1998 
Rat liver 
membranes 
Oleamide 5 ± 2 N.D. Patterson et al., 1996 
 
Table 6.3: Previously reported values of Km and Vmax for fatty acid amide 
hydrolase. N.D. = Not determined. 
 
 
6.3.2 FAAH Inhibitor Studies 
If the results observed using the novel spectrophotometric assay system were truly 
due to the hydrolysis of oleamide by FAAH, known inhibitors of the FAAH 
should inhibit the enzyme in a concentration-dependent manner. To demonstrate 
this, the effects of methylarachidonyl fluorophosphonate (MAFP), PMSF and 
anandamide on the assay were investigated. MAFP is a potent, selective and 
irreversible inhibitor of FAAH, while PMSF is a broad spectrum serine protease 
inhibitor, which has also been shown to inhibit FAAH irreversibly. As 
anandamide is a substrate of FAAH, it was also included in this work as a 
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competitive inhibitor of oleamide hydrolysis. It is also possible that the products 
of anandamide hydrolysis would inhibit FAAH.  
 
FAAH Inhibitor Assays 
Assays were performed essentially as described for the oleamide concentration-
response assays, except the volume of buffer in the assay solution was reduced 
from 192 to 190 Pl. When the absorbance of the initial assay solution was 
constant, 2 Pl of ethanolic inhibitor was added to each cuvette followed by 2 Pl of 
oleamide solution. The assay solutions were then stirred and absorbance measured 
against one blank containing neither inhibitor nor oleamide and a second blank 
containing oleamide but no inhibitor. Oleamide was present in the assay at 100 
PM, while MAFP was assayed at concentrations between 10 nM and 1 PM, PMSF 
between 3.125 and 50 PM and anandamide between 10 and 320 PM. Each 
inhibitor concentration was assayed in triplicate using rat liver CPFs from three 
different animals. 
 
Data Analysis: 
Slopes were calculated as described previously and the blank containing neither 
inhibitor nor oleamide subtracted from the test samples. The percentage inhibition 
of oleamide hydrolysis was then calculated by comparing the inhibitor samples 
with the second blank containing oleamide but no inhibitor. The mean ± SEM 
inhibition was calculated from the triplicate inhibitor concentrations was then 
plotted against concentration (log M) and a variable slope sigmoidal curve fitted 
by non-linear regression using GraphPad Prism. The IC50 values generated for 
each tissue by the program were combined as the mean ± SEM.  
 
Results: 
Representative curves generated by these assays are shown in figure 6.12. The 
validity of this assay was confirmed by the concentration-dependent inhibition of 
FAAH-catalysed oleamide hydrolysis by these compounds. As predicted, the 
order of potency was MAFP > PMSF > anandamide, with IC50 values of  264 ± 49 
nM, 17 ± 3 PM and 171 ± 40 PM for the three compounds, respectively. These 
values for MAFP and PMSF are higher than expected, as can be observed when 
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they are compared to IC50 values described in the literature (table 6.4). There is 
no reported IC50 value for inhibition of FAAH activity by anandamide. There are 
two possible explanations of these discrepancies. Firstly, as mentioned before, the 
kinetics of inhibition may have been affected by the lower than optimal pH and 
temperature employed in this assay. Secondly, it was thought that the lack of 
preincubation of the inhibitors with FAAH may have affected these results, as 
methods described in the literature involve preincubating the inhibitors with the 
enzyme preparations for times of 10 to 20 minutes. The investigation of this 
possibility is described below. 
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Figure 6.12: Representative data showing the effect of MAFP (¹), PMSF (|) 
and anandamide (~) on the FAAH-catalysed hydrolysis of 100 PM oleamide in 
solubilized rat liver CPF. Data are expressed as the mean ± SEM of three 
determinations of percentage inhibition. 
 
 
 
 
 
ibitor (Log M) 
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Tissue Substrate Compound IC50 Reference 
N18TG2, approx. 
10x FAAH 
purification 
100 PM 
anandamide 
MAFP 3 nM 
De Petrocellis et al., 
1997 
RBL-1, approx. 
10x FAAH 
purification 
100 PM 
anandamide 
MAFP 1 nM 
De Petrocellis et al., 
1997 
Rat brain 
homogenate 
30 PM 
anandamide 
PMSF 290 nM
Deutsch et al., 
1997b 
Rat brain 
membranes minus 
cerebellum 
2 PM 
anandamide 
PMSF 3.7 PM Fowler et al., 1997 
 
Table 6.4: Previously reported IC50 values for inhibition of FAAH activity by 
MAFP and PMSF. 
 
 
Preincubation Assays 
To investigate the effect of preincubating FAAH with an inhibitor, the enzyme 
preparation was preincubated with 10 PM PMSF for different periods of time.  
 
Assay Procedure: 
The assay procedure was essentially as described above for the inhibitor studies. 
The effect of 10 PM PMSF on the hydrolysis of 100 PM oleamide was studied 
with preincubation times 10, 20 and 30 minutes in comparison to no 
preincubation. Each condition was assayed in triplicate with three different 
solubilized rat liver CPF preparations. The percentage inhibition of oleamide 
hydrolysis was calculated and the combined mean ± SEM plotted against 
preincubation time. To determine whether preincubation significantly affected the 
inhibition of enzyme activity, one-way analysis of variance was performed on the 
data. P values were determined by comparing the level of inhibition in 
preincubated samples with the control using GraphPad Prism. 
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Results: 
The results of the preincubation assays are shown in figure 6.13. It is clear that 
preincubation of FAAH with 10 PM PMSF caused a significant increase in the 
inhibition of the FAAH-catalysed hydrolysis of 100 µM oleamide compared to the 
control. This may at least partially explain the higher than expected IC50 values 
reported above. 
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Figure 6.13: The effect of preincubation with 10 PM PMSF on the FAAH-
catalysed hydrolysis of 100 PM oleamide in solubilized rat liver CPF. Data are 
expressed as the mean ± SEM of three independent experiments and were 
analysed by one-way ANOVA (*** P < 0.0001). 
 
 
The Effect of FAAH Inhibitors on Glutamate Dehydrogenase 
To complete the validation of this assay, it was necessary to demonstrate that the 
observed inhibition of oleamide hydrolysis was not due to the inhibition of 
glutamate dehydrogenase activity.  
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Assay Procedure: 
Using the solutions described in section 6.3.1, 140 Pl of solution A, 14 Pl of 
solution B, 192 Pl of buffer (1 mM EDTA, 50 mM Tris; pH 7.4) and 2 Pl of GDH 
solution were placed in acrylic cuvettes. Solutions were stirred then gently shaken 
for at least 10 minutes to allow equilibration and the cuvettes then placed in a 
Beckman DU650 spectrophotometer. Absorbance was measured at 340 nm and, 
when constant, 2 Pl of ethanol or ethanolic inhibitor solution was added to the 
cuvettes followed by 100 Pl of buffer or ammonium acetate solution (0.45 mM in 
buffer). Solutions were stirred and absorbance then automatically measured every 
38 seconds for up to 30 minutes. Assays consisted of two blank cuvettes, two 
control cuvettes to measure the GDH reaction rate and two cuvettes to examine 
the effect of the FAAH inhibitor. Triplicate assays were performed with each 
inhibitor using MAFP, PMSF and anandamide at assay concentrations of 1, 100 
and 320 PM, respectively. 
 
Data Analysis: 
Absorbance was plotted against time. Reaction rates were linear up to 300 
seconds, so the slopes of the curves were determined from 0 to 266 seconds by 
linear regression of the data using GraphPad Prism. Initial reaction rates 
(nmol/min/mg protein) were calculated as described above and the rates of the 
blanks subtracted from those of the test samples. The rate of the GDH reaction in 
the presence and absence of FAAH inhibitor was calculated as the mean ± SEM of 
the combined data and the rate in the presence of inhibitor was then expressed as a 
percentage of the control rate. To determine whether the reaction rate in the 
presence of FAAH inhibitor was significantly different from the control rate, the 
data were analysed by paired t-tests using GraphPad Prism. 
 
Results: 
The effect of FAAH inhibitors on the rate of the GDH reaction is shown in table 
6.5, which clearly demonstrates that none of the inhibitors tested had a significant 
effect on GDH activity. These data confirm that the observed, concentration-
dependent inhibition of oleamide hydrolysis by these compounds was not due to 
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an effect on GDH and, therefore, finally confirmed that the assay procedure was 
an effective means of measuring FAAH activity.  
 
 
FAAH 
Inhibitor 
Control Rate 
(nmol/min/mg 
protein) 
Rate with 
Inhibitor 
(nmol/min/mg 
protein) 
 
% of Control 
 
P Value
MAFP 
(1 PM) 205 ± 2 199 ± 2 96.9 ± 1.4 0.069 
PMSF 
(100 PM) 202 ± 2 200 ± 2 99.1 ± 1.3 0.161 
Anandamide 
(320 PM) 226 ± 3 228 ± 3 100.7 ± 1.8 0.182 
 
Table 6.5: The effect of FAAH inhibitors on the rate of GDH-catalysed glutamate 
production using 100 PM ammonium acetate. Data represent the mean ± SEM of 
three independent experiments with each inhibitor and were analysed by paired t-
tests using GraphPad Prism. 
 
With the completion of the assay validation, it was it was decided to perform one 
more investigation using this spectrophotometric procedure. To test its versatility, 
the assay was used to examine FAAH activity in various tissue preparations in 
order to determine whether there might be tissue-dependent differences, perhaps 
indicating the existence of more than one form of the enzyme. These experiments 
are described below. 
 
6.4 Comparison of FAAH Activity in Different Tissue 
Preparations 
 
The activity of FAAH has been shown to be broadly similar in brain and liver 
although, as described in section 1.5.4, there is evidence for the existence of other 
enzymes that hydrolyse endocannabinoids. However, most work published 
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concerning FAAH has involved the use of either solubilized or untreated tissue 
preparations and no direct comparisons have been made between the two. The 
original isolation and protein sequencing of FAAH was carried out using soluble 
protein from rat liver membranes, obtained by treatment with TX-100. This 
solubilization was used to characterize the FAAH activity in the assays described 
above, but no consideration was given to any FAAH activity that might be present 
in the pellet of insoluble protein that remained after solubilization. In the work 
described below, the FAAH activity in the solubilized and insoluble protein from 
the crude particulate fraction of rat liver and rat brain was examined. 
 
Preparation of Crude Particulate Fractions: 
Frozen livers or brains from Wistar or hooded Lister rats were thawed, weighed 
and homogenized in 10 volumes of ice-cold buffer (1 mM EDTA, 50 mM Tris; 
pH 7.4) using a Polytron homogenizer. The homogenate was centrifuged at 1,000g 
for 5 minutes at 4 qC, and the supernatant was then centrifuged at 36,000g for 20 
minutes at 4 qC. The resulting pellet was then suspended in 4 volumes (original 
wet weight) of ice-cold buffer and manually re-homogenized with a glass/teflon 
hgomogenizer. Aliquots of the CPF (1 ml) were frozen at -80 qC until required. 
 
Preparation of Soluble and Insoluble Protein Solutions from Rat Liver and Brain 
CPFs: 
Equal volumes of either rat liver or brain crude particulate fraction and 
solubilization buffer (1 mM EDTA, 50 mM Tris; pH 7.4, 1 % (w/v) TX-100) were 
mixed, placed on ice and vortexed three times in a fifteen minute period. The 
mixture was then centrifuged at 9,000g for 5 minutes at 4 qC and the supernatant 
retained as the soluble protein solution. The insoluble protein was then 
resuspended, with the aid of sonication, in the original volume of TX-100-free 
buffer. 
 
Assay of FAAH Activity: 
Using the solutions described in section 6.3.1, 140 Pl of solution A, 14 Pl of 
solution B, 2 Pl of GDH solution, 192 Pl of buffer and 100 Pl of soluble or 
insoluble protein were placed in acrylic cuvettes and stirred. The solutions were 
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gently shaken for at least 10 minutes to allow equilibration and then placed in a 
Beckman DU650 spectrophotometer. Absorbance was measured at 340 nm until 
constant and the assay initiated by the addition of 2 Pl of ethanol or ethanolic 
oleamide solution (22.5 mM). The solutions were stirred and absorbance 
automatically measured every 38 seconds for up to 30 minutes at room 
temperature. Each assay consisted of two blank cuvettes containing ethanol and 
four test cuvettes containing oleamide. Duplicate assays were performed with both 
soluble and insoluble protein. 
 
Data Analysis: 
The concentration of protein in each tissue solution was determined using the 
adaptation of the Bradford method (1976) as described in section 4.3.1. Rates of 
oleamide hydrolysis were calculated from the slopes generated by linear 
regression of the data from 0 to 494 seconds using GraphPad Prism. The mean 
blank rate in each assay was subtracted from the observed rate for each sample 
and the mean ± SEM rate of hydrolysis calculated using the data from the 
duplicate assays. 
 
Results: 
The results of this assay are shown in figure 6.14. The rates of oleamide 
hydrolysis using solubilized protein were 3.29 ± 0.08 and 1.05 ± 0.11 
nmol/min/mg protein in liver and brain, respectively. This contrasts with the rates 
observed using the insoluble protein which, for liver and brain, were 10.52 ± 0.18 
and 12.58 ±0.60 nmol/min/mg protein. This suggests that the majority of FAAH 
activity in both rat liver and brain was not solubilized by treatment with TX-100 
and remained bound to the plasma membrane. The FAAH activity in the insoluble 
liver protein was 3.2 times greater than that in the solubilized protein whereas, for 
brain, the insoluble protein possessed an activity 12.0 times greater than that 
found in the soluble protein. These results may indicate that the fifteen minute 
period used for the solubilization of the protein from these tissues was not 
adequate to achieve effective solubilization. Alternatively, the data may be 
evidence for the existence of two or more different FAAH activities in rat liver 
and brain. If this is the case, the activity evident in the insoluble protein 
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preparations may be more strongly anchored to the plasma membrane than the 
activity in the soluble preparations. The observed ratios of activities may also be 
indicative of a variation in the expression of these hypothetical enzymes in the 
two organs. In order to investigate the possible existence of multiple FAAH 
activities in these tissues, additional characterization would be required and this, 
unfortunately, was beyond the scope of this work. 
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Figure 6.14: The rate of FAAH-catalysed hydrolysis of 100 PM oleamide in 
solubilized and insoluble protein solutions from rat liver and brain crude 
particulate fraction. Data represent the mean ± SEM of eight determinations of the 
hydrolysis rate. 
 
Unlike existing procedures, the spectrophotometric nature of this assay gave it the 
potential for high-throughput screening (HTS) of compounds for inhibition of 
FAAH activity. The next section describes the adaptation of the assay for use on a 
96 well microtiter plate for the purpose of HTS. 
 
6.5 Adaptation of the FAAH Assay for Use on a Microtiter Plate 
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Inhibition of FAAH results in an increase in the levels of endogenous 
cannabinoids and, therefore, it is a potential drug target. However, screening large 
numbers of compounds for potential inhibitors using existing assays of FAAH 
activity would be impractical and expensive. The adaptation of this 
spectrophotometric assay for use on a 96 well (or greater) microtiter plate format 
would enable the cheap and rapid HTS of compound libraries for their effect on 
FAAH. Although the sensitivity of the spectrophotometric assay is not sufficient 
to detect very low levels of FAAH inhibition, the aim of HTS is to identify potent 
inhibitors and this would be easily achievable.  
 
As the key process in the assay was the use of GDH to detect the ammonia 
generated by FAAH-catalysed oleamide hydrolysis, it was first necessary to 
demonstrate that the GDH assay could be adapted for use on a microtiter plate. 
This procedure is described in the following section. 
 
6.5.1 Measurement of GDH Activity Using a Microtiter Plate 
Assay 
To adapt the GDH methodology for use on a microtiter plate, the major alteration 
required was a reduction of the assay volume from 450 to 200 Pl. To achieve this, 
the solutions used in the assay were adapted so that the assay concentrations of the 
individual components were the same as those in the spectrophotometer assay, 
despite the altered volumes used in this assay. 
 
 
 
GDH Microtiter Plate Assay Procedure: 
The assay solution was made up by placing 4.5 ml of solution A (49.38 mM D-
ketoglutarate, 2.96 mM ADP, 691.36 mM triethanolamine; pH 8.0), 600 Pl of 
solution B (7.41 mM E-NADH, 125.15 mM NaHCO3), 9.4 ml of buffer (1 mM 
EDTA, 50 mM Tris; pH 7.4) and 500 Pl of GDH solution (1600 kU/dm3 stock in 
50 % glycerol diluted to 284.4 kU/dm3 with buffer) in a universal tube. The 
solution was thoroughly mixed by vortexing and 150 Pl of the mixture placed in 
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each well of a 96 well microtiter plate. The absorbance of the solutions was 
measured at 340 nm on a Dynatech MR5000 microplate reader and, when 
constant, 50 Pl of buffer or ammonium acetate solution (12.5 to 800 PM, in 
buffer) was added to the assay solutions with a multi-tip pipette. The plate was 
then shaken for 10 seconds and the absorbance of each well was measured every 
30 seconds for 5 minutes. Of the eight rows on the plate, one row contained the 
buffer blank while the other seven each contained a different concentration of 
ammonium acetate. 
 
Data Analysis: 
For each of the eight assay conditions, the wells were treated individually. 
Absorbance was plotted against time and the slopes of the lines were determined 
by linear regression using GraphPad Prism. As the concentration of protein in the 
GDH solution was known, slopes were converted to reaction rates using the 
equation described in section 6.2.2 and the mean ± SEM rate was determined 
from the twelve repeats of each assay condition. The rate at each concentration of 
ammonium acetate was then determined by subtracting the blank rate from the 
observed rate. Reaction rate was plotted against ammonium acetate concentration 
and the data fitted by linear regression using GraphPad Prism. 
 
Results: 
The results of this assay are shown in figure 6.15, in comparison to those obtained 
using the spectrophotometer assay. 
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Figure 6.15: Comparison of the effect of ammonium acetate concentration on the 
rate of GDH-catalysed glutamate formation using spectrophotometer (|) and 
microtiter plate (¹) assays. Data are expressed as the mean ± range of two 
determinations of rate (spectrophotometer assay) or the mean ± SEM of twelve 
determinations of rate (microtiter plate assay) and were fitted by linear regression 
using GraphPad Prism. 
 
The reproducibility between these two sets of data clearly demonstrates that the 
spectrophotometric GDH assay could be effectively adapted for use on a 
microplate reader. The next logical step, therefore, was to investigate whether the 
same reproducibility existed for the FAAH spectrophotometer assay. 
 
6.5.2 Measurement of FAAH Activity Using a Microtiter Plate 
Assay 
Preliminary Assays 
The spectrophotometric FAAH assays were initiated by the addition of 2 Pl of 
ethanolic oleamide solution. To scale down this amount of oleamide solution for 
use in the microtiter plate assay, it would have been necessary to add 0.89 Pl of 
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ethanolic solution to each well. This was not readily achievable with any 
accuracy, so it was decided to dilute ethanolic oleamide in buffer before addition 
to the assays. This proved impossible to achieve as the oleamide consistently 
precipitated out of solution when diluted in buffer. This problem was not 
encountered in the spectrophotometer assay as the presence of TX-100 kept it in 
solution. To counter this problem, the ethanolic oleamide solution was diluted in 
buffer containing TX-100 and, to limit the amount of the detergent in the assay, 
tissue was not solubilized and was used directly in the assay. This was achieved as 
described below. 
 
Assay Procedure: 
Frozen aliquots of rat liver CPF were thawed and a tissue solution made up by 
mixing 2.2 ml of tissue homogenate with 2.8 ml of buffer (1 mM EDTA, 50 mM 
Tris; pH 7.4). Oleamide was dissolved to appropriate concentrations in ethanol 
and 20 Pl of the ethanolic solution, or ethanol for the blank solution, was diluted 
by the addition of 980 Pl of buffer containing 1 % (w/v) TX-100. Assay solutions 
were made up by adding 450 Pl of solution A, 60 Pl of solution B, 50 Pl of GDH 
solution, 500 Pl of oleamide solution and 440 Pl of buffer in a test tube. The 
solutions were thoroughly mixed by vortexing and 150 Pl of each solution placed 
in the wells of one column of a 96 well microtiter plate. The absorbance of the 
solutions was measured at 340 nm on a Dynatech MR5000 microplate reader and, 
when constant, 50 Pl of tissue solution was added to the assay solutions with a 
multi-tip pipette. The plate was then shaken for 10 seconds and the absorbance of 
each well was measured every 30 seconds for 5 minutes. The microtiter plate 
layout consisted of one column of eight blank solutions and six columns 
containing oleamide at assay concentrations of 3.75 to 200 PM. 
 
Data Analysis: 
The absorbance of each well was plotted against time and the rate of reaction 
(absorbance/sec) was determined by linear regression using GraphPad Prism. The 
mean ± SEM rate was calculated from the eight repeats of each assay condition 
and the rate at each concentration of oleamide was then determined by subtracting 
the blank rate from the observed rate. The concentration of oleamide was plotted 
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against the rate of hydrolysis and the data fitted by non-linear regression (one-site 
binding) using GraphPad Prism. 
 
Results: 
The results of this preliminary FAAH microtiter plate assay are shown in figure 
6.16. It is clear from these data that this preliminary assay was not successful. The 
reason for this undesirable result was unclear, although one factor that may have 
affected the outcome was the concentration of TX-100 present. In this assay, the 
TX-100 concentration was 0.245 % (w/v), compared to 0.111 % in the  
spectrophotometer FAAH assay. Both of these concentrations exceed the critical 
micelle concentration, the concentration of detergent at which micelles 
spontaneously form in solution. It is possible that the presence of micelles could 
cause light scattering, therefore affecting absorbance reading, although this did 
not appear to have any detrimental effects on the spectrophotometer assay. 
However, the absorbance readings from the microtiter plate assay were lower than 
the corresponding spectrophotometer assay because of the smaller path length 
involved. Any effects of light scattering by micelles would, therefore, have a 
greater effect on the plate assay than the spectrophotometer assay. This, combined 
with the higher TX-100 concentration, may be the reason for the failure of this 
preliminary assay. The next section describes how this problem was investigated 
using oleamide solutions with different concentrations of detergent. 
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Figure 6.16: The effect of oleamide concentration on the rate of FAAH-catalysed 
oleamide hydrolysis using a microtiter plate assay. Data are expressed as the mean 
± SEM of eight determinations of rate and were fitted by non-linear regression 
(one-site binding) using GraphPad Prism. 
 
 
Comparison of Oleamide Solutions and Tissue Preparations 
The method of oleamide solubilization described for the preliminary microtiter 
plate assay (solution one) was compared against an oleamide solution with 
significantly less TX-100. This solution (solution two) was made by diluting 200 
Pl of the appropriate concentration of ethanolic oleamide with 1.8 ml buffer 
containing 1 % (w/v) TX-100. This solution was then diluted five-fold in 
detergent-free buffer. Both oleamide solutions were then assayed using neat or 
solubilized rat liver crude particulate fraction to determine which appeared most 
effective. 
 
Assay Procedure: 
Two initial assay solutions were made up by placing 2.25 ml of solution A, 300 Pl 
of solution B and 250 Pl of GDH solution in universal tubes. For assays using neat 
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tissue, 1.1 ml of rat liver CPF and 3.6 ml of buffer was added to the initial assay 
solution. For assays using solubilized tissue, rat liver CPF was solubilized as 
previously described and 2.2 ml of this solution and 2.5 ml of buffer was added to 
the initial solution. Solutions were thoroughly mixed by vortexing and 150 Pl of 
each solution placed in the relevant wells of a 96 well microtiter plate. The 
absorbance of the solutions was measured at 340 nm on a Dynatech MR5000 
microplate reader and, when constant, 50 Pl of the appropriate oleamide solution 
or blank solution was added with a multi-tip pipette. The plate was then shaken 
for 10 seconds and the absorbance of each well was measured every 30 seconds 
for 5 minutes. Each of the two oleamide solutions and their corresponding blank 
solutions were assayed in both neat and solubilized rat liver CPF with oleamide 
concentrations of 60 and 120 PM. Eight determinations of oleamide hydrolysis 
rate were made for each assay condition and rates of oleamide hydrolysis were 
determined as described for the preliminary FAAH microtiter plate assay. 
 
Results: 
The data in figure 6.17 show the effect of the oleamide and tissue solutions on the 
rate of oleamide hydrolysis by FAAH in comparison with typical data from the 
standard FAAH spectrophotometer assay. It is apparent from this data that the use 
of oleamide solution two, with the reduced level of TX-100, resulted in a greatly 
reduced blank rate compared to the rate of hydrolysis in the presence of oleamide. 
Assays A and C, with the highest levels of detergent, were ineffective. Of the 
remaining microtiter plate assays, assay D showed the greatest correlation with 
the data from the spectrophotometer assay. The distinction between the two 
oleamide concentrations was greater in this assay, suggesting that solubilization of 
the rat liver CPF was more effective than the use of the neat tissue preparation. 
This was not unexpected, as the conditions in assay D were the closest to those 
used in the spectrophotometer assay. 
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Figure 6.17: The rate of FAAH-catalysed oleamide hydrolysis in microtiter plate 
assays using oleamide solutions one and two with neat (A and B) or solubilized (C 
and D) tissue, compared to data obtained from a typical FAAH spectrophotometer 
assay (E). Data are expressed as the mean ± SEM of eight determinations of rate 
for the plate assay and three determinations for the spectrophotometer assay. The 
numbers in brackets represent the TX-100 concentration in each assay. 
 
 
To determine whether these conditions were also effective at lower oleamide 
concentrations, concentration-response assays were performed. Quadruplicate 
determinations of the rate of oleamide hydrolysis were made at oleamide assay 
concentrations of 3.75 to 120 PM using three different solubilized rat liver CPFs. 
Reaction rates (absorbance/sec) were determined as described above and plotted 
against oleamide concentration. The results of these assays are shown in figure 
6.18. It is clear from these data that there was no evident relationship between the 
concentration of oleamide and the rate of its hydrolysis by FAAH using the 
microtiter plate assay. The rates of hydrolysis at the lower oleamide 
concentrations were not distinguishable from one another, making any kinetic 
     (0.245)          (0.045)         (0.355)          (0.155)         (0.111) 
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analysis impossible so, due to these disappointing results and time constraints, no 
further kinetic investigations were undertaken using this FAAH assay procedure. 
However, as the main aim of this adaptation was the high throughput screening of 
potential FAAH inhibitors, the effect of PMSF on the rate of hydrolysis of 
oleamide by FAAH was examined as described below. 
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Figure 6.18: The effect of oleamide concentration on the rate of FAAH-catalysed 
oleamide hydrolysis using adapted microtiter plate assays. Data are expressed as 
the mean ± SEM of four determinations of rate and were fitted by non-linear 
regression (one-site binding) using GraphPad Prism. 
 
 
6.5.3 Investigation of the Effect of PMSF on FAAH Activity Using 
a Microtiter Plate Assay 
If this assay was to be used to screen a library of compounds for potential potent 
inhibitors of FAAH activity, it would only be necessary to examine the effect of 
the compounds on the hydrolysis of a single concentration of oleamide. If a 
potential FAAH inhibitor was identified, more detailed kinetic studies could then 
be undertaken using the spectrophotometer FAAH assay or a “traditional” assay 
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for FAAH activity. The use of higher oleamide concentrations appeared to be the 
only effective measure of the rate of FAAH-catalysed oleamide hydrolysis in the 
attempted microtiter plate assays so, to investigate the viability of using this assay 
for HTS, the effect of 10 PM PMSF on the rate of hydrolysis of 100 PM oleamide 
by FAAH was investigated. This concentration of oleamide was chosen so a direct 
comparison could be made between this assay and the spectrophotometer assays 
with PMSF, which also used oleamide at 100 PM. 
 
Assay Procedure: 
Frozen rat liver crude particulate fraction was thawed and solubilized with an 
equal volume of buffer (1 mM EDTA, 50 mM Tris; pH 7.4) containing 1 % TX-
100 (w/v), as described previously. Oleamide was dissolved to 20 mM in ethanol, 
diluted ten-fold with buffer containing 1 % TX-100 (w/v) and this solution was 
then diluted five-fold in detergent-free buffer. PMSF was dissolved to 1 mM in 
ethanol, then assay solutions made by combining 900 Pl of solution A, 120 Pl of 
solution B, 100 Pl of GDH solution, 880 Pl of solubilized rat liver crude 
particulate fraction, 960 Pl of buffer and 40 Pl of ethanol or PMSF solution in a 
test tube. This solution was mixed by vortexing and 150 Pl per well placed in a 96 
well microtiter plate. After 30 minutes preincubation of PMSF with FAAH, the 
absorbance of the solutions was measured at 340 nm on a Dynatech MR5000 
microplate reader and, when constant, 50 Pl of oleamide solution or oleamide-free 
blank solution was added with a multi-tip pipette. The plate was then shaken for 
10 seconds and the absorbance of each well was measured every 30 seconds for 5 
minutes. Assays consisted of eight wells containing blank solutions, eight wells 
with oleamide and eight wells with oleamide and PMSF. Triplicate assays were 
performed using rat liver CPFs from three different animals. 
 
Data Analysis: 
The absorbance of each well was plotted against time and the rate of reaction 
(absorbance/min) determined by linear regression of the data using GraphPad 
Prism. The mean ± SEM rate was calculated from the eight determinations at each 
assay condition and the blank rate subtracted from the observed rates of 
hydrolysis for oleamide and oleamide in the presence of PMSF. To test if the rate 
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of oleamide hydrolysis in the presence of PMSF was significantly different from 
that of the control, data were analysed with un-paired t tests using GraphPad 
Prism. 
 
Results: 
The effect of 10 PM PMSF on the FAAH-catalysed hydrolysis of 100 PM 
oleamide in the microtiter plate assay is shown in figure 6.19. These data show 
that PMSF significantly inhibited FAAH activity. The mean inhibition of 
oleamide hydrolysis in the three experiments was 55.96 ± 1.90 % which compares 
well with the spectrophotometer assay, where 10 PM PMSF inhibited the 
hydrolysis of 100 PM oleamide by 34.35 ± 1.45 %. The difference in inhibition 
can be explained by the lack of preincubation of PMSF with FAAH prior to the 
spectrophotometer assays. These results give clear evidence that this microtiter 
plate assay can be used for the HTS of libraries of compounds for inhibitors of 
FAAH activity. 
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Figure 6.19: The effect of 10 PM PMSF on the rate of FAAH-catalysed 
hydrolysis of 100 PM oleamide using a microtiter plate assay. Data represent the 
mean ± SEM of eight determinations of hydrolysis rate and were analysed using 
un-paired t-tests (*** P < 0.0001). 
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The final investigations using this novel assay system concerned the examination 
of the effects of the aryl ethanolamide and phosphinic acid test compounds on 
FAAH activity. These experiments are described below. 
 
 
6.6 Investigation of the Effects of Test Compounds on FAAH 
Activity 
 
The effects of the novel test compounds on the hydrolysis of 100 PM oleamide by 
FAAH were examined using the same methodology described for the known 
inhibitors of the enzyme. Each compound was tested in triplicate at an assay 
concentration of 10 or 100 PM, depending on their solubility in ethanol, and 
duplicate assays were performed using solubilized preparations of rat liver CPFs 
from two different animals. After subtracting the blank slope from the test slopes, 
the percentage inhibition of oleamide hydrolysis by each compound was 
calculated by comparison with the control rate. The mean ± range percentage 
inhibition was then calculated. The results from these assays are shown in figure 
6.20. 
 
It is clear from these data that, as with the other potential targets investigated, the 
test compounds had no effect on the rate of FAAH-catalysed oleamide hydrolysis. 
These results are especially disappointing considering that the two 
alklylphosphinic acids were designed to be the phosphinic acid analogues of 
known FAAH inhibitors. This suggests that the phosphinic acid moiety is not a 
transition state inhibitor of the hydrolysis of endocannabinoids and oleamide by 
FAAH.  
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Figure 6.20: The effect of the novel aryl ethanolamide and phosphinic acid test 
compounds on the FAAH-catalysed hydrolysis of 100 PM oleamide. Data are 
expressed as the mean ± range of two independent experiments, each performed 
with triplicate concentrations of test compound. 
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Chapter 7: 
 
Summary and General 
Discussion 
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7.1 CB1 Receptor Binding Studies 
 
It is clear from the data presented in chapter 3 that the novel aryl ethanolamide 
and phosphinic acid compounds synthesized during this research had very little or 
no affinity for the CB1 receptor. The only two compounds that exhibited even low 
CB1 receptor affinity were the aryl ethanolamides AE5 and AE6, although the 
approximate Ki value for both compounds was >76.5 PM. In rat brain membranes, 
no increase in [35S]-GTP-J-S binding was observed above basal levels in the 
presence of the target compounds suggesting that, in addition to the CB1 receptor, 
the target compounds did not activate any other GPCRs in this tissue. Of course, 
this does not rule out the possibility that these compounds are antagonists of other 
GPCRs, but the investigation of this possibility was beyond the scope and aims of 
this work. This lack of pharmacological activity is not entirely unexpected for the 
alkylphosphinic acid compounds. The lack of unsaturation in the alkyl chains of 
APA2 and APA3 resulted in these compounds being analogous to saturated fatty 
acid amides which do not possess CB1 receptor affinity. The incorporation of 
carbon-carbon double bonds in the alkyl chain, as was the ultimate aim for these 
compounds, may result in an increased CB1 receptor affinity, although this is 
purely speculative. 
 
Despite these disappointing results, research published since the completion of 
this work has shown that the aryl ethanolamide template was a valid target for the 
synthesis of potential cannabimimetic drugs. Berglund et al. (2000) synthesized a 
series of monocyclic and bicyclic alkyl amide cannabinoid receptor ligands, 
structurally very similar to the aryl ethanolamide compounds described in this 
thesis. The structures of some of these compounds and their Ki values at the CB1 
and CB2 receptors are shown in table 7.1. It is apparent from these data, that the 
compounds described by Berglund et al. were generally selective for the CB1 
receptor. Structurally, when compared to the aryl ethanolamides, it is clear that 
affinity for the cannabinoid receptors is greatly increased by the incorporation of 
an alkyl chain with a cis double bond at the ortho or meta position of the benzene 
ring. It can only be assumed that similar structural modifications applied to the 
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phenylphosphinic acid compounds would also confer affinity for the cannabinoid 
receptors and resistance to hydrolysis in vivo.  
Compound Structure 
CB1 Ki 
(nM) 
CB2 Ki 
(nM) 
CB1/CB2 
Ratio 
AE5 
O
N
H
OH
 
>76.5 PM - - 
AE6 
O
H
N
OH
 
>76.5 PM - - 
1 
O
N
H
OH
 
371 474 0.78 
2 
O
H
N
OH
 
359 672 0.53 
3 
O
N
H
OH
 
38 99 0.38 
4 
O
N
H
OH
 
59 305 0.19 
5 N
H
O
OH
 
6800 849 8.00 
 
Table 7.1: The structures and Ki values at the CB1 and CB2 receptors of 
compounds synthesized by Berglund et al. (2000) in comparison to AE5 and AE6. 
 
The development of these novel cannabinoid ligands by Berglund et al. offers the 
possibility that the synthesis of compounds of this type with even higher receptor 
affinities is possible. No mention was made by these authors, however, of the 
ability of these cyclic alkyl amides to inhibit anandamide uptake or FAAH. These 
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compounds would possibly act as modulators of these targets given that they are 
structural mimics of the endogenous cannabinoids. Therefore, the hypothesis that 
aryl ethanolamides are potential cannabimimetic drugs has been shown to be 
valid, although the compounds generated lacked sufficient structural diversity. 
This cannabimimetic potential may also apply to phenylphosphinic acid 
compounds. 
 
 
7.2 CB2 Receptor Binding Studies 
 
To date, the porcine CB2 receptor has not been cloned and little research has been 
performed to elucidate the binding profile of this receptor. The data presented in 
chapter 4 demonstrate the development of an effective cannabinoid competition 
assay using porcine spleen membranes. The Kd of CP-55,940 in this tissue 
preparation was shown to be 1.55 nM with a Bmax value of 169 fmol/mg protein. 
This Kd value compares well with values in the literature using the cloned human, 
murine and rat CB2 receptors. The Ki values of a number of cannabinoid receptor 
ligands were determined using this assay system and also compared favourably 
with data from cloned CB2 receptors. Confirming reports in the literature that 
there is only a low level of FAAH activity in the spleen, pre-treatment of spleen 
membranes with PMSF prior to competition assays with anandamide had no effect 
on the Ki value of this endocannabinoid. The differences in the Kd and Ki values 
compared to data in the literature are likely to be due to inter-species differences 
in the CB2 receptors and the unavoidable presence of CB1 receptors in the spleen 
membranes, albeit at much lower levels than the CB2 receptor. Attempts at 
developing a [35S]-GTP-J-S binding assay using porcine spleen membranes were 
unsuccessful, however, presumably due to the low number of cannabinoid 
receptors in this tissue compared to brain membranes in which [35S]-GTP-J-S 
binding assays were possible. 
 
The potential affinities of the target compounds for the CB2 receptor was also 
examined using this assay. The presence of CB1 receptors in the spleen 
membranes had no effect on these experiments as very little or no affinity for the 
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CB1 receptor was observed for these compounds. Similarly, this was also the case 
for the CB2 receptor, with no compound showing even low affinity. As described 
for CB1 receptor affinity in section 7.1, the lack of CB2 receptor affinity 
exhibited by the alkylphosphinic acid compounds was not unexpected. The 
endogenous saturated fatty acid amides, of which these compounds are analogues, 
do not bind to the CB2 receptor, although it would be interesting to examine the 
effects of these compounds on the postulated CB2-like receptor(s) with which 
palmitoylethanolamide, itself an saturated species, may interact. It is likely that 
the lack of unsaturation in these compounds was a major impediment to their 
ability to bind to the CB2 receptor. 
 
However, since the synthesis of the target aryl ethanolamide and phosphinic acid 
compounds was completed, a worldwide patent by Japan Tobacco Inc. (1997) 
disclosed highly selective ligands for the CB2 receptor that were based on an aryl 
ethanolamide template. Of 391 compounds tested, 32 proved to be potent 
cannabinoid receptor ligands and some of these species are shown in table 7.2.  
 
Structure CB1 Ki (nM) CB2 Ki (nM) CB1/CB2 Ratio 
O
N
H
OH
O
O
 
>3300 0.44 >7500 
O
N
H
NH2
S
O
 
>4300 1.9 >2263 
N
O NH2
O
O
 
330 0.11 3000 
 
Table 7.2: The structures and Ki values at the CB1 and CB2 cannabinoid receptor 
of highly selective CB2 receptor ligands developed by Japan Tobacco. 
 
It is evident that these compounds are the most selective CB2 ligands yet and, 
although their pharmacology has not been examined in detail, they have great 
therapeutic potential and may inhibit endocannabinoid uptake and degradation. 
Structurally, these compounds differ from the aryl ethanolamides by the inclusion 
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of a substituted phenyl group in place of the hydroxy group and alkyl ester or 
alkyl sulphide substituents at the meta or para positions of the benzene ring. The 
phenylphosphinic acid equivalents of these compounds may also exhibit high 
affinity for the cannabinoid receptors while being resistant to hydrolysis. 
Therefore, as for the CB1 receptor, the hypothesis that aryl ethanolamides, and 
possibly their corresponding phenylphosphinic acids, are potential 
cannabimimetic drugs has been shown to be valid although more structural 
diversity was required than in the compounds whose synthesis this thesis 
describes. 
 
 
7.3 Anandamide Uptake Studies 
 
Accumulation of anandamide into the mouse neuroblastoma cell line N18TG2 
was previously demonstrated by Deutsch & Chin (1993) but, until now, this 
mechanism had not been characterized. [3H]-Anandamide uptake into cultured 
N18TG2 cells was shown to be concentration-, time- and temperature-dependent. 
In addition, this accumulation was inhibited by the selective anandamide transport 
inhibitor AM404 and the prostaglandin E2 uptake inhibitor bromocresol green, 
confirming the characteristics of the anandamide uptake system observed by 
Beltramo et al. (1997) in rat neurones and astrocytes. However, although not fully 
characterized, the kinetics of anandamide uptake into N18TG2 cells differed from 
those reported by Beltramo et al. The Km observed in N18TG2 cells fell between 
the Km values reported for rat neurone and astrocyte anandamide accumulation 
and the time taken to achieve 50 % of the maximal rate appeared considerably 
greater than in these two rat cell types. Nonetheless, the presence of an 
anandamide uptake system was confirmed in N18TG2 cells, allowing the effects 
of the aryl ethanolamide and phosphinic acid target compounds on this transporter 
to be investigated. 
 
None of the target compounds displayed any significant inhibitory effect on 
anandamide uptake into cultured N18TG2 cells. The only compound that was a 
possible anandamide uptake inhibitor, PPA2, displays some structural similarities 
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with AM404. However, higher concentrations of PPA2 than the single 10 PM 
assay concentration used would be required to confirm any effects. All inhibitors 
of anandamide uptake described in the literature, with the exception of 
bromocresol green, show at least some affinity for one or both cannabinoid 
receptors. Considering the lack of cannabinoid receptor affinity displayed by the 
compounds synthesized in the course of this research, it is perhaps not surprising 
that they were not effective in inhibiting anandamide uptake. However, since the 
chemical synthesis of the target compounds was completed, it has been shown that 
the vanilloid receptor ligand olvanil and its derivatives inhibit anandamide uptake 
with IC50 values approaching that of AM404. Some of these compounds are 
shown in table 7.3. 
 
 
Structure IC50 (PM) 
O
N
H
OH
2.2 
N
H
O
OMe
OH
9.0  
N
H
O
OMe
OH
7.0  
O
N
H
OMe
OH
5.0  
N
H
O
OMe
OH
3.6  
 
Table 7.3: The structures and IC50 values at the anandamide transporter of 
AM404 and some of the vanilloid receptor ligands (Melck et al., 1999b). 
 
AM404 
Olvanil 
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The structural similarities between these compounds and the long alkyl chain 
phenylphosphinic acids are obvious. It is entirely possible that incorporation of a 
para-hydroxy group into the benzene ring of PPA5 (octadecylphenylphosphinic 
acid) and at least one carbon-carbon double bond in the alkyl chain would enable 
this compound to inhibit anandamide uptake. Unfortunately, the anandamide 
transporter and its inhibitors were unknown at the time the target compounds were 
synthesized and, therefore, they were not designed as uptake inhibitors. However, 
as with the CB1 and CB2 receptor affinity, their lack of structural diversity 
appears to have severely limited their biological activity. 
 
 
7.4 Fatty Acid Amide Hydrolase Studies 
 
Chapter 6 describes a novel spectrophotometric assay for rat liver FAAH activity 
as an alternative to the widely used radiochemical- and HPLC-based assays. Using 
this methodology, the Km and Vmax values for FAAH-catalysed oleamide 
hydrolysis were determined and found to be similar to values published in the 
literature. In addition, inhibition of FAAH by MAPF, PMSF and anandamide was 
observed in a concentration-dependent manner, although the IC50 values of these 
compounds were higher than previously published data. However, “traditional” 
FAAH assays often involve pre-incubation of the enzyme with an inhibitor prior 
to initiation of the reaction. Using the spectrophotometric assay, PMSF was pre-
incubated with FAAH for up to 30 minutes and this procedure significantly 
increased the level of inhibition. It was also shown that the levels of FAAH 
activity in solubilized and insoluble membrane fractions of rat brain and liver 
were significantly different. This may be due to the presence of more than one 
FAAH enzyme in these tissues, although further research is required to confirm 
this. In addition, due to the spectrophotometric nature of this assay, the possibility 
of scaling down the protocol for use on microtiter plates was examined. Although 
kinetic analysis of FAAH activity was not readily achievable on a microtiter plate, 
the assay was shown to have the potential for high-throughput screening of 
chemical libraries for FAAH inhibitors. This may prove important in the 
development of novel cannabimimetic drugs.  
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When the novel aryl ethanolamide and phosphinic acid target compounds were 
assayed for their ability to inhibit FAAH activity, no biological activity was 
apparent. The aryl ethanolamides and phenylphosphinic acids were ineffective as 
ligands for the CB1 and CB2 cannabinoid receptors and, therefore, would not be 
expected to compete with endogenous fatty acid amides for FAAH. However, 
although inactive in cannabinoid receptor competition and anandamide uptake 
assays, it was hoped that the alkylphosphinic acids would inhibit FAAH. These 
compounds were primarily designed as transition state FAAH inhibitors, being the 
phosphinic analogues of potent FAAH inhibitors, so these results are especially 
disappointing. Therefore, it is apparent that the phosphinic acid moiety does not 
inhibit the transition state of FAAH-catalysed amide bind hydrolysis. As 
described in section 1.5.3, new evidence now supports the proposal that FAAH 
catalyses the hydrolysis of both amide and ester bonds by a novel mechanism 
(Patricelli et al., 1999; Patricelli & Cravatt, 1999). This novel activity may be a 
contributary factor in the failure of the alkylphosphinic acid compounds to inhibit 
oleamide hydrolysis. It is also apparent from existing FAAH inhibitors that a good 
leaving group, such as a fluorine atom, is necessary for reaction with serine or 
cysteine residues at the active site of the enzyme. This is demonstrated for the 
sulphonyl fluoride and methyl fluorophosphonate compounds in scheme 7.1.  
 
 
 
 
 
 
 
 
 
 
 
Scheme 7.1: Proposed mechanism by which sulphonyl fluorides and methyl 
fluorophosphonates inhibit FAAH, demonstrating the importance of a good 
leaving group (Di Marzo & Deutsch, 1998). R = O or S. 
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It is likely that modifying APA2 and APA3 by replacing the hydrogen atom or 
hydroxyl group of the phosphinic acid moiety with a good leaving group would 
confer the ability to inhibit to FAAH on these compounds. This effect could be 
increased by the incorporation of at least one carbon-carbon double bond in to the 
alkyl chain, thereby mimicking FAAH substrates such as oleamide. Such 
modifications may also impart inhibitory activity on the phenylphosphinic acid 
compounds, although a deal of work is required to confirm these assumptions. 
 
 
7.5 Conclusion 
 
None of the novel target compounds described in this thesis proved to be 
cannabimimetic. It is clear that the limited structural diversity of these compounds 
compromised their biological activity and, therefore, future work inevitably 
requires the inclusion of more varied substituent groups into species. However, 
the potential remains for the development of modulators of endocannabinoid 
signalling based on the aryl ethanolamide, phenylphosphinic acid and 
alkylphosphinic acid templates. Compounds analogous to the aryl ethanolamides 
have already been shown to act as cannabinoid receptor ligands by Berglund et al. 
and Japan Tobacco. There are no reports in the literature, however, of 
cannabimimetic compounds containing the phosphinic acid moiety, although 
phosphorus-containing compounds are able to bind to the CB1 receptor and 
FAAH, demonstrated by the methyl fluorophosphonates which are CB1 receptor 
agonists and potent FAAH inhibitors (Martin et al., 2000). Therefore, as described 
in this chapter, structural modifications of the phenylphosphinic and 
alkylphosphinic acids may confer affinity for the cannabinoid receptors or the 
ability to inhibit endocannabinoid uptake and FAAH. The activity of these 
compounds would be enhanced by their metabolic stability, imparting an extended 
half-life in vivo. 
Research in to the endocannabinoid system is still at a relatively early stage and it 
is highly likely that there are targets for cannabimimetic drugs that remain 
undiscovered. Indeed, there is mounting evidence for the existence of enzymes 
other than FAAH that catalyse endocannabinoid degradation (Goparaju et al., 
 196
1999; Ueda et al., 1999) the presence of peripheral CB1-like (Pertwee, 1999) and 
CB-2 like (Griffin et al., 1997; Calignano et al., 1998) receptors in the body. To 
date, these receptors have been implicated in the tumour suppressive effects (De 
Petrocellis et al., 1998), vasodilatory effects (Harris et al., 1999; Járai et al., 1999) 
and attenuation of pain responses (Calignano et al., 1998) that are modulated by 
endocannabinoids and may present opportunities for novel therapies. Of particular 
interest is the dissociation of the potential psychotropic effects of cannabimimetics 
from their positive therapeutic effects. Peripheral CB1- and CB2-like receptors 
offer a real possibility of achieving this goal. Therefore, although the novel target 
compounds described in this thesis possessed no biological activity at the known 
targets involved in endocannabinoid signalling, it may be that they, or their 
derivatives, may act as specific ligands for undiscovered components of the 
endogenous cannabinoid signalling pathways. 
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Appendix A: 
 
Synthetic Chemistry Protocols 
and Physical Data 
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A1. Physical Measurements 
 
Analytical thin layer chromatography was performed on aluminium-backed Merck 
silica gel 60 F254 plates and visualization of spots achieved using ultraviolet light 
or potassium permanganate staining. Flash column chromatography was 
performed using Merck silica gel 60, particle size 0.04-0.063 mm. 
Melting point determinations were carried out using Griffin melting point 
apparatus.  
All 1H and 31P NMR spectra were obtained using a Bruker ARX250 nuclear 
magnetic spectrometer and chemical shifts are quoted as parts per million on the G 
scale. Mass spectra were recorded on a Micromass Platform mass spectrometer by 
Dr Catherine Ortori in the School of Pharmaceutical Sciences, University of 
Nottingham. Microanalysis was performed by Mr Trevor Spencer in the 
Microanalysis Laboratory, School of Chemistry, University of Nottingham. 
 
A2. Synthesis of Aryl Ethanolamides 
 
Acid Chloride Strategy 
 
Typical Experimental Protocol: 
The appropriate carboxylic acid (3.0 mmol) was dissolved in a suitable solvent 
(30 to 50 ml) in the presence or absence of DMF (1.50 to 4.77 mmol). The stirred 
solution was cooled to 0 qC in an ice bath, oxalyl chloride (3.27 to 5.73 mmol) 
was added and the solution stirred at room temperature under an inert atmosphere 
or with a silica guard tube for between 30 minutes and 3 hours. After this time, the 
solution was cooled to 0 qC and ethanolamine (5.40 to 16.50 mmol) added. 
Stirring was continued for between 20 minutes and 2 hours at room temperature 
and the solution then washed potassium hydrogen sulphate solution (1 M, 20 ml), 
saturated sodium hydrogen carbonate solution (20 ml), distilled water (20 ml) and 
saturated sodium chloride solution (20 ml). The solution was dried over 
magnesium sulphate, filtered and solvent removed in vacuo to yield the crude 
product, which was purified by flash column chromatography. 
 199
 
The following compounds were synthesized using this methodology: 
 
N-(2-Hydroxyethyl)-3-phenylpropionamide (AE5) as a crude white solid (0.26 g, 
40 %), purified by flash chromatography using DCM:MeOH (95:5) as eluent to 
yield a crystalline white solid (0.17 g, 26 %), Rf 0.30,  m.p. 77-79 qC; GH (250 
MHz, CDCl3) 2.50 (2H, t, J=7.63 Hz, PhCH2), 2.97 (2H, t, J=7.63 Hz, 
PhCH2CH2), 3.35 (2H, q, J=5.00 Hz, NHCH2), 3.62 (2H, t, J=4.88 Hz, CH2OH), 
5.97 (1H, s, NH), 7.18-7.32 (5H, m, CH2C6H5); m/z 194.4 (MH+, 100 %), MH+ 
requires 194.4. C 67.64; H 7.63; N 6.71 %. C11H15NO2 requires C 68.37; H 7.82; 
N 7.25 %. 
 
N-(2-Hydroxyethyl)-2-phenylpropionamide (AE6) as crude yellow oil (0.50 g, 78 
%), purified by flash chromatography using DCM:MeOH (95:5) as eluent to yield 
a pale yellow oil (0.40 g, 62 %), Rf  0.37, GH (250 MHz, CDCl3) 1.55 (3H, d, 
J=7.25 Hz, CH3), 3.34 (2H, m, NHCH2), 3.58 (3H, m, CHCONHCH2CH2OH), 
6.08 (1H, s, NH), 7.24-7.40 (5H,  m, C6H5); m/z 194.4 (MH+, 100%), MH+ 
requires 194.2. C 68.50; H 7.99; N 7.20 %. C11H15NO2 requires C 68.37; H 7.82; 
N 7.25 %. 
 
N-(2-Hydroxyethyl)-3-chlorobenzamide (AE9) as a crude, pale yellow solid (0.45 
g, 71 %), purified by flash chromatography using DCM:MeOH (95:5) as eluent to 
yield a pale yellow crystalline solid (0.45 g, 71 %), Rf  0.22, m.p. 101-103 qC; GH 
(250 MHz, MeOH-d4) 3.67 (2H, t, J=5.63 Hz, NHCH2), 3.88 (2H, t, J=5.75 Hz, 
CH2OH), 7.59-8.04 (4H, m, COC6H4Cl); m/z 200.3 (MH+, 100%), MH+ requires 
200.6. C 54.20; H 5.13; N 6.96 %. C9H10NO2Cl requires C 54.15; H 5.05; N 7.02 
%. 
 
N-(2-Hydroxyethyl)-2-naphthylacetamide (AE14) as a crude, pale yellow solid 
(1.09 g, 89 %), purified by flash chromatography using EtOAc as eluent to yield a 
pale yellow crystalline solid (0.60 g, 49 %), Rf  0.17, m.p. 134-136 qC; GH (250 
MHz, CDCl3) 2.71 (1H, s, OH), 3.40 (2H, s, CH2CO), 3.69 (2H, t, J=4.75 Hz, 
NHCH2), 3.81 (2H, m, CH2OH) 6.32 (1H, s, NH), 7.40 (1H, d, J=9.0 Hz, Naph 
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C3H), 7.51 (2H, m, Naph C6,7H), 7.75-7.88 (4H, m, Naph C1,4,5,8H); m/z 230.1 
(MH+), 212.1 (MH+-H2O), MH+ requires 230.3. C 71.14; H 6.62; N 6.00 %. 
C14H15NO2 requires C 73.34; H 6.59; N 6.11 %. 
 
 
Coupling Strategy 
Only one compound was successfully synthesized using the EDC coupling 
strategy. The following is the experimental protocol used in this reaction: 
 
4-Biphenylacetic acid (0.5 g, 2.36 mmol) and EDC (0.5 g, 2.61 mmol) were 
dissolved in dichloromethane (40 ml) and a catalytic amount of DMAP was 
added. The solution was stirred at room temperature for 15 minutes, then 
ethanolamine (5.0 mmol) was added dropwise. The reaction was stirred at room 
temperature with a silica guard tube for 20 hours then the solution was then 
washed with hydrochloric acid (2 M, 2 x 30 ml), saturated sodium hydrogen 
carbonate solution (2 x 30 ml), distilled water (30 ml) and saturated sodium 
chloride solution (30 ml). The solution was dried over magnesium sulphate and 
the solvent removed in vacuo to yield N-(2-hydroxyethyl)-4-biphenylacetamide 
(AE13) as a crude, pale yellow solid (0.39 g, 65 %) which was purified by flash 
chromatography using DCM:MeOH (95:5) as eluent to yield a white solid (0.32 g, 
53 %), Rf  0.21, m.p. 185-186 qC; GH (250 MHz, MeOH-d4) 1.86 (1H, br s, 
CH2OH), 3.44 (2H, q, J=5.0 Hz, NHCH2), 3.72 (4H, m, CH2CONHCH2CH2), 
7.29-7.64 (9H, br m, aryl); m/z 256.0 (MH+, 100%), MH+ requires 256.3. C 54.20; 
H 5.13; N 6.96 %. C9H10NO2Cl requires C 54.15; H 5.05; N 7.02 %. 
 
A3. Synthesis of Phenylphosphinic Acids 
 
Typical Experimental Protocol: 
Phenylphosphinic acid (14.1 mmol) was placed under an inert atmosphere, 
dissolved in dry dichloromethane (30 ml) and cooled to 0 qC in an ice bath. 
Diisopropylamine (31.0 mmol) and trimethylsilyl chloride (31.5 mmol) were 
added, the solution stirred for 3 hrs at room temperature and then cooled to 0 qC. 
The appropriate electrophile (21.2 mmol) was added, the solution stirred for 7 to 
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12 days at room temperature and then washed with hydrochloric acid (2M, 5 x 20 
ml) and sodium hydroxide solution (1M, 40 ml). The organic phase was discarded 
and the remaining aqueous phase acidified with hydrochloric acid (2M, 50 ml) to 
liberate the phenylphosphinic acid. The product was redissolved in 
dichloromethane (2 x 20 ml) and this organic phase was then washed with 
distilled water (30 ml) and saturated sodium chloride solution (30 ml). The 
solution was dried over magnesium sulphate, filtered and the solvent removed in 
vacuo to yield the phenylphosphinic acid. The following compounds were 
synthesized using this methodology: 
 
Decylphenylphosphinic acid (PPA2) as a white solid (2.26 g, 57 %), m.p. 60-61 
qC; GH (250 MHz, CDCl3) 0.86 (3H, t, J=3.25 Hz, CH3), 1.17-1.44 (16H, m, CH2-
(CH2)8-CH3), 1.69-1.85 (2H, m, P-CH2), 7.38-7.48 (3H, m, Ph C3,4,5H), 7.67-7.75 
(2H, m, Ph C2,6H), 9.20 (1H, s, P-OH); GP (101 MHz, CDCl3) 47.63;  m/z 283.2 
(MH+, 100%), MH+ requires 283.4. C 66.87; H 9.91 %. C16H27PO2 requires C 
68.06; H 9.64 %. 
 
Isobutylphenylphosphinic acid (PPA4) as a white solid (0.59 g, 21 %), m.p. 64-67 
qC; GH (250 MHz, CDCl3) 0.91 (6H, d, J=7.5 Hz, CH(CH3)2), 1.71-2.00 (3H, m, 
CH2CH), 7.35-7.47 (3H, m, Ph C3,4,5H), 7.66-7.74 (2H, m, Ph C2,6H), 10.61 (1H, 
s, POH); GP (101 MHz, CDCl3) 47.49;  m/z 199.1 (MH+, 100%), MH+ requires 
199.2. C 59.76; H 7.42 %. C10H15PO2 requires C 60.60; H 7.63 %. 
 
Octadecylphenylphosphinic acid (PPA5) as a white solid (3.48 g, 63 %), m.p. 79-
82 qC; GH (250 MHz, CDCl3) 0.91 (3H, t, J=6.50 Hz, CH3), 1.22-1.46 (32H, m, 
CH2(CH2)16CH3), 1.69-1.90 (2H, m, PCH2), 7.40-7.55 (3H, m, Ph C3,4,5H), 7.67-
7.79 (2H, m, Ph C2,6H), 9.48 (1H, s, POH); GP (101 MHz, CDCl3) 48.34; m/z 
395.5 (MH+, 100%), MH+ requires 395.6. C 73.07; H 10.93 %. C24H43PO2 
requires C 73.06; H 10.98 %. 
 
Hexadecylphenylphosphinic acid (PPA7) as a white solid (4.08 g, 79 %), m.p. 73-
76 qC; GH (250 MHz, CDCl3) 0.88 (3H, t, J=6.5 Hz, CH3), 1.19-1.57 (28H, m, 
(CH2)14CH3), 1.71-1.88 (2H, m, PCH2), 7.38-7.50 (3H, m, Ph C3,4,5H), 7.68-7.76 
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(2H, m, Ph C2,6H), 7.95 (1H, s, POH); Gp (101 MHz, CDCl3) 48.60;  m/z 367.5 
(MH+, 100%), MH+ requires 367.5. C 72.08; H 10.87 %. C22H39PO2 requires C 
72.09; H 10.73 %. 
 
Propylphenylphosphinic acid (PPA8) as a white solid (1.77 g, 68 %), m.p. 85-87 
qC; GH (250 MHz, CDCl3) 0.88 (3H, t, J=7.50 Hz, CH3), 1.44-1.53 (2H, m, 
CH2CH3), 1.72-1.84 (2H, m, PCH2), 7.25-7.48 (3H, m, Ph C3,4,5H), 7.67-7.75 (2H, 
m, Ph C2,6H), 11.92 (1H, s, POH); GP (101 MHz, CDCl3) 46.86;  m/z 351.3 
((2M)H+-H2O, 100%), MH+ requires 185.2. C 58.50; H 6.83 %. C9H13PO2 
requires C 58.69; H 7.11 %. 
 
A4. Synthesis of Alkylphosphinic Acids 
 
Ammonium Phosphinate Synthesis: 
Hypophosphorus acid (50 % w/w, 0.27 mmol) was placed in a round-bottomed 
flask and cooled to 0qC in an ice bath. Concentrated ammonia solution was added 
dropwise with stirring until in excess, then as much water as possible was 
removed in vacuo. The remaining water was azeotroped with cyclohexane, the 
mixture removed in vacuo and the product dried over phosphorus pentoxide to 
yield ammonium phosphinate as a white solid in quantitative yield. 
 
 
Mono-Substituted Alkylphosphinic Acids   
 
Typical Experimental Protocol: 
Ammonium phosphinate (2.5 g, 30.1 mmol) and hexamethyldisilazane (33.1 
mmol) were heated together at 110-120 qC for 3 hours under an inert atmosphere. 
The mixture was then cooled to 0 qC, dry dichloromethane (30 ml) and the 
appropriate alkyl iodide (27.1 mmol) injected and the solution stirred at room 
temperature for 3 to 7 days. After this time, the solution was filtered, washed with 
hydrochloric acid (2 M, 3 x 30 ml) and dried over magnesium sulphate. The 
solvent was then removed in vacuo to yield the crude product which was re-
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suspended in methanol (40 ml) and stirred for 2 hours. The methanol was then 
rmoved in vacuo, the product washed with ethyl acetate (3 x 30 ml) and filtered. 
The following compounds were synthesized using this methodology: 
 
Hexadecylphosphinic acid (APA2) as a white solid (1.62 g, 26 %), m.p. 58-61 qC; 
GH (250 MHz, CDCl3) 0.86 (3H, t, J=6.50 Hz, CH3), 1.14-1.81 (30H, m, 
(CH2)15CH3), 6.01 and 8.18 (1H, d, J=541.75 Hz, PH), 7.68 (1H, s, POH); GP (101 
MHz, CDCl3) 41.26; m/z 291.7 (MH+, 100%), MH+ requires 291.4. C 66.82; H 
12.23 %. C16H35PO2 requires C 66.17; H 7.63 %. 
 
Octadecylphosphinic acid (APA3) as a white solid (1.98 g, 26 %), m.p. 68-71 qC; 
GH (250 MHz, CDCl3) 0.92 (3H, t, J=6.75 Hz, CH3), 1.22-1.87 (34H, m, 
(CH2)17CH3), 6.09 and 8.25 (1H, d, J=541.50 Hz, PH), 4.63 (1H, s, POH); GP (101 
MHz, CDCl3) 42.09; m/z 319.2 (MH+, 100%), MH+ requires 319.5. C 68.04; H 
12.65 %. C18H39PO2 requires C 67.88; H 12.34 %. 
 
 
A5. Synthesis of Oleamide 
 
Oleic acid (1.70 g, 6.02 mmol) was placed under an atmosphere of dry nitrogen 
and dissolved in dichloromethane (30 ml). The solution was cooled to 0 qC and 
oxalyl chloride (1.60 ml, 18.62 mmol) injected with stirring. The solution was 
stirred for 4 hours at room temperature and the solvent removed under vacuum to 
yield a pale yellow residue, which was redissolved in dichloromethane (30 ml). 
Excess aqueous ammonia was slowly added to the stirred solution at 0 qC and 
stirring was continued for 30 minutes at room temperature. The white precipitate 
formed was then filtered off and the solution washed with sodium hydroxide 
solution (1 M, 3 x 20 ml), dried over magnesium sulphate, filtered and solvent 
removed in vacuo. The crude white solid (1.53 g, 90.3 %) was purified by flash 
column chromatography using EtOAc:hexane (80:20) as eluent to yield oleamide 
as a white solid (1.23 g, 72.5 %), Rf 0.32, m.p. 76-78 qC; GH (250 MHz, CDCl3) 
0.90 (3H, t, CH3), 1.28-1.32 (20H, m, (CH2)4CH2CH2CO, CH3(CH2)4), 1.65 (2H, 
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t, CH2CH2CO), 2.02 (4H, d, CH2CH=CHCH2), 2.25 (2H, t, CH2CO), 5.36 (2H, t, 
CH=CH), 5.63 (2H, s, NH2); m/z 282.4 (MH+, 100%), MH+ requires 282.5. C 
76.88; H 12.53; N 5.06. C18H35NO requires C 76.81; N 12.53; N 4.98%. 
 
A6. Synthesis of Anandamide 
 
Arachidonic acid (1 g, 3.28 mmol) was placed under an atmosphere of dry 
nitrogen in a foil-wrapped flask and dissolved in dry benzene (10 ml) and DMF 
(0.3 ml, 3.90 mmol). The solution was cooled to 0 qC and oxalyl chloride (1.0 ml, 
11.64 mmol) injected with stirring. The solution was stirred for 2 hours at room 
temperature and the solvent removed under vacuum to yield an orange residue, 
which was re-dissolved in dichloromethane (30 ml). Ethanolamine (2.0 ml, 33.24 
mmol) was added slowly to the stirred solution at 0 qC and stirring was continued 
for 40 minutes at room temperature. The solution was then washed with potassium 
hydrogen sulphate solution (1 M, 2 x 30 ml), saturated sodium hydrogen 
carbonate solution (2 x 30 ml), distilled water (30 ml) and saturated sodium 
chloride solution (30 ml) and dried over magnesium sulphate. The solvent was 
removed in vacuo to yield a crude, pale yellow oil (1.125 g, 98.6 %) which was 
purified by flash column chromatography using EtOAc as eluent to yield 
anandamide as a pale yellow oil (0.917 g, 80.3 %), Rf 0.23; GH (250 MHz, CDCl3) 
0.88 (3H, t, J=6.75 Hz, CH3), 1.25-1.38 (6H, m, (CH2)3CH3), 1.72 (2H, quin, 
J=7.50 Hz, CH2CH2CO), 2.01-2.16 (4H, m, Anan C4,16CH2), 2.27 (2H, t, J=7.75 
Hz, CH2CO), 2.82 (6H, q, J=5.83 Hz, Anan C7,10,13H2), 3.41 (2H, q, J=4.75 Hz, 
NHCH2), 3.72 (2H, t, J=5.00 Hz, CH2OH), 4.16 (1H, s, OH), 5.27-5.45 (8H, m, 
4(CH=CH)), 6.69 (1H, s, NH); m/z 348.4 (MH+, 100%), MH+ requires 348.5. 
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Appendix B: 
 
Selected NMR and Mass Spectra 
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Figure B1: 1H NMR spectrum (A) and mass spectrum (B) of compound AE6. 
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Figure B2: 1H NMR spectrum (A) 31P NMR spectrum (B) and mass spectrum (C) 
of compound PPA4. 
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Figure B3: 1H NMR spectrum (A) 31P NMR spectrum (B) and mass spectrum (C) 
of compound APA2. 
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Figure B4: 1H NMR spectrum (A) and mass spectrum (B) of synthetic 
anandamide. 
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